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Virus infection of mammalian cells induces several stress mechanisms, including 
autophagy and type-I interferon (IFN). Autophagy, a cellular homeostatic mechanism 
in which intracellular materials are sequestered into double-membrane vesicles and 
targeted to lysosomes for degradation, is also activated in response to virus infection. 
Most positive single-stranded RNA viruses studied to date utilise autophagy to 
increase virus replication. IFN is a potent anti-viral mechanism, which can be 
divided into two parts: (i) induction and secretion of IFN and (ii) IFN  signalling and 
priming of uninfected cells for a rapid response upon infection and induction of an 
anti-viral state in infected cells. Alphaviruses are medically important RNA viruses. 
Semliki Forest virus (SFV) provides a well-characterised model for studying 
alphavirus infection. A number of strains have been identified, which differ in 
virulence in adult mice. In this thesis three hypotheses were investigated: (i) that 
SFV infection induces autophagy in cell culture and utilises this response to enhance 
virus replication, (ii) that the quality, quantity and/or protective efficacy of the IFN 
response differ between virus strains and between human and murine cells and (iii) 
that non-structural protein (nsP)-2 and/or nsP3 antagonise the IFN response. 
SFV4, SFV L10 and SFV A7(74) infection induced autophagy in Huh7 cells 
as early as one hour post-infection. Pharmacological induction or inhibition of 
autophagy had no affect on SFV4 replication, except at a very low multiplicity of 
infection. NsP3, capsid and dsRNA rarely colocalised with the autophagosome 
marker LC3. Taken together these results indicate that SFV does not use 
autophagosomes for replication and autophagy is not important in controlling SFV4 
infection at a high MOI, at least in Huh7 cells. However, autophagy may be 
important in controlling SFV4 spread at a low MOI. 
An IFN bioassay was established. In fibroblasts, SFV4, SFV L10 and SFV 
A7(74) induced relatively little IFN in comparison to that induced by Sendai virus. In 
human fibroblasts, similar levels of IFN were induced by all three virus strains. In 
mouse fibroblasts, SFV4 induced more IFN than SFV L10. Treatment of fibroblasts 
with IFN prior to infection greatly reduced, but did not abolish, the replication and 




signalling demonstrated that all three strains of SFV inhibited STAT1 
phosphorylation during infection of fibroblasts. The growth and viability of SFV 
infected cells varied between human and mouse cells. The complete genetic 
sequences of SFV L10 and SFV A7(74) were determined using Solexa (Illumina) 
sequencing and compared to the sequence of SFV4. The sequences of SFV L10 and 
SFV4 were extremely similar; only seven differences were identified. Multiple 
amino acid substitutions were identified in SFV A7(74) compared to SFV4, these 
mostly mapped to nsP3.  
To investigate the hypothesis that nsP2 and or nsP3 antagonise the IFN 
response, two virus mutants were studied: SFV4nsP2RDR and SFV4nsP3∆50. 
SFV4nsP2RDR encodes a point mutation in the nuclear localisation signal of nsP2, 
which largely restricts nsP2 to the cell cytoplasm. SFV4nsP3∆50 contains a deletion 
of 50 amino acids in the C-terminus hyperphosphorylated region of nsP3. Neither 
mutant inhibited STAT1 phosphorylation as efficiently as WT SFV4; 
SFV4nsP2RDR was particularly poor at inhibiting STAT1 phosphorylation. Both 
mutants induced more IFN in fibroblasts than SFV4.  
In summary, autophagy had a limited affect on SFV replication. In contrast, 
strains of SFV were highly sensitive to IFN, but antagonised this response through 
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Arthropod-borne viruses (arboviruses) include medically important viruses that 
mostly belong to four virus families: Togaviridae, Flaviviridae, Bunyaviridae and 
Reoviridae. Alphaviruses are positive single-stranded (ss) ribonucleic acid (RNA) 
arboviruses of the Togaviridae family. Semliki Forest virus (SFV) provides a well-
characterised model to study alphavirus infection. In this thesis the interaction of 
SFV with host cell stress responses, specifically autophagy and the type-I interferon 
(IFN) response, will be investigated. In chapter 3, the role of autophagy during SFV 
infection will be explored. In chapter 4, the interaction of different strains of SFV 
with both the human and mouse type-I IFN system will be analysed. This interaction 
will be investigated further at the genetic level in chapter 5. In chapter 6, the genetic 
sequence of three well-characterised strains of SFV will be sequenced and 
differences between the strains will be identified. Overall, the research presented 
here will enhance current understanding concerning the relationship between SFV 
and the host cell stress responses. 
 
1.1 Alphaviruses  
Alphaviruses are positive ssRNA arboviruses of the Togaviridae family. The 
Togaviridae family consists of two genera: Alphavirus, which has 40 members, and 
Rubivirus, which has one member, rubella virus. Alphaviruses are defined as Old 
World or New World viruses based on their geographical origin of isolation. The 
New World viruses are located in the Americas and include Venezuelan equine 
encephalitis virus (VEEV), Western equine encephalitis virus (WEEV) and Eastern 
equine encephalitis virus (EEEV) (Garmashova et al., 2007b). The Old World 
viruses are located in Africa and Asia and include SFV, sindbis virus (SINV), 
chikungunya virus (CHIKV) and O’Nyong-nyong virus (ONNV). Ross River virus 
(RRV) was isolated in Australia and is considered to be an Old World alphavirus 
(Garmashova et al., 2007). Alphaviruses have been isolated on every continent of the 
world, apart from Antarctica (Powers et al., 2001). 
The geographical location of alphaviruses is restricted, in part, by their 
vectors. Alphaviruses cycle between vertebrate hosts and arthropod vectors. 
Vertebrate hosts are normally small rodents or birds, but large mammals such as 
humans can be infected. Humans are considered dead-end hosts as the viraemia is 
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generally too low to enable transmission (Gibbs, 1976). Alphavirus vectors include 
mosquitoes, ticks and lice in which alphaviruses produce persistent infections with 
low-level virus production (Weaver et al., 1988;Weaver et al., 1992).  
Alphaviruses are responsible for serious epidemics of polyarthralgia and 
encephalitis in humans, equines, rodents and birds. The Old World and New World 
viruses have different disease phenotypes: New World viruses generally cause 
encephalitis, while Old World viruses induce arthralgia, myalgia and a rash. VEEV is 
epidemic in South and Central America and can cause tens of thousands of cases of 
febrile disease during an outbreak, as occurred in Columbia, 1995 (Weaver et al., 
1992). RRV is endemic in Australia with multiple clinical cases recorded between 
1992 and 2003 (Horwood & Bi, 2005). Since 2005, CHIKV has caused thousands of 
clinical cases of disease in Africa, Asia and, for the first recorded time, Europe. On 
the Indian Ocean island of La Reunion, near East Africa, 40% of the population 
developed severe arthralgia during an outbreak of CHIKV between 2005 and 2006 
(Enserink, 2007). In India, CHIKV has become a major medical burden with 
1,400,000 clinical cases reported in 2006 alone (Pialoux et al., 2007). In 2007, the 
first cases of febrile disease caused by CHIKV infection were reported in Italy. An 
individual returning from India (index case) transferred CHIKV to local mosquitoes 
resulting in an outbreak (Rezza et al., 2007). In 2010, the first confirmed cases of 
autochthonous CHIKV were reported in southeast France (Grandadam et al., 2011). 
VEEV is the only alphavirus for which there is a vaccine available (Edelman et al., 
1979;Edelman et al., 2003). The continuing threat of CHIKV spread has driven 
research towards a vaccine (Akahata et al., 2010;Mallilankaraman et al., 2011).  
 
1.1.1 Alphaviruses: genome and replication   
The alphavirus genome is positive ssRNA and measures between 11 and 12 kb (11.5 
kb for SFV). The genome contains two open reading frames (ORF) that encode nine 
proteins: the non-structural proteins (nsP) 1-4 are located in the 5’ two-thirds and the 
structural proteins are located in the 3’ third of the genome (Fig. 1.1). The structural 
proteins consist of capsid (C), the envelope glycoproteins (E) 1-3 and the 6 kDa (6K) 
protein (Kaariainen et al., 1987).  
 




Figure 1.1: Schematic representation of the SFV genome. 
Blue boxes correspond to the non-structural proteins (nsP1-4) and yellow boxes 
correspond to the structural proteins: capsid protein (C), the envelope glycoproteins 
(E1-3) and the 6 KDa (6K) protein. The arrows represent promoters (reproduced with 
permission from Fragkoudis (2007). 
 
E2 is located on the surface of alphaviruses in spikes and binds to specific 
cell surface receptors (Strauss & Strauss, 1994;Smith et al., 1995). Several 
alphavirus receptors have been identified in both mammalian and mosquito cells 
(Tsai et al., 2002), although the receptor which binds SFV E2 is unknown. E2 
binding induces endocytosis of the alphavirus into clathrin-coated pits (Helenius et 
al., 1980;Marsh et al., 1983). The pits fuse with endosomes and then lysosomes in 
the cell cytoplasm (Strous & Govers, 1999). The increasingly acidic pH induces a 
conformational change in the glycoprotein spike that promotes E1 mediated fusion of 
the virus envelope with the host membrane. The nucleocapsid enters the cytoplasm, 
disassembles and the virus genome is released (Helenius et al., 1982;Wahlberg & 
Garoff, 1992;Fuller et al., 1995).  
Alphaviruses replicate in the cytoplasm of cells, as shown in Fig. 1.2. The 
alphavirus genome has a 5’ cap and a 3’ polyadenylated tail, which enables it to 
function like messenger RNA (mRNA) and be directly translated by the cellular 
replication machinery (Strauss et al., 1983). Translation of the first ORF produces 
the nsP polyproteins (Takkinen, 1986). Certain alphaviruses, including SINV, encode 
an opal stop codon (UAG) between nsP3 and nsP4 with read-through occurring at a 
frequency of 10-20%. As a result, P123 is produced in preference to P1234. In other 
alphaviruses the opal codon is replaced with an arginine residue and P1234 alone is 
produced (Strauss et al., 1983;Takkinen, 1986). In most strains of SFV the opal 
codon is replaced with an arginine, apart from in the strain SFV A7(74) which will 
be discussed further in 1.1.2.  
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P1234 is sequentially cleaved by the protease domains of nsP2 (Merits et al., 
2001). NsP4 is released first, followed by nsP1 and finally nsP3 that associate to 
form the replication complex (RC) (Kim et al., 2004). NsP1 and, potentially nsP3, 
target the RC to modified endosomes, lysosomes and the plasma membrane (Spuul et 
al., 2007). Alphavirus replication is associated with cytopathic vacuoles (CPV) I and 
II (Kujala et al., 2001). CPV I contain numerous inward invaginations called 
spherules, in which the alphavirus genome is replicated. Virus maturation occurs on 
CPV II membranes (Pathak et al., 1976). 
 
Figure 1.2: Schematic representation of alphavirus replication and 
polyprotein production. 
The non-structural proteins (nsPs) are translated first and sequentially cleaved, which 
facilitates the replication of the genome. The structural proteins are translated from 
the sub-genomic RNA. Black, blue and red arrows indicate cleavage sites and amino 
acid (aa) positions are labelled (reproduced with permission from Fragkoudis, 
(2007)). 
 
In CPV I, the RC, comprising of P123 and nsP4, transcribes negative-strand 
RNA from the positive strand RNA genome. The continued processing of P123 to 
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produce mature nsPs results in the decreased ability of the RC to transcribe negative-
strand RNA. Instead, the RC transcribes new genomic RNA by producing full length 
positive-strand RNA from the 3’ end or sub-genomic (sg) RNA from the sg 
promoter. The sg RNA can be co-translationally and post-translationally processed 
into the structural proteins (Grimley et al., 1968;Kaariainen et al., 1987;Froshauer et 
al., 1988;Kujala et al., 2001;Kim et al., 2004). 
C has an autoproteolytic function, which facilitates its rapid release from the 
structural polyprotein leaving p62-6K-E1 (Aliperti & Schlesinger, 1978). Removal of 
C exposes an N’ terminal signal in p62, which directs p62 to the endoplasmic 
reticulum (ER) (Bonatti et al., 1984). Both E1 and p62 have transmembrane domains 
that anchor them in the ER membrane (Melancon & Garoff, 1986). The ER and the 
Golgi apparatus process and modify the proteins by adding carbohydrate chains, fatty 
acids and side chains. The glycoproteins are transported to the cell membrane and 
form the alphavirus spikes. E3 associates with the virion spike in some alphaviruses, 
such as SFV, and in others it remains in the cell cytoplasm. C proteins form a 12 
pentamer and 30 hexamer structure, which binds to a packaging signal present in the 
virus RNA to form the nucleocapsid (Weiss et al., 1989;Geigenmuller-Gnirke et al., 
1991). The E2 cytoplasmic domain associates with the nucleocapsid C-terminal 
domain and drives new virions to bud from the cell membrane (Pathak et al., 
1976;Suomalainen et al., 1992;Lopez et al., 1994). The 6K protein is essential for 
assembly of new virions (McInerney et al., 2004). 
 
1.1.2 Roles of the non-structural proteins  
The alphavirus genome encodes four multifunctional nsPs.  
 
NsP1 
NsP1 forms part of the RC and, together with nsP3, targets the RC to cellular 
membranes (Spuul et al., 2007). NsP1 attaches to host membranes via an 
amphipathic helix and palmitoylation residues (Froshauer et al., 1988;Laakkonen et 
al., 1996;Kujala et al., 2001). NsP1 also initiates the synthesis of negative-strand 
RNA from the positive-strand genome (Wang et al., 1991;Shirako et al., 2000). 
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Finally, NsP1, together with nsP2, caps the newly produced RNA through its RNA 
triphosphatase, methyl- and guanyl-transferase activity (Vasiljeva et al., 2000).  
 
NsP2 
NsP2 contains NTPase, GTPase, ATPase and RNA helicase activity in the N-
terminal region (Rikkonen et al., 1994;Rikkonen, 1996;Gomez de et al., 1999). The 
helicase domain is involved in unwinding and replicating the alphavirus genome. 
NsP2 is implicated in terminating negative-strand replication and in mediating sg 
RNA synthesis (Suopanki et al., 1998). NsP2 is cytotoxic to the host cell when 
expressed alone or in a vector (Garmashova et al., 2006). In Old World alphaviruses, 
nsP2 is implicated in host protein shutoff (Frolova et al., 2002;Garmashova et al., 
2006;Breakwell et al., 2007). The C-terminal region of nsP2 contains papain-like 
cysteine proteinases, which sequentially cleave the non-structural polypeptide to 
release the nsPs (Merits et al., 2001). In addition, the C-terminal region contains a 
nuclear localisation signal (NLS), which consists of a core peptide 
(A645LPRRRVTWN) (Rikkonen et al., 1992). In cell culture, approximately 50 % of 
SFV4 nsP2 locates to the nucleus by 5 h post-infection (Rikkonen et al., 1992). The 
mutation of the second R residue to D results in the mutant virus termed SFV4-RDR, 
in which nsP2 is largely restricted to the cell cytoplasm (Rikkonen et al., 1992). 
Inoculation by the intracerebral (ic) route of BALB/c mice with SFV4 is fatal, 
whereas infection with SFV4-RDR is avirulent (Fazakerley et al., 2002). The 
avirulence of SFV4-RDR has been linked to the type-I interferon (IFN) response 
(Breakwell et al., 2007), which will be discussed further in 1.4.10. 
 
NsP3 
NsP3 contains three domains: the first third of nsP3, termed the macrodomain, is 
conserved between alphaviruses, rubella virus, hepatitis E virus (HEV) and 
coronaviruses (Koonin & Dolja, 1993;Neuvonen & Ahola, 2009); the second third is 
conserved between the alphaviruses, and the final third is hypervariable and varies 
between alphaviruses both in length and in amino acid sequence (Strauss & Strauss, 
1994). The crystal structure of the macrodomain has been generated for both CHIKV 
and VEEV and contains an adenosine binding pocket (Malet et al., 2009). The 
hypervariable domain is hyperphosphorylated and has no predicted secondary 
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structure (Peranen, 1991). NsP3 is implicated in sg 26S and negative-strand RNA 
synthesis (Hahn et al., 1989;Wang et al., 1994;LaStarza et al., 1994b), cleavage of 
the polyprotein by nsP2 (de Groot et al., 1990), attaching the RC to membranes 
(Peranen & Kaariainen, 1991) and determining virus virulence in adult mice. NsP3 
attachment to membranes is mediated by host cell Src-homology 3 (SH3) domains of 
amphiphysin-1 and -2, targeting a region within the hypervariable domain of nsP3 
(Neuvonen et al., 2011). In addition, studies have implicated nsP3 as a crucial factor 
in determining the virulence of different strains of SFV (Tuittila et al., 2000;Vihinen 
et al., 2001;Tuittila & Hinkkanen, 2003). 
 
NsP4 
NsP4 functions as an RNA-dependent RNA polymerase for replication of the 
alphavirus genome (Keranen & Kaariainen, 1979). NsP4 also has protease activity 
and contributes to the cleavage of nsP3 from nsP4 during the processing of the nsP 
polyprotein (Kamer & Argos, 1984;Takkinen et al., 1990). 
 
1.1.2 Semliki Forest virus: strains  
SFV is an alphavirus found in sub-Saharan Africa and primarily spread by Aedes 
africanus and Aedes aegypti mosquitoes. SFV has been isolated from equines, 
primates and humans, although the natural host of SFV remains unknown. There are 
several wild-type (WT) strains of SFV, which can be divided into two groups based 
on their virulence in adult mice (Bradish et al., 1971). Virulent strains include SFV 
L10, V13, Prototype and Osterrieth virus (Bradish et al., 1971;Glasgow et al., 1991). 
Avirulent strains include A8, A7, SFV A7(74), MRS MP 192/7 and V42 (Henderson 
et al., 1970;Bradish et al., 1971;Deuber & Pavlovic, 2007). All strains of SFV 
studied to date are virulent in neonatal or suckling mice (Bradish et al., 1971). 
Following intraperitoneal (ip) inoculation in adult mice, SFV replicates in smooth 
muscles, including the cardiac muscle, and a high plasma viraemia is detected by 24 
h post-infection (Pusztai et al., 1971;Amor et al., 1996). SFV is neuroinvasive and 
enters the brain, probably across cerebral endothelial cells (Pathak & Webb, 1974). 
SFV infects oligodendrocytes and neurones (Pathak & Webb, 1983;Balluz et al., 
1993). A number of strains have been sequenced and cloned, including SFV4 (Garoff 
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et al., 1980;Takkinen, 1986;Liljestrom & Garoff, 1991;Liljestrom et al., 
1991;Glasgow et al., 1994;Santagati et al., 1995;Tarbatt et al., 1997;Santagati et al., 
1998;Tuittila et al., 2000). Strains of particular relevance to this project are SFV L10, 
SFV A7(74) and SFV4.  
SFV L10 was isolated from a pool of 130 Aedes africanus mosquitoes in the 
Semliki Forest, Uganda (Smithburn & Haddow, 1944) and passaged eight times by ic 
inoculation in adult mouse brains followed by two passages ic in neonatal mouse 
brains (Bradish et al., 1971). Following ip inoculation of adult mice, SFV L10 
rapidly disseminates throughout the brain producing a fatal panencephalitis by 4 – 5 
days post-infection (Fazakerley et al., 1993). In adult mice infected with SFV L10, a 
neuronal morphology appears normal while in neonatal mice neuronal cell death is 
apparent (Fazakerley, 2002). The mechanism by which SFV L10 induces 
panencephalitis remains unclear. 
Prototype virus was isolated from the same mosquito sample as SFV L10 and 
passaged 4 times by ic inoculation in mice. SFV4 is a molecular cDNA clone of 
Prototype virus (Liljestrom & Garoff, 1991;Liljestrom et al., 1991). SFV L10 and 
SFV4 have similar replication kinetics in cell culture. SFV4 is virulent in adult mice 
following ic inoculation or intranasal (in) inoculation at a high dose. However, unlike 
SFV L10, ip inoculation with SFV4 is avirulent in adult mice, unless administered at 
a high dose (Glasgow et al., 1991;Fazakerley, 2002). One possible explanation for 
the difference in virulence between SFV L10 and SFV4 is that a nucleotide 
substitution occurred during the cloning process which changed the ability of SFV4 
to function in vivo. SFV4 is a very useful molecular tool, as explained in 1.1.3. 
The SFV strain AR2006 was isolated from Aedes argenteopunctatus 
mosquitoes in Mozambique (McIntosh et al., 1961). SFV A7(74) was derived from 
the AR2006 strain of SFV by passaging seven times by ic inoculation in neonatal 
mice, followed by clonal selection from plaques in monolayers of primary chick 
embryo cells (Bradish et al., 1971). SFV A7(74), like SFV L10, is virulent in mice 
under 11 days old and rapidly spreads throughout the brain. However, as mice 
become older the spread of SFV A7(74) is restricted, at least in the brain, to 
perivascular foci and the mice survive (Pathak & Webb, 1974;Fleming, 
1977;Fazakerley et al., 1993;Oliver et al., 1997;Oliver & Fazakerley, 1998). 
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Following ic inoculation of adult mice, SFV A7(74) is detected in oligodendrocytes 
and the major white matter tracts of the brain, but infection is avirulent (Fazakerley 
et al., 2006). The age-related virulence of SFV A7(74) in mice is suggested to be a 
function of the maturity of central nervous system (CNS) cells. SFV A7(74) can 
replicate in immature neurones, but is generally non-destructive in mature neurones 
(Fazakerley, 2002). Possible explanations for the age-related virulence of SFV 
A7(74) include (i) mature neurones lose their ability to produce smooth membrane 
vesicles on which SFV replicates and (ii) mature neurones upregulate anti-apoptotic 
genes and are less prone to SFV A7(74)-induced death (Fazakerley, 2002).  
SFV4 and A7 or SFV A7(74) have been sequenced and compared; 
differences are present in E2, the 5’ untranslated region and nsP3 (Santagati et al., 
1995;Tarbatt et al., 1997;Santagati et al., 1998;Tuittila et al., 2000;Tuittila & 
Hinkkanen, 2003). Most differences map to nsP3 (Tuittila et al., 2000). Several 
studies have demonstrated that nsP3, in part, determines the virulence of SFV4 and 
SFV A7(74) in adult mice (Tuittila et al., 2000;Tuittila & Hinkkanen, 2003). SFV 
A7(&4) encodes an opal codon in the C-terminus of nsP3, while SFV4 encodes an 
arginine residue (Strauss et al., 1983; Takkinen, 1986). Replacement of the opal 
codon in SFV A7(74) with arginine produces a virulent infection in BALB/c mice, 
while a reciprocal mutation in SFV4 produces an avirulent infection even at a high 
dose (Tuittila et al., 2000). Replacing nsP3 in SFV A7(74) with SFV4 nsP3 produces 
a neurovirulent virus in mice, while a reciprocal change in SFV4 produced an 
avirulent infection (Tuittila & Hinkkanen, 2003). Substituting individual amino acids 
in SFV A7(74) nsP3 for those in SFV4 increases neurovirulence (Tuittila & 
Hinkkanen, 2003). Deletion of 50 amino acids in the hyperphosphorylated region of 
nsP3 produced a mutant virus named SFV4nsP3∆50 (Vihinen et al., 2001). 
SFV4nsP3∆50 replicates less efficiently in vitro and is less virulent in vivo than WT 
SFV4 (Vihinen et al., 2001). The potential interaction of nsP3 with the innate 
immune response has not been investigated.  
 
1.1.3 Semliki Forest virus: a useful molecular tool 
Several strains of SFV have been sequenced and cloned, including the molecular 
cDNA clone SFV4 (Garoff et al., 1980;Takkinen, 1986;Liljestrom & Garoff, 
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1991;Liljestrom et al., 1991;Glasgow et al., 1994;Santagati et al., 1995;Tarbatt et al., 
1997;Santagati et al., 1998;Tuittila et al., 2000). SFV4 is widely used in research due 
to the relatively simple manipulation of its genome to include mutations or encode 
foreign protein(s). Foreign proteins used are Renilla luciferase (RLuc) and ZsGreen 
that enable the indirect measurement of SFV4 replication, as opposed to the 
traditional plaque assay. In addition, SFV4 can be engineered to encode proteins 
useful for vaccination (Atkins et al., 1996;Atkins et al., 1999;Lundstrom et al., 
2001). Foreign gene(s) can be inserted into various locations in the genome with 
varying stability and expression (Fig. 1.3).  
 
Figure 1.3: Schematic representation of possible insertion positions 
within the SFV4 genome. 
(a) SFV4 genome showing two ORFs: the replicase ORF (blue) and the structural 
ORF (yellow). (b) SFV4 genome with a foreign gene (green) inserted into the 
replicase ORF between nsP3 and nsP4. (c) Foreign gene inserted after the structural 
ORF under the control of a duplicated subgenomic promoter (d) Structural ORF 
replaced with a foreign gene. (e) Structural ORF replaced with a foreign gene and 
another foreign gene inserted under the control of a duplicated subgenomic promoter. 
 
Foreign gene(s) can be inserted into the replicase ORF, into the structural 
ORF or added after or before the structural ORF under the control of a duplicated sg 
promoter to produce viable viruses expressing foreign genes. For example, SFV4 has 
been engineered to express enhanced green fluorescent protein (eGFP) fused to nsP3 
in a virus called SFV4(3F)eGFP. This enables the visualisation of nsP3 and virus 
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replication complexes both in cell culture and in the mouse model (Tamberg et al., 
2007). 
Alternatively, the structural ORF can be replaced with foreign gene(s) 
producing a virus replicon particle (VRP) (Smerdou & Liljestrom, 1999). VRPs do 
not encode structural proteins and therefore can only undergo one round of 
replication. To generate VRPs, the VRP RNA and helper RNA encoding only the 
structural proteins are supplied in trans (Fig. 1.4). The structural proteins can be 
supplied in the helper system (all structural proteins) or in the split helper system (the 
Capsid protein and the envelope glycoproteins are encoded on separate RNA). The 
split helper system minimises the risk of recombination and production of infectious 
virus. VRPs are particularly useful for reasons of biosafety when investigating 
alphaviruses of greater risk to human health, such as CHIKV. 
 
Figure 1.4: Schematic representation of VRP production using the 
helper system. 
The replicon (blue) with the foreign gene insert (green) and the C, 6K and the 
envelope genes (yellow) in plasmid form are in vitro transcribed, electroporated into 
BHK-21 cells and VRPs are released. In the split helper system, capsid and 
glycoproteins are encoded on separate plasmids (reproduced by permission of Prof. 
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1.2 The cell stress response: introduction  
The cell stress response is a highly conserved process induced by the loss of 
homeostasis within the cell. The cell stress response functions to restore the cell to its 
normal state. If the cellular environment cannot be rescued then a cell death pathway 
is activated, such as apoptosis. The cell stress response was originally identified in 
Drosophila salivary gland cells that undergo morphological changes following 
temperature change or exposure to chemicals (Ritossa, 1962). At the molecular level, 
stressed salivary gland cells have a different RNA profile compared to control cells 
and upregulate heat shock proteins (HSP) (Schlesinger, 1990). HSP, such as hsp70, 
are chaperones that promote the correct folding of cellular proteins. HSPs have been 
identified in a diverse range of organisms (Lindquist & Craig, 1988). Since then 
other cellular pathways have been associated with the cell stress response, including 
IFN production, the unfolded protein response (UPR) and autophagy. Several cell 
stress inducers have been identified that can be broadly categorised into chemical 
and physical inducers, such as ultra-violet (UV) light. More recently, virus infection 
has been shown to induce the cell stress response. Studies have demonstrated that 
SFV infection induces type-I IFN production, the UPR and apoptosis (Bradish et al., 
1975;Glasgow et al., 1997;Scallan et al., 1997;Barry et al., 2010). The interaction of 
SFV with type-I IFN and the role of autophagy in SFV infection have not been fully 
elucidated.   
 
1.3 The cell stress response: autophagy 
Autophagy, meaning ‘self-eating’, describes the process in which cytoplasmic 
materials are degraded by lysosomes. Autophagy can be divided into three types: 
macroautophagy, microautophagy and chaperone-mediated autophagy. During 
macroautophagy, hereafter called autophagy, cytoplasmic materials are sequestered 
into double-membrane vacuoles and degraded by fusion with the lysosomes, 
described in 1.3.1. In microautophagy, the lysosomal membrane forms invaginations 
which deliver cytoplasm materials into the lysosome for degradation (Mortimore et 
al., 1988;Li et al., 2012b). In chaperone-mediated autophagy, proteins are unfolded 
by chaperone proteins (Dice & Chiang, 1989;Agarraberes et al., 1997); and are 
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directly transported into lysosomes via the lysosomal-associated membrane (LAMP)-
2a transporter for degradation (Cuervo & Dice, 1996;Cuervo & Dice, 2000). 
 Autophagy is a conserved homeostatic process, which maintains the internal 
conditions of the cell by removing dysfunctional organelles or by creating a source of 
amino acids during starvation conditions. In the late 1950s, mitochondria 
and lysosomal enzymes were detected within membrane-bound compartments in 
sections from mouse kidneys (Clark, 1957;Novikoff, 1959). Another study observed 
semi-digested mitochondria and the ER in membrane-bound vacuoles within the 
hepatocytes of rats (Ashford & Porter, 1962). In 1963, the term autophagy was used 
to describe double-membrane vacuoles that contain cytoplasmic proteins and 
organelles in various stages of degradation (De & Wattiaux, 1966). Later, autophagy 
was identified in yeast (Takeshige et al., 1992) and, since then, autophagy has been 
observed in plants and other animals, including human cells. Genetic screening of 
yeast cells has identified over 30 autophagy (Atg) genes and homologues of most of 
these have been identified in mammals (Tsukada & Ohsumi, 1993;Matsuura et al., 
1997;Mizushima et al., 1998b).  
Autophagy is implicated in an increasing number of cellular processes both as 
a homeostatic process and as a defence mechanism against intracellular microbes. As 
a homeostatic process, autophagy has been linked to cell survival (Kourtis & 
Tavernarakis, 2009), development (Mizushima & Levine, 2010), aging (Lipinski et 
al., 2010), cancer (Liang et al., 1999;Qu et al., 2003;Degenhardt et al., 2006), 
inflammatory disease (Cadwell, 2010;Singh, 2010) and neurodegenerative diseases 
(Shibata et al., 2006). Multiple studies have implicated autophagy in the innate and 
adaptive immune responses against diverse intracellular pathogens including bacteria 
(Gutierrez et al., 2004;Nakagawa et al., 2004;Birmingham et al., 2006), parasites 
(Andrade et al., 2006;Zhao et al., 2008) and viruses. The role of autophagy in the 
innate and adaptive immune systems and the link between autophagy and viruses 
will be further explored below.  
 
1.3.1 Autophagy: mechanism 
The autophagy process can be divided into four stages: (i) initiation, (ii) elongation 
and completion of the autophagosome, (iii) fusion with the lysosome and (iv) 
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degradation or autophagy flux (Fig. 1.9). Autophagy is a dynamic process that 
rapidly cycles between these stages based on different stimuli. Our knowledge about 
autophagy and its mechanism is rapidly expanding, although the precise mechanism 
and the proteins involved remain to be fully determined. Current understanding of 
the mechanism is described below.  
 
Initiation  
Following induction of autophagy, the isolation membrane (also known as an 
omegasome or a phagophore) forms in the cell cytoplasm. The source of the isolation 
membrane remains unknown, although studies strongly suggest the involvement of 
the ER (Axe et al., 2008;Yla-Anttila et al., 2009;Hayashi-Nishino et al., 2009) 
potentially in conjunction with the Golgi apparatus (van, V & Reggiori, 2010;Yen et 
al., 2010), the plasma membrane (Ravikumar et al., 2010) and the mitochondria 
(Hailey et al., 2010). To date, two pathways are known to stimulate the formation of 
the isolation membrane: (i) the ULK1 protein kinase pathway, which includes the 
mammalian target of rapamycin (mTOR) and (ii) the Class III phosphatidylinositol 
3-phosphate kinase (PI3K) pathway, which includes Beclin 1.  
 In the ULK1 protein pathway, mTOR is in a complex with the proteins 
ULK1, Atg13, FIP200 and Atg101 (Hara et al., 2008;Hosokawa et al., 2009;Jung et 
al., 2009). Active mTOR prevents autophagy by hyperphosphorylating ULK1 and 
Atg13 (Hosokawa et al., 2009). mTOR is inhibited by various signals, including 
genotoxic stress, hypoxia and, potentially, starvation, while growth factors, IL-4 and 
IL-13 prevent mTOR activation of autophagy. The pharmacological chemical 
rapamycin induces autophagy by inhibiting mTOR (Chiu et al., 1994;Sabatini et al., 
1994). Following the inhibition of mTOR, ULK1, Atg13, FIP200 and Atg101 initiate 
autophagy, although the mechanism is not fully elucidated. 
In the Class III PI3K pathway, Beclin 1 (mammalian homologue of yeast 
Atg6) is in a complex with the proteins Vps34 and Vps15. Studies have reported 
other proteins associated with the Class III PI3K complex, which regulate different 
stages of autophagosome development. Proteins implicated in the Class III PI3K 
complex include Atg14, Rubicon and UVRAG (Liang et al., 2007;Itakura et al., 
2008;Matsunaga et al., 2009;Zhong et al., 2009). Bcl-2 binds Beclin 1 and inhibits 
the induction of autophagy (Pattingre et al., 2005). The Class III PI3K pathway is 
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activated by various signals, including starvation and immune signals, and results in 
the formation of the isolation membrane. The pharmacological chemical 3-
methyladenine (3MA) inhibits the class III PI3K pathway and, therefore, prevents 
autophagy (Seglen & Gordon, 1982). 
Other proteins involved in the production of the isolation membrane are 
double FYVE-containing protein 1 and WD repeat domain phosphoinositide-
interacting family proteins (Axe et al., 2008;Polson et al., 2010). However, the exact 
involvement of these proteins in production of the isolation membrane remains 
unclear. 
 
Elongation and completion of the autophagosome  
The isolation membrane elongates and fuses to form a double-membrane 
autophagosome surrounding cytoplasmic proteins or organelles. This elongation 
requires two ubiquitin-like conjugation systems: (i) the Atg5 system and (ii) the 
microtubule-associated protein light chain 3 (LC3) system. In the Atg5 system, Atg5 
covalently conjugates to Atg12 forming Atg5-Atg12, which is facilitated by the E1-
like enzyme Atg7 and the E2-like enzyme Atg10. Atg5-Atg12 then non-covalently 
associates with Atg16L1 (mammalian homologue of Atg16 in yeast) to form Atg5-
Atg12-Atg16L1 (Hanada et al., 2007;Fujita et al., 2008). Atg5-Atg12-Atg16L1 
locates to the surface of the isolation membrane where it is believed to mediate the 
expansion and curvature of the developing autophagosome (Mizushima et al., 
1998a;Mizushima et al., 1998b;Xie et al., 2008;Xie et al., 2009). On completion of 
the autophagosome, Atg9 and Atg18 facilitate the removal of Atg5, Atg12 and 
Atg16L1 from the surface of the autophagosome.  
 In the LC3 system, LC3-I (mammalian homologue of yeast Atg8) is 
dispersed throughout the cell cytoplasm until LC3-I is cleaved by the protease Atg4 
together with Atg7. Phosphatidylethanoloamine (PE) is then attached to a conserved 
glycine in the C-terminus of LC3-I by the E2-like enzyme Atg3 to produce LC3-II, 
which is also known as LC3-PE. LC3-II locates to both the inner and the outer 
membranes of the autophagosome (Ichimura et al., 2000;Kabeya et al., 2000). Both 
the double-membrane autophagosome and the presence of LC3-II are considered to 
be hallmarks of the autophagy process, as described in 1.3.7. 




Fusion of the autophagosome with the lysosomes 
The final two stages of the autophagy process are the least well understood. The 
autophagosome targets and fuses with the lysosomes to form the autolysosome. The 
lysosomal enzymes mediate the degradation of the inner membrane and the contents 
to produce amino acids. The amino acids can be exported into the cytoplasm and 
recycled by the cell (Ericsson, 1969;Lee et al., 1989;Lawrence & Brown, 1992). 
However, the mechanism(s) by which the autophagosome detects and fuses with the 
lysosomes and the proteins involved remain largely unknown. 
 
Degradation or autophagy flux 
After prolonged starvation, mTOR reactivates (Yu et al., 2010), presumably due to 
release of amino acids from the autolysosome elevating starvation conditions. mTOR 
induces the production of tubules from the autolysosome, which are termed 
protolysosomes. The protolysosomes form vesicles that mature into lysosomes and, 
therefore, prepare the cell for the next round of autophagy (Yu et al., 2010). 
 
Figure 1.5: Simplified schematic diagram of the autophagy pathway. 
Autophagy is a dynamic process that can be divided into four steps. 1) Initiation of 
the isolation membrane involves the activation of the ULK1 protein pathway, which 
includes mTOR, and the Class III PI3K pathway, which includes Beclin1. 2) The 
isolation membrane elongates and fuses to form the double-membrane 
autophagosome. This process involves Atg5-Atg12 conjugation and LC3-II 
formation. LC3-II is expressed on the inner and outer membranes of the 
autophagosome. 3) The autolysome fuses with the lysosome, loses its inner 
membrane and the lysosomal enzymes enter and degrade the contents. Amino acids 
are released from the autolysosome, which induces 4) formation of protolysosomes 
from the autolysome. Protolysosomes mature into lysosomes and the autophagy 
pathway can be repeated. Rapamycin inhibits mTOR and induces autophagy 
initiation. 3MA targets the Class III PI3K pathway and inhibits autophagy initiation. 




1.3.2 Autophagy and innate immunity 
Several studies have linked autophagy to the innate immune response. Studies 
suggest that autophagy can both regulate and be regulated by the innate immune 
system. In addition, autophagy is induced during microbial infection by pathogen-
associated molecular patterns (PAMPs) binding to their pattern-recognition receptors 
(PRRs). Furthermore, autophagy can behave as an immune mechanism against 
invading microbes. 
 
Autophagy regulates the innate immune response 
Autophagy can induce the innate immune response by facilitating the activation of 
PRR. During Sendai virus and vesicular stomatitis virus (VSV) infection of 
plasmacytoid dendritic cells (pDC), autophagy delivers virus ssRNA to the lumen of 
endosomal compartments in which toll-like receptor (TLR) 7 is located (Lee et al., 
2007). Autophagy can also inhibit the innate immune response, including secretion 
of type-I IFN (Jounai et al., 2007;Tal & Iwasaki, 2009) and interleukin (IL)-1b and 
IL-18 (Saitoh et al., 2008). In addition, autophagy can prevent the retinoic-acid-
inducible gene-I (RIG-I) signalling pathway through the Atg5-Atg12 conjugate 
(implicated in elongation of the autophagosome) binding to RIG-I, melanoma 
differentiation-associated gene-5 (mda-5) and IFN-β promoter stimulator protein 1 
(IPS-1) (Jounai et al., 2007).  
Studies suggest that autophagy is regulated by cytokines in the innate 
immune response, including IFN-γ, IL-4, IL-13 (Harris et al., 2007;Subauste et al., 
2007), tumour necrosis factor (TNF)-α and nuclear factor kappa B (NF-KB) 
(Djavaheri-Mergny et al., 2006;Subauste et al., 2007). Taken together, the data 
suggest that the immune response mediates autophagy, which could provide a 
mechanism for degrading components of the immune response and prevent their over 
expression. 
 
Activation of pattern recognition receptors induces autophagy  
Several studies suggest that autophagy is induced following detection of PAMPs by 
their PRRs. In general, these studies have focused on bacterial recognition by TLRs 
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and nod-like receptors (NLR). TLR4 induces autophagy by binding 
lipopolysaccharide (LPS) (Yuan et al., 2009), which facilitates the dissociation of 
Beclin 1 from Bcl-2 and, therefore, the induction of autophagy (Shi & Kehrl, 2010). 
Nod1 and Nod2 reportedly interact with Atg16L1 and can direct Atg16L1 to the 
plasma membrane at the site of bacterial entry (Travassos et al., 2010). The role of 
the TLRs and NLRs in activating autophagy during viral infection remains to be fully 
elucidated. TLR7 was activated in pDCs following infection with SeV or VSV (Lee 
et al., 2007). Potentially, TLR3 induces autophagy on detecting double-stranded (ds) 
RNA and could, therefore, activate autophagy following virus infection (Shi & 
Kehrl, 2008;Delgado et al., 2008). Similarly, autophagy is activated by RIG-I like 
receptors (RLR) family detecting dsRNA (Tormo et al., 2009). However, whether 
the RLRs induces autophagy following virus infection remains to be explored.  
 Based on autophagy studies, a new class of PRRs has been proposed, termed 
the Sequestosome 1/p62-like receptors (SLR). The SLRs contain cargo recognition 
and capture domains and an LC3-interacting domain (Yoshikawa et al., 2009;Zheng 
et al., 2009;Orvedahl et al., 2010). SLRs include the autophagy adaptor proteins p62 
and NBR1, which bind cytoplasmic proteins and transport them to the 
autophagosomes for degradation. In bacterial studies p62, NDP2 and optineurin have 
been implicated in the recognition and capturing of the antigens (Zheng et al., 
2009;Thurston et al., 2009;Wild et al., 2011). In viral studies, SINV capsid protein 
immunopreciptated with p62 in HeLa cells and p62 is suggested to transport SINV 
capsid protein to the autophagosomes for degradation (Orvedahl et al., 2010).  
Another potential sensor of virus infection that induces autophagy is protein 
kinase R (PKR). PKR is required for autophagy induction following Herpes simplex 
virus type 1 (HSV-1) (Talloczy et al., 2006). Potentially PKR detects dsRNA 
produced during HSV-1 infection and induces autophagy.  
 
Autophagy as an anti-microbial defence mechanism 
Multiple studies have implicated autophagy in the innate immune responses against 
diverse intracellular pathogens, including bacteria (Gutierrez et al., 2004;Nakagawa 
et al., 2004;Birmingham et al., 2006), parasites (Andrade et al., 2006;Miller et al., 
Chapter 1  Introduction 
20 
 
2008;Zhao et al., 2008) and viruses. The role of autophagy as an antiviral mechanism 
is discussed in 1.3.4. 
 
1.3.3 Autophagy and adaptive immunity 
Autophagy can facilitate major histocompatibility complex (MHC) II antigen 
presentation by delivering cytosolic proteins to the lumen of the MHC II antigen 
processing and loading compartments in DCs and B cells (Schmid & Munz, 2007). 
Autophagy may also support MHC I presentation of viral antigens (English et al., 
2009). Furthermore, one study reported that autophagy contributes to the selection of 
the CD4 T cell repertoire in the thymus and is essential for tolerance (Nedjic et al., 
2008). In addition, autophagy may affect the homeostasis of immune cells, including 
T cells (Pua & He, 2009), B cells (Miller et al., 2008) and Paneth cells in the 
intestinal epithelium (Cadwell et al., 2008). Finally, studies suggest a role for 
autophagy in controlling Th1/Th2 polarisation (Djavaheri-Mergny et al., 2006;Harris 
et al., 2007). In vaccine development studies autophagy enhanced the efficacy of the 
influenza vaccine (Schmid & Munz, 2007) and the BCG vaccine in the animal model 
of tuberculosis (Jagannath et al., 2009).  
 
1.3.4 Autophagy as an antiviral mechanism 
Several studies in plants, invertebrates and vertebrates have described autophagy as a 
defence mechanism against both DNA and RNA viruses. In plants, the ATG genes 
BECLIN 1, ATG7, ATG3 and VPS34 control the replication of tobacco mosaic virus 
(TMV) and limit cell death induced by the hypersensitive response (Liu et al., 2005). 
In Drosophila, the ATG genes ATG5, ATG8 and ATG18 protect against VSV 
infection in both cell culture and in vivo (Shelly et al., 2009). In vertebrates, over-
expression of Beclin 1 in neurones protects neonatal mice against lethal SINV 
infection (Liang et al., 1998). Furthermore, in mice lacking Atg5, SINV capsid 
persisted in the neurones and there was increased neuronal death in contrast to the 
WT infection (Orvedahl et al., 2010). However, the absence of Atg5 did not affect 
SINV replication. Taken together, these results suggest that autophagy may function 
to clear SINV capsid in neurones. In support of this hypothesis, SINV capsid 
immunoprecipitated with p62, which may, the authors suggest, target capsid to the 
autophagosomes for degradation (Orvedahl et al., 2010).  
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 In further support of autophagy as an antiviral mechanism, certain viruses 
have developed mechanisms to inhibit autophagy. HSV-1 protein ICP34.5 binds to 
Beclin 1 and inhibits autophagy both in cell culture and in mice (Talloczy et al., 
2006;Orvedahl et al., 2007). Deletion of the Beclin 1 binding domain in ICP34.5 
produces a mutant named HSV-134.5∆68-87, which is less neurovirulent and more 
rapidly cleared in mice than WT HSV-1 (Orvedahl et al., 2007;Leib et al., 2009). 
Interestingly, both HSV-134.5∆68-87 and the WT HSV-1 have similar replication 
kinetics in vitro and only differ in neurovirulence in vivo. Therefore, the role of 
autophagy may vary in in vitro and in vivo studies, potentially due to differences 
between cell types. γ-herpesviruses encode a virus Bcl-2 product that binds to Beclin 
1 and inhibits autophagy (Sinha et al., 2008;Ku et al., 2008). Similarly, HIV Nef 
protein binds Beclin 1, which inhibits autophagy in macrophages (Kyei et al., 2009). 
Taken together, these results indicate that viruses have evolved mechanism(s) to 
inhibit autophagy, which is presumably a result of the antiviral role of autophagy. 
 
1.3.5 Autophagy as a proviral mechanism 
In most positive ssRNA virus infections studied to date autophagy actually enhances 
virus replication. Pharmacological induction of autophagy by rapamycin or 
tamoxifen increases polio virus (PV) replication in HeLa cells, while 3MA had the 
opposite affect (Jackson et al., 2005). PV replication proteins 2BC and 3A co-
localised with GFP-LC3 and the autophagy protein LAMP1 in HEK293 cells 
(Jackson et al., 2005). This study indicated that PV utilises the autophagosome as a 
site of replication. Similarly, pharmacological induction of autophagy enhances virus 
replication in coxsackievirus B3 virus (Wong et al., 2008), foot-and-mouth-disease 
virus (FMDV) (O'Donnell et al., 2011), DENV (Lee et al., 2008), Japanese 
encephalitis virus (JEV) (Li et al., 2012a), severe acute respiratory coronavirus 
(SARS-CoV) (Prentice et al., 2004) and hepatitis C virus (HCV) (Dreux & Chisari, 
2009) infections in cell culture.  
Recently, autophagy was reported to be a proviral mechanism for CHIKV 
infection in HEK293 cells (Krejbich-Trotot et al., 2011). This study conflicts with 
observations made with SINV infection in which autophagy had no affect on SINV 
replication in mouse embryonic fibroblasts (MEFs) and was suggested to clear SINV 
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capsid (Orvedahl et al., 2010). Possible explanations for the differences between the 
role of autophagy in SINV and CHIKV infection include (i) different viruses interact 
with autophagy differently and/or (ii) the host cell type is fundamental in 
determining the outcome of autophagy following infection and/or (iii) the different 
methods used to study autophagy affected the results.  
 
1.3.6 Autophagy as neither an antiviral or a proviral 
mechanism 
Despite the number of studies suggesting that autophagy is a proviral or an antiviral 
innate mechanism, several studies demonstrate that autophagy has no effect on the 
replication of certain viruses. Murine hepatitis virus (MHV) had similar replication 
kinetics in WT MEFs and in MEFs lacking the ATG5 gene (Zhao et al., 2007b). 
Atg5 is required for elongation and maturation of the autophagosome, as described in 
1.3.1. Similarly, induction of autophagy with rapamycin or tamoxifen or inhibition of 
autophagy with 3MA had no affect on replication of human rhinovirus (HRV2) 
(Brabec-Zaruba et al., 2007). Furthermore, autophagosomes were not detected on 
infection with HRV2 (Brabec-Zaruba et al., 2007), unlike in PV (Jackson et al., 
2005). Similar titres of SINV were detected in the supernatant of WT MEFs and in 
MEFs lacking the ATG5 gene (Orvedahl et al., 2010). In a study published during 
the writing of this thesis, neither the induction of autophagy by rapamycin nor the 
inhibition of autophagy in Atg5 negative cells had any effect on SFV4 replication 
(Eng et al., 2012). In conclusion, the role of autophagy appears to depend on the 
virus and, potentially, the host cell line investigated. 
 
1.3.7 Methods used to study autophagy 
The last ten years have witnessed a surge in the number and the quality of assays 
available to study autophagy. The hallmark of autophagy is the formation of the 
double-membrane autophagosome. The autophagosome can be detected directly 
using electron microscope imaging or indirectly using molecular techniques. A 
frequently used method to indirectly detect autophagosome formation is via LC3. 
LC3-I is diffused throughout the cytoplasm of healthy cells, while during autophagy 
phosphatidylethanolamine is conjugated and this forms LC3-II, which locates to the 
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as autophagosome, as described in 1.3.1. LC3 can be visualised in the cytoplasm by 
immunostaining or by fluorescently tagging LC3 with GFP and expressing from a 
plasmid or a transgene in a stable cell line or a mouse model (Kabeya et al., 
2000;Mizushima, 2004;Jackson et al., 2005;Ding et al., 2007). The translocation of 
LC3-II to the autophagosomes produces punctuate staining, which is a recognised 
feature of autophagy accumulation in cells. Punctate staining can be enumerated 
manually or, as more recently reported, by FACS analysis (Shvets et al., 2008;Eng et 
al., 2010). Alternatively, LC3-I and LC3-II, which differ slightly in molecular weight 
(16 kD and 14 kD respectively), can be detected by Western blot (Kabeya et al., 
2000). The techniques mentioned above measure the accumulation of 
autophagosomes, which could be due to induction of autophagy or downstream 
inhibition of autophagy. Therefore, these techniques are used in conjunction with 
other methods to delineate the autophagy response. 
 More recently, alternative methods of indirectly studying autophagy have 
been established. Several studies have analysed the interaction of virus proteins with 
the autophagy proteins p62 or NBR1 by immunostaining and immunoprecipitation 
(Pankiv et al., 2007;Kirkin et al., 2009). P62 and NBR1 collect cytoplasmic proteins 
and target them to the autophagosomes for degradation (Pankiv et al., 2007;Kirkin et 
al., 2009;Zheng et al., 2009;Thurston et al., 2009). Colocalisation and 
immunoprecipitation of virus proteins with p62 and NBR1 together with the classic 
LC3 assays to show the accumulation of autophagosomes may indicate that specific 
virus proteins are transported to the autophagosomes for degradation (Orvedahl et 
al., 2010). 
 Autophagy is in a constant state of flux in which autophagosomes are formed 
and degraded. Autophagy flux can be prevented by inhibiting lysosomal activity, 
which causes the accumulation of autophagosomes in the cytoplasm. Lysosomal 
activity can be blocked using chemicals including ammonium chloride, chloroquine 
or bafilomycin A, or by targeting the lysosomal proteases with E64d or pepstatin A. 
Following inhibition of the lysosomes, autophagy flux can analysed by (i) observing 
LC3 punctate staining and degradation visually, by FACS or by Western blot, (ii) 
transfecting cells with a plasmid expressing mRFP fused to GFP and LC3 (mRFP-
GFP-LC3) (Kimura et al., 2007) or (iii) measuring bulk degradation of long-lived 
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proteins by measuring production of isotope-labelled amino acids (Mizushima et al., 
2010). mRFP-GFP-LC3 translocates to the autolysosomes in which GFP is rapidly 
degraded and RFP is not (Kabeya et al., 2000;Bampton et al., 2005;Kimura et al., 
2007). Therefore, it can be visually determined if the autolysomes are functioning. 
Combinations of the techniques mentioned above are used to study autophagy flux. 
A well-documented method to establish the affect of autophagy on virus 
infection is to modulate autophagy activity. Autophagy can be induced by starvation 
or pharmacologically, using chemicals such as rapamycin, an inhibitor of mTOR. 
Autophagy is pharmacologically inhibited by treatment with 3MA, wortmannin or 
LY294002 (Blommaart et al., 1997;Itakura et al., 2008;Matsunaga et al., 2009). 
3MA inhibits the class III PI3K pathway and, therefore, prevents autophagy through 
this pathway (Seglen & Gordon, 1982). However, chemicals can affect cellular 
processes other than autophagy. For example, 3MA function is implicated in 
lysosomal acidification, endocytosis and mitochondrial permeability (Caro et al., 
1988;Punnonen et al., 1994;Xue et al., 2002). Therefore, genetic approaches to 
silence specific genes, including Atg3 (Sou et al., 2008), Atg5 (Mizushima et al., 
2001), Beclin 1 (Qu et al., 2003), Atg7 (Komatsu et al., 2005), Atg9a (Saitoh et al., 
2009), Atg16L1 (Cadwell et al., 2008), FIP200 (Hara et al., 2008) and Ambra1 
(Fimia et al., 2007) have been described both in vitro and in vivo. 
 In conclusion, autophagy research is a rapidly developing field and, as such, 
the techniques reported and reagents available to study autophagy are increasing.  
 
1.4 The cell stress response: interferon  
IFNs are a large group of secreted cytokines with roles in antiviral activity, cell 
growth regulation and immune activation. The antiviral activity of IFN was first 
discovered in 1957 (Isaacs & Lindenmann, 1957). Since then several different IFNs 
have been identified that can be divided into type-I, type-II or type-III based on their 
amino acid sequence, receptor usage and biological activity.  
 
1.4.1 Type-I interferon 
Type-I IFN has several members including IFN-α, -β -ω, ε, -τ, -δ and -ζ, which are 
summarised in Table 1.1. The best characterised of the type-I IFNs are IFN-α and 
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IFN–β. In humans, IFN-α is encoded by 13 genes which are located on chromosome 
9 (Nagata et al., 1980). The mature IFN-α proteins share 75 – 99 % homology 
(Bekisz et al., 2004). In contrast, only one gene encodes IFN-β in humans; this gene 
is also is located on chromosome 9 (Roberts et al., 1998). IFN-α and IFN–β are 
probably the most important innate antiviral defence mechanisms. IFN-α and IFN–
β are produced by cells in direct response to virus infection and have both an 
autocrine and a paracrine function. IFN-α is primarily secreted by leucocytes, such 
as the pDC (Siegal et al., 1999). IFN-β can be produced by most cells, but is 
primarily associated with fibroblasts. Both IFN-α and IFN–β bind a common 
receptor, termed IFNAR, which appears to be ubiquitously expressed. The activated 
IFNAR induces the IFN-signalling pathway, including the proteins Janus kinase 
(previously termed just another kinase) (JAK)-1, the signal transducers and activators 
of transcription (STAT) and interferon response factor (IRF)-9, which causes the 
transcription of various genes, termed the IFN-stimulated genes (ISG) (described in 
section 1.4.4). Together the ISG create an antiviral state within the target cell, which 
is unfavourable for virus replication. The induction and signalling pathways of IFN-
α and IFN–β are described in 1.4.3 and 1.4.5. 
Other type-I IFNs expressed in humans are IFN-ω, IFN-κ and IFN-ε. IFN-ω was 
discovered in 1985 and shares 60 – 70 % homology with IFN-α (Capon et al., 
1985;Feinstein et al., 1985;Hauptmann & Swetly, 1985). IFN-ω, like IFN-α, binds 
the IFNAR and is implicated in the antiviral response (Flores et al., 1991). IFN-κ is 
secreted by keratinocytes and acts through IFNAR to induce the antiviral state in 
cells (LaFleur et al., 2001). Relatively little is known about IFN-ε, but it is 
constitutively expressed in mouse placental and ovarian tissues which indicates a role 
for IFN-ε in pregnancy (Hardy et al., 2004;Krause & Pestka, 2005). 
IFN- ζ, IFN-τ and IFN-δ are not expressed by humans. IFN- ζ, also known as 
limitin, is expressed by mice, shares a 30 % homology with IFN-α and acts through 
the IFNAR (Oritani et al., 2000;Oritani et al., 2001). IFN- ζ is associated with 
antiviral activity, but unlike IFN-α, it does not affect the proliferation of normal 
myeloid or erythroid progenitors (Oritani et al., 2000;Kawamoto et al., 2003). IFN-δ 
has 140 amino acids and is produced by trophoblasts in the pig. IFN-δ appears to 
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facilitate pregnancy as opposed to inducing the antiviral state (La et al., 
1991;Lefevre et al., 1998). In ruminants IFN-τ is produced by trophoblasts and, like 
IFN-δ, facilitates pregnancy (Imakawa & Roberts, 1989;Imakawa et al., 1989;Martal 
et al., 1998). However, IFN-τ is most similar to IFN-ω with 75 % homology (Martal 
et al., 1998). IFN-τ can act across species and studies suggest a potential application 
for IFN-τ  in human antiviral therapy (Martal et al., 1998). 
This thesis focuses on IFN-α and IFN–β and, hereafter, type-I IFN will only refer 
to IFN-α and IFN-β. 
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IFN-ω  Human IFNAR Induction of 
the antiviral 
state 




nn & Swetly, 
1985;Flores et 
al., 1991) 
IFN-ε  Placental 
mammals  
IFNAR  (Hardy et al., 
2004) 
IFN-τ Trophoblasts Ruminant IFNAR Facilitates 
pregnancy 
(Martal et al., 
1998) 
IFN-δ Trophoblasts Pig IFNAR Facilitates 
implantation  
(La et al., 
1991;Lefevre 
et al., 1998). 
IFN-
 ζ / 
limitin 
 Mouse IFNAR Induction of 
the antiviral 
state 
(Oritani et al., 
2000;Kawamot
o et al., 2003) 
IFN-κ Keratinocytes Human  Induction of 
the antiviral 
state 
(LaFleur et al., 
2001) 
 
1.4.2 Type-II interferon 
Type-II IFN has one member, IFN-γ, which is encoded on chromosome 12 (Naylor 
et al., 1983). IFN-γ is structurally unrelated to type-I IFN and binds to a different 
receptor, named IFNGR. Historically, IFN-γ was believed to be secreted by CD4 Th1 
cells, CD8 cytotoxic suppressor cells and natural killer (NK) cells (Bach et al., 
1997). However, several studies indicate that B cells, NK T cells and professional 
antigen-presenting cells (APC) also secrete IFN-γ (Carnaud et al., 1999;Harris et al., 
2000;Frucht et al., 2001). IFN-γ is induced following the detection of virus antigens 
or mitogens on MHC class I and II molecules and cytokines, such as IL-12 and -18 
that attract NK cells to the site of infection (Otani et al., 1999;Golab et al., 
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2000;Fukao et al., 2000;Akira, 2000;Munder et al., 2001). IFN-γ expression is 
negatively regulated by cytokines, such as IL-12, IL-4 and IL-10 (Schindler et al., 
1992;Fukao et al., 2000;Frucht et al., 2001;Hochrein et al., 2001).  
IFN-γ signals through the IFNGR and induces the transcription of ISGs that 
together produce the antiviral state (Huang et al., 1993;Muller et al., 1994). In 
addition, IFN-γ  induces microbiocidal effector functions and regulates cell 
proliferation and apoptosis in macrophages (Schroder et al., 2004). IFN-γ signalling 
also increases the quantity and diversity of MHC class I and II complexes on the cell 
surface, which enhances cytotoxic T cell recognition of antigens and also 
immunomodulates the CD4+ T cell response (Mach et al., 1996;Boehm et al., 
1997;Schroder et al., 2004). Finally, IFN-γ stimulates the trafficking of leucocytes to 
the site of infection by inducing cytokine production (Schroder et al., 2004). 
 
1.4.2 Type-III interferon 
Type-III IFNs were discovered in 2003 and are named IFN-λ1, IFN-λ2 and IFN-λ3 
or IL-29, IL-28A and IL-28B (Kotenko et al., 2003;Sheppard et al., 2003). Type-III 
IFNs share approximately 5 – 18 % homology with type-I IFNs and were originally 
thought to be members of the type-I IFN group (Sheppard et al., 2003;Kotenko et al., 
2003). However, type-III IFNs bind to a novel receptor named IFN-λR1 (also known 
as IL-28RA), which is composed of the IFN-λR1 and IL-10R2 chains (Kotenko et 
al., 2003;Sheppard et al., 2003). The IL-10R2 chain is also an essential component 
of receptors that bind IL-10, IL-22 and IL-26 (Donnelly et al., 2004). Type-I and 
type-III IFNs bind to different surface receptors, but appear to signal through the 
same type-I IFN signalling pathway to induce the antiviral state (Kotenko et al., 
2003;Dumoutier et al., 2004). Microarray analysis demonstrates that type-I and type-
III IFNs induce the expression of similar genes (Doyle et al., 2006;Marcello et al., 
2006). Several studies have demonstrated type-III IFN antiviral activity against 
various virus infections, including encephalomyocarditis virus (EMCV) and VSV 
(Kotenko et al., 2003;Sheppard et al., 2003;Ank et al., 2006). In inoculation of 
influenza A virus in mice produces higher levels of type-III IFN than type-I IFN in 
the lungs, which suggests a role for type-III IFN in the first line of defence against 
virus infection (Jewell et al., 2010). Type-III IFNs can amplify the antiviral activity 
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induced by type-I IFN (Biron, 2001;Le & Tough, 2002;Pestka et al., 2004). 
Similarly, studies indicate that type-I IFN amplifies the production of type-III IFN 
during influenza or SeV infections (Osterlund et al., 2005;Siren et al., 2005). Type-I 
and type-III IFNs are co-expressed by virus-infected cells, including SINV, Dengue 
virus (DENV), EMCV and VSV (Kotenko et al., 2003;Sheppard et al., 2003). In 
addition to inducing the antiviral state, type-III IFN is implicated in anti-proliferative 
activity (Maher et al., 2008) and anti-tumour activity (Lasfar et al., 2006;Sato et al., 
2006;Numasaki et al., 2007). Furthermore, type-III IFN may serve as a therapeutic 
reagent for treatment against viruses such as HCV and hepatitis B virus (HBV) 
(Pagliaccetti & Robek, 2010). 
 The key difference between type-I and type-III IFN activity is the limited 
distribution of IFN-λR1. Type-III IFN, unlike type-I IFN, cannot induce STAT 
phosphorylation in primary fibroblasts, human umbilical vein endothelial cells, 
murine splenocytes or most leucocytes (Lasfar et al., 2006). Instead, type-III IFN is 
associated with cells of epithelial origin that express high levels of IFN-λR1 (Lasfar 
et al., 2006;Sommereyns et al., 2008;Witte et al., 2009). Therefore, type-III IFN may 
provide a vital first line of defence against viruses entering the body through the skin. 
 
1.4.3 Induction of type-I interferon  
Type-I IFN is induced following the detection of PAMPs found on parasites, bacteria 
and viruses by PRRs. Several PRRs have been identified, such as the TLRs and the 
RIG-I-like receptors (RLRs), which facilitate the detection of virus at various stages 
of infection. PRRs detecting viruses can be divided into those located in the 
endosomes and those in the cytoplasm. Some PRRs are located on the cell surface, 
but these are generally associated with bacteria or parasite detection. All PRR 
pathways ultimately induce the transcription factors NF-KB and IFN regulatory 
factor-3 (IRF-3). NF-KB and IRF-3 together with the transcription factors ATF-2 and 
c-Jun translocate to the nucleus and form the enhancesome for IFN-β production 
(Baeuerle & Henkel, 1994;Thanos & Maniatis, 1995;Au et al., 1995). In fibroblasts, 
IFN-β and mouse IFN-α4 are produced in the first wave of IFN production, while 
the other IFN-α and IFN-β are secreted in the second wave. SFV is an RNA virus; 
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therefore this section will mainly focus on the induction of type-I IFN by RNA 
viruses.  
 
Induction of type-I interferon by pattern recognition receptors located in 
endosomal compartments 
TLR-3, TLR-7 and TLR-9 are located in endosomal compartments and detect 
phagocytosed material including viruses through the endosomal pathway (Honda et 
al., 2005). TLR-3 binds dsRNA, which is a replication intermediate produced during 
virus infection (Alexopoulou et al., 2001;Tabeta et al., 2004;Hewson et al., 2005). 
TLR-7 detects single-stranded RNA, such as the genome of VSV and influenza virus 
(Lund et al., 2004). TLR-9 recognises DNA unmethylated at CpG residues (Hemmi 
et al., 2000;Lund et al., 2004). Other TLRs include TLR-2 and TLR-4, which are 
generally associated with bacterial infection, but can detect virus infection: TLR-2 
binds the haemagglutinin protein of measles virus (MeV) (Bieback et al., 2002) and 
TLR-4 binds the fusion protein of respiratory syncitial virus (Kurt-Jones et al., 
2000). 
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TLR-3 signals, in a myeloid differentiation primary response gene 88 
(MyD88)-independent manner, through Toll/IL-1R domain-containing adaptor-
inducing IFN-β (TRIF) (Yamamoto et al., 2003). The induction of type-I IFN by 
TLR-3 involves TLR-3 binding to dsRNA which causes TLR-3 dimerisation and 
tyrosine phosphorylation (Sarkar et al., 2003). Dimerised TLR-3 recruits TRIF that 
activates both IRF-3 and NF-KB (Jiang et al., 2004), shown in Figs 1.5 and 1.6. To 
induce NF-KB, a protein complex composed of receptor-interacting protein 1 (RIP1) 
(Meylan et al., 2004;Cusson-Hermance et al., 2005), tumour necrosis factor receptor-
associated factor (TRAF) 6 (Sato et al., 2003;Jiang et al., 2004), transforming growth 
factor β-activated kinase 1 (TAK1) (Deng et al., 2000;Wang et al., 2001) and NF-KB 
essential modifier (NEMO), which is also known as IKB kinase complex, (Ea et al., 
2006;Li et al., 2006;Wu et al., 2006) is recruited to TRIF. The protein complex 
associates with IKappa kinase (IKK) α and IKKβ and IKKβ is phosphorylated by 
TAK1 (Wang et al., 2001). Activated IKKα and IKKβ induce the activation and 
translocation of NF-KB to the nucleus, as described in ‘activation of NF-KB’ below. 
TLR-3 activation of IRF-3, shown in Fig. 1.6, involves the recruitment of 
TRAF-3 to TRIF (Hacker et al., 2006;Oganesyan et al., 2006). These proteins then 
associate with TRAF family member-associated NF-kB activator (TANK) (Li et al., 
2002), TANK-binding kinase 1 (TBK-1) (Pomerantz & Baltimore, 1999) and IKKε, 
which facilitate the activation and translocation of IRF-3 to the nucleus (Fitzgerald et 
al., 2003;Sharma et al., 2003), described in ‘activation of IRF-3’ below. 
 
Induction of type-I interferon by pattern recognition receptors located in the 
cytoplasm 
RLRs are located in the cell cytoplasm and include mda-5, RIG-I and a receptor 
called “laboratory of genetics and physiology 2” (LGP2) (Yoneyama et al., 
2004;Rothenfusser et al., 2005;Hornung et al., 2006;Kato et al., 2006). RIG-I and 
mda-5 are composed of an RNA-binding helicase domain and two caspase 
recruitment domains (CARDS) (Yoneyama et al., 2004), while LGP2 does not 
possess CARDs. Several studies have identified RIG-I and mda-5 as essential PRR 
in detecting RNA viruses, including Flaviviridae, Paramyxoviridae, 
Orthomyxoviridae, and Rhabdoviridae (Loo & Gale, Jr., 2011). However, the RNA 
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form that RIG-I and mda-5 detect remains controversial. Different studies have 
reported that RIG-I can bind dsRNA, ssRNA, uridine and adenosine-rich regions 
and/or the 5’ triphosphate region on RNA (Yoneyama et al., 2004;Hornung et al., 
2006;Pichlmair et al., 2006). The 5’ triphosphate group on cellular mRNA is 
removed by capping or post-translational modification, which may provide a 
mechanism to differentiate some virus ssRNA from cellular ssRNA (Hornung et al., 
2006). One study suggests that the RNA must have an element of dsRNA, perhaps 
through a hairpin loop, to be detected by RIG-I (Schmidt et al., 2009). 
Mda-5 can detect poly(I:C) and, in addition, the positive sense RNA genome 
of picornaviruses (Kato et al., 2006;Gitlin et al., 2006). A panel of parmyxoviruses 
were found to bind and antagonise mda-5 through the viral V protein, which 
indicates the importance of mda-5 as an antiviral protein (Andrejeva et al., 2004). 
Some viruses are detected by both RIG-I and mda-5, including West Nile virus 
(WNV) and DENV (Fredericksen et al., 2008;Loo et al., 2008). In SINV infection, 
mda-5 is associated with virus recognition (Burke et al., 2009). LGP2 was originally 
associated with the negative regulator of RLR (Rothenfusser et al., 2005). However, 
one study using LGP2 knock-out mice suggests that LGP2 may actually positively 
regulate RLR signalling (Venkataraman et al., 2007).  
On detecting RNA, RIG-I and mda-5 bind and activate a mitochondrion-
associated adaptor protein called IPS-1, also known as CARD adaptor-inducing IFN-
β (Cardif)/virus-induced signalling adaptor (VISA) and mitochondrial antiviral 
signalling protein (MAVS) (Kawai et al., 2005;Meylan et al., 2005;Seth et al., 
2005;Xu et al., 2005). IPS-1 induces the activation and translocation of NF-kB and 
IRF-3 to the nucleus through pathways apparently similar to that employed by TLR-
3 (Kawai et al., 2005;Meylan et al., 2005;Seth et al., 2005;Xu et al., 2005), see Figs 
1.5 and 1.6. To induce NF-KB activation, RIG-I directly interacts with TRAF6 (Xu et 
al., 2005) in a protein complex with RIP1, NEMO and TAK-1 (Zhao et al., 2007a). 
The protein complex recruits and activates IKKα and IKKβ which induces NF-KB 
activation. To induce IRF-3 activation, IPS-1 associates with TRIF, TANK, TBK-1 
and IKKε, which facilitates the activation and translocation of IRF-3 to the nucleus.  
Another cytoplasmic PRR is PKR, which binds dsRNA via dsRNA binding 
motifs (dsRBM) located in the N-terminal region of PKR (Clemens et al., 1993). 
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Binding dsRNA induces autophosphorylation and homodimerisation of PKR, which 
then activates the transcription factor NF-KB (Kirchhoff et al., 1999;Cheshire et al., 
1999). 
 
Activation of NF-kB (Fig. 1.6) 
NF-KB is located in an inactive form in the cytoplasm associated with inhibitor of 
NF-KB (IkB) (Lenardo & Baltimore, 1989;Beg & Baldwin, Jr., 1993). On detection 
of virus infection, IkB is phosphorylated and undergoes ubiquitination and 
degradation by proteosomes, which releases NF-KB (Karin & Ben-Neriah, 2000). 
The NLS on the p65 subunit of NF-KB is exposed, which facilitates the translocation 
of NF-KB to the nucleus (Ganchi et al., 1993). In the nucleus, NF-KB forms part of 
the enhanceosome together with the transcription factors IRF-3 and ATF-2/c-jun. 
ATF-2 and c-Jun are required for optimal induction of IFN-β (Thanos & Maniatis, 
1995). ATF-2 and c-Jun are activated through the stress activated mitogen activated 
kinase (MAP) kinase pathway by dsRNA recognition (Chu et al., 1999;Iordanov et 
al., 2001;Servant et al., 2002). Active ATF-2 and c-Jun associate to form AP-1, 
which translocates to the nucleus and forms part of the enhanceosome. The 
transcription factors NF-KB, IRF-3 and ATF-2/c-Jun associate with specific positive 
regulatory domains (PRD) of the IFN-β promoter in the enhanceosome. The PRD are 
located upstream of the IFN-β promoter. PRD I and III associate with IRF-3 and -7, 
PRD II binds NF-KB and PRD IV associates with ATF-2/c-Jun (Maniatis et al., 
1998;Berkowitz et al., 2002;Panne et al., 2004). However, studies suggest that IFN-β 
secretion can occur without the activation and recruitment of NF-KB and ATF-2/c-
Jun to the enhanceosome (Ellis & Goodbourn, 1994;Peters et al., 2002). The 
enhanceosome is stabilised by association of the high mobility group I (Y) proteins 
(HMG I (Y)) with PRD II and PRD IV (Yie et al., 1999). However, HMG I (Y) is 
not required in all models of the enhancesome (Berkowitz et al., 2002;Panne et al., 
2004). The enhanceosome recruits CREB-binding protein (CBP)/p300, which 
promotes the assembly of the basal transcriptional machinery and RNA polymerase 
to induce IFN-β production (Zhong et al., 1998). 




Figure 1.6: Schematic representation of the NF-KB induction pathway. 
Cytoplasmic PRR RIG-I or mda-5 detect foreign RNA and converge on the adaptor 
IPS-1/Cardif/VISA/MAVS located on the surface of mitochondria. Active IPS-1 
forms a protein complex, which induces the phosphorylation of the inhibitor of NF-
KB (IkB) in the cytoplasm. NF-KB is released, translocates to the nucleus, binds PRD 
II and forms part of the enhancesome together with ATF-2/c-jun and IRF-3. The 
enhanceosome induces the transcription of IFN-β. 
 
Activation of IRF-3 (Fig. 1.7) 
IRF-3 is located in the cellular cytoplasm in an inactive form (Au et al., 
1995;Yoneyama et al., 2002). Following PAMP detection, the C-terminus of IRF-3 
is phosphorylated which facilitates the dimerisation of two IRF-3 proteins (Au et al., 
1995;Lin et al., 1998). The dimerisation of IRF-3 exposes an NLS, which facilitates 
translocation of IRF-3 into the nucleus (Lin et al., 1998;Dragan et al., 2007;Panne et 
al., 2007). In the nucleus, IRF-3 binds to PRD I/III to form the enhanceosome 
together with NF-KB and ATF-2/c-jun, as described in ‘activation of NF-KB’ above. 
IRF-3 remains in the nucleus until it is dephosphorylated (Kumar et al., 2000). 




Figure 1.7: Schematic representation of the IRF-3 induction pathway. 
Cytoplasmic PRR RIG-I or mda-5 detect foreign RNA and converge on the adaptor 
IPS-1/Cardif/VISA/MAVS located on the surface of mitochondria. Active IPS-1 
forms a protein complex, which induces the phosphorylation and dimerisation of 
IRF-3. IRF-3 translocates to the nucleus, binds PRD I/III and forms part of the IFN-β 
enhanceosome together with ATF-2/c-jun and NF-KB, which induces the 
transcription of IFN-β. TLR-3 detects dsRNA in endosomes and activates TRIF, 
which appears to converge on a similar pathway to IPS-1 to induce IFN-β 
production.  
 
1.4.4 Interferon regulatory factors and their role in the type-I 
interferon response 
IRFs contain a DNA binding domain at the N-terminus and an IRF-association 
domain at the C-terminus. In addition to IRF-3, IRF-5, IRF-7 and IRF-9 are 
implicated in the induction of type-I IFN and the ISGs. As mentioned above, IRF-3 
is a transcription factor required for the production of IFN-β and mouse IFN-α4 
(Schafer et al., 1998). IRF-5 is induced by TLR-3, TLR-4, TLR-5, TLR-7 and TLR-9 
Chapter 1  Introduction 
36 
 
and promotes production of pro-inflammatory genes and several ISGs (Takaoka et 
al., 2005;Moynagh, 2005). IRF-7 is produced following IFN-β expression and is 
reported to enhance the production of IFN-α (Marie et al., 1998). IFN-α/β signalling 
through the type-I IFNAR promotes the formation of the ISGF3, which is composed 
of IRF-9 and the STAT1-STAT2 complex (see 1.4.5 for details). ISGF3 induces the 
production of genes with the IFN-stimulated response element (ISRE) within their 
promoters.  
 
1.4.5 Type-I interferon signalling pathway  
Type-I IFN signals through the type-I IFNAR located on the surface of the infected 
cell and neighbouring cells. Type-I IFN binds IFNAR and activates the JAK/STAT 
pathway that produces the antiviral state (summarised in Fig. 1.8). IFNAR is 
heterodimeric and consists of two subunits, IFNAR1 and IFNAR2, which are located 
in close proximity on the cell surface. The cytoplasmic tail of IFNAR1 associates 
with tyrosine kinase 2 (Tyk2) and IFNAR2 is bound to JAK-1 and STAT2. STAT2 is 
weakly associated with STAT1 (Colamonici et al., 1994;Novick et al., 1994;Stancato 
et al., 1996;Precious et al., 2005;Tang et al., 2007). IFN binding causes the receptor 
subunits to associate, which promotes the phosphorylation of Tyk2 and JAK-1 
(Velazquez et al., 1992;Soh et al., 1994;Gauzzi et al., 1996). Active Tyk2 
phosphorylates IFNAR1 at tyrosine 466 (Yan et al., 1996). STAT2 docks, is 
phosphorylated at tyrosine 690 by Tyk1 and generates a binding site for STAT1 (Fu 
et al., 1992;Fu, 1992;Schindler et al., 1992). STAT1 docks and is phosphorylated by 
JAK-1 at tyrosine 701 (Leung et al., 1995). The newly phosphorylated STAT 
molecules form a stable heterodimer, which exposes a NLS (Banninger & Reich, 
2004). The NLS promotes the translocation of the STAT1-STAT2 complex into the 
nucleus (Improta et al., 1994). 
STAT1-STAT2 complexes associate with IRF-9 to form IFN stimulated gene 
factor 3 (ISGF3) that binds to the ISRE located in the promoters of most ISGs and 
induces the transcription of the ISGs (Fu et al., 1990;Kessler et al., 1990;Veals et al., 
1992). Association of the STAT heterodimer with IRF-9 was thought to occur in the 
nucleus, but may occur at the plasma membrane (Tang et al., 2007). The C-terminal 
domain of STAT2 is a strong transcriptional inducer (Qureshi et al., 1995) and 
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recruits CBP/p300, which is important for transcription (Bhattacharya et al., 1996). 
IRF-9 binds DNA through its N-terminus and associates with STAT1:STAT2 
through its C-terminus (Veals et al., 1993;Horvath et al., 1996). 
Alternatives to the traditional type-I IFN signalling model have been 
suggested. For example, STAT1 homodimers or STAT1-STAT2 heterodimers can 
induce transcription of ISGs (Decker et al., 1991;Li et al., 1996). The importance of 
these complexes in infected cells remains unclear. 
 
Figure 1.8: Schematic representation of the type-I IFN signalling 
pathway. 
Type-I IFN binds to and induces the dimerisation of IFNAR1 and IFNAR2 in the 
IFNAR receptor. This activates Tyk2 and JAK-1 (JAK1), which phosphorylate 
STAT1 and STAT2. STAT1 and STAT2 form a heterodimer, which associates with 
IRF-9 either in the cytoplasm or the nucleus forming ISGF3. ISGF3 binds to the 
IFN-stimulated response element (ISRE), which induces the transcription of multiple 
IFN-stimulated genes.  
 
Signal Transducers and Activators of Transcription (STAT) 
The STAT family transmits signals from a receptor to the nucleus and induces the 
expression of hundreds of genes. The STAT family consists of seven members: 1, 2, 
3, 4, 5a, 5b and 6. The seven members share a similar protein structure, but are 
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associated with different phenotypes within the cell. The STAT protein structure 
consists of discrete protein domains, as shown in Fig. 1.9. A coiled-coiled domain 
and a DNA binding domain are located towards the N-terminus. A Src-homology 2 
(SH2) domain and a transactivation domain are located towards the C-terminus. The 
coiled-coiled domain enables protein-protein interactions. The DNA binding domain 
facilitates STAT association with the IRES in the nucleus. The SH2 domain allows 
STAT to associate with phosphorylated tyrosines located on receptors, such as active 
IFNAR, or on other peptides. The transactivation domain facilitates the interaction of 
STAT with other transcription factors. Downstream of the SH2 domain is a tyrosine 
residue, which is phosphorylated by IFNAR activation to activate STAT. Following 
the phophorylation of tyrosine, STAT dimerises and translocates to the nucleus. This 
general structure and the location of the tyrosine residue vary slightly between the 
STAT family members. 
 
 
Figure 1.9: Schematic representation of the protein domains in human 
STAT1. 
Schematic representation of the protein domains in STAT1, which is similar in 
structure to other STAT proteins. N-terminus (ND), coil-coiled domain (CCD), DNA 
binding domain (DBD), linker region (L), SH2 domain (SH2) and the transactivator 
domain (TAD) are shown. Y represents the tyrosine domain in STAT1 that is 
phosphorylated by JAK-1. 
 
STAT1 and STAT2 are strongly associated with the type-I IFN signalling 
pathway (Fu et al., 1990;Kessler et al., 1990;Veals et al., 1992). STAT1 deficient 
mice are viable and develop normally, but are very sensitive to virus infection 
(Durbin et al., 1996;Meraz et al., 1996). Similarly, STAT2 deficient mice are 
susceptible to virus infection and cells derived from these mice cannot respond to 
type-I IFN (Park et al., 2000). The role of STAT1 and STAT2 in type-I IFN 
signalling has been described in 1.4.5. Active STAT1 has been implicated in 
stimulation of the immune system and establishing the antiviral state, inhibition of 
cell growth, regulation of cell death, cell differentiation and tumour suppression 
(Horvath et al., 1996;Bromberg et al., 1996;Huang et al., 2002;Najjar & Fagard, 
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2010). STAT1 is essential for type-I IFN signalling and, as such, examples of human 
homozygous and heterozygous STAT1 mutations are very rare. Clinical cases of 
heterozygous STAT1 mutations have been reported, in which the patients were 
highly susceptible to mycobacterial infections, but not viral infections (Dupuis et al., 
2001). In contrast, two unrelated infants that succumbed to virus infections had 
homozygous STAT1 mutations (Dupuis et al., 2003).  
Initially STAT3 proved difficult to study, as mice lacking STAT3 died early 
in embryogenesis (Takeda et al., 1998). Since then, studies have demonstrated that 
STAT3 is activated by type-I IFN signalling (Yang et al., 1996;Pfeffer et al., 
1997;Rani et al., 1999). Several studies have also associated STAT3 with 
experimental tumour models and in primary tumours; over-expression of STAT3 can 
transform cells (Bromberg et al., 1998;Bromberg & Wang, 2009). STAT3 is 
emerging as a possible target for cancer immunotherapy (Hwa et al., 2011). 
STAT4 are STAT6 are implicated in the adaptive immune response. STAT4 
is activated by IL-12 and promotes T helper cell differentiation. In addition, STAT4 
is required for immunoglobulin class switching and the production of IgE by B cells 
in mice (Kaplan et al., 1996;Thierfelder et al., 1996;Alonso et al., 1999). STAT6 is 
primarily activated by IL-4 and IL-13. Studies have implicated STAT6 in the 
development of T helper type 2 cells, development of IL-9-secreting T cells, 
differentiation of CD8+ T cells, immunoglobulin class switching and surface 
molecule presentation in B cells and in mediating gene expression in macrophages 
and dendritic cells (Kaplan et al., 1996;Shimoda et al., 1997;Takeda et al., 
1997;Dardalhon et al., 2008;Huber et al., 2010;Chang et al., 2010). In addition, 
STAT6 is essential for establishing allergic inflammation (Kuperman et al., 1998) 
and in immunity against helminth parasites, including Schistosoma mansoni and 
Trichinella spiralis (Kaplan et al., 1996;Finkelman et al., 2004). 
STAT5a and STAT5b are activated by a range of cytokines as well as 
tyrosine kinase receptors. STAT5a and STAT5b share a 92 % homology at the amino 
acid level and were originally thought to be the same protein (Hwa et al., 2011). 
Differences between the amino acid sequences in the C-terminal domain clarified 
that STAT5a and STAT5b are different proteins and they are associated with 
different phenotypes in mice. In STAT5a deficient mice the mammary glands did not 
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develop (Liu et al., 1997). In STAT5b deficient mice, reduced levels of insulin-like 
growth factors were detected and males and females grew less efficiently than WT 
mice (Udy et al., 1997). Deletion of both STAT5a and STAT5b prevented fertility 
developing in mice (Teglund et al., 1998). In humans, mutations in STAT5b were 
described in patients with growth hormone insensitivity syndrome, severe insulin-
like growth factor-1 deficiency and postnatal growth retardation (Hwa et al., 2011).  
 
1.4.6 Augmentation of type-I interferon signalling  
The IFN response is regulated by several proteins including IRF-7, suppressors of 
cytokine signalling (SOCS), protein inhibitor of activated STAT (PIAS) proteins, 
SH2 domain-containing protein tyrosine phosphatase (SHP)-1 proteins, receptor 
internalisation and proteasomal degradation of signalling adaptor molecules. IRF-7 is 
induced following activation of the IFN-β promoter, as described in 1.4.5. IRF-7 
translocates to the nucleus and induces the production of IFN-α genes, including 
IFN-α2, IFN-α5, IFN-α6 and IFN-α8. These IFNs create a varied IFN response 
(Marie et al., 1998), which is believed to mediate the expression of pro-inflammatory 
and antiviral genes.  
SOCS proteins are expressed following cytokine signalling and regulate over 
30 proteins, including the type-I IFN signalling proteins JAK-1 and IFNAR (Naka et 
al., 1997). Eight SOCS proteins have been indentified to date, SOCS 1 – 7 and 
cytokine inducible SH2-containing proteins (CIS); of these SOCS1, SOCS2, SOCS3 
and CIS are primarily associated with the regulation of the type-I IFN response. 
SOCS1, SOCS2, CIS and, possibly, SOCS3 bind JAK and IFNAR at different 
residues. SOCS association with JAK directly blocks type-I IFN signalling, while 
targeting IFNAR limits the number of STAT1/2 proteins that can bind IFNAR (Endo 
et al., 1997;Yasukawa et al., 1999;Sasaki et al., 1999;Seki et al., 2003;Fenner et al., 
2006). 
PIAS proteins directly interact with activated STAT to prevent DNA binding 
and transcription of the ISG (Chung et al., 1997). PIAS contain five members, which 
includes PIAS-1 and PIASy. PIAS-1 directly binds STAT1 and prevents DNA 
binding (Liu et al., 1998). In contrast, PIASy allows STAT1 to bind to DNA, but 
specifically prevents its transcriptional activity (Liu et al., 2001). SHP-1 directly 
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interacts with JAK-1 kinases and induces their dephosphorylation (David et al., 
1993;ten et al., 2002).  
 
1.4.7 Interferon stimulated genes (ISG)  
Hundreds of ISG are upregulated following type-I IFN signalling (Der et al., 1998). 
ISG products have been implicated in diverse roles, including establishing the 
antiviral state, antigen presentation, apoptosis, cell stress pathways and membrane 
trafficking, although many of the ISG are uncharacterised (Stark et al., 
1998;Williams, 1999;Sen, 2000;Enninga et al., 2002). Examples of well 
characterised ISG with antiviral properties will be described here. 
 PKR is an ISG associated with regulating translation, induction of IFN and 
cytokines and triggering apoptosis. PKR is constitutively expressed by most cells, 
although the amount varies with cell type and stage of differentiation (Haines, III et 
al., 1993). PKR is also upregulated following IFN signalling, which makes it an ISG 
(Kuhen & Samuel, 1997). PKR is activated by virus-derived dsRNA, cellular RNA 
and the protein activator of PKR (Clemens et al., 1993). The best characterised 
inducer of PKR is dsRNA, which is a replication intermediate produced during RNA 
virus replication. PKR binds dsRNA via the N-terminal domain, which causes 
homodimerisation and activation. Active PKR inhibits translation by phosphorylating 
the eukaryotic translation initiation factor 2α (eIF-2α) at serine 51 (Meurs et al., 
1992). EIF-2α initiates translation by associating with GTP and Met-tRNA and then 
transferring Met-tRNA to the 40S ribosomal subunit. GTP is hydrolysed to produce 
GDP, which promotes the release of eIF-2α bound to GDP from the ribosome. eIF-
2B mediates the exchange of GDP for GTP, which enables translation to continue. 
Following PKR activation, phosphorylated eIF-2α binds eIF-2B and prevents the 
exchange of GDP for GTP and, therefore, inhibits translation. Active PKR can 
promote IFN and cytokine production and induce apoptosis by activating the IKK 
complex, which induces the transcription factor NF-KB (Clemens et al., 1993;Henry 
et al., 1994;Kumar et al., 1994;Lee & Esteban, 1994;Mundschau & Faller, 1995;Gil 
& Esteban, 2000). 
2’-5’-oligoadenylate synthase (OAS) and RNase-L are the ISGs primarily 
associated with ssRNA degradation (Floyd-Smith et al., 1981). The human genome 
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encodes three OASs; small OAS1, medium OAS2 and large OAS3 (Justesen et al., 
2000). 2’-5’ OASs bind dsRNA which induces the polymerisation of ATP and 
produces 2’-5’oligoadenylates (2’-5’ A) (Kerr & Brown, 1978). 2’-5’ A binds 
RNase-L via the N-terminal domain and induce homodimerisation and activation of 
RNase-L (Hassel et al., 1993). Active RNase-L cleaves specific sequence motifs 
present in both cellular and viral ssRNAs (Floyd-Smith et al., 1981). RNase-L can 
degrade 28S ribosomal RNA and, therefore, enhance the inhibition of translation 
(Iordanov et al., 2000). 
 
1.4.8 Dendritic cells are a source of type-I interferon 
Dendritic cells (DC) link the innate immune response to the adaptive immune 
response. Immature migratory DC circulate in tissues and the blood. On detecting 
PAMPs via PRRs, DCs are activated and mature, secrete cytokines and migrate to 
the lymph nodes (LNs) in which they activate the adaptive immune response, 
including CD8+ cytotoxic T lymphocytes and CD4+ helper T cells. DC can be 
divided into subsets based on their function, morphology, location in the LNs and 
cell surface markers. Three important subsets of DCs are the myeloid DC (mDC), the 
plasmacytoid DC (pDC) and the Langerhans cells (LC). mDC are primarily APCs 
and activate T cells (Foti et al., 2004), while pDC are believed to be major producers 
of type-I IFN in response to viruses, including HSV-1, murine cytomegalovirus, 
influenza virus and VSV (Hemmi et al., 2003;Heil et al., 2004;Krug et al., 
2004;Lund et al., 2004). LCs are primarily located in the epidermis of the skin and 
are associated with detecting pathogens there (Mutyambizi et al., 2009). 
pDC, also called IFN producing cells, were first described in humans. In 
1958, cells with a similar morphology to plasma cells, but lacking B cell and plasma 
cell markers were described in the T cell zone of human LNs (Lennert & Remmele, 
1958). Later studies reported cells with a plasma cell-like morphology that did not 
express CD4, CD31, CD36, CD68 or other cell lineage markers (Trinchieri et al., 
1978;Muller-Hermelink et al., 1983;Prasthofer et al., 1985). These cells secreted 
large amounts of type-I IFN in response to infection with virus (Cella et al., 
1999;Siegal et al., 1999). In 2001, mouse pDC were identified that express CD11c, 
Ly-60, B220, but lack the lineage marker CD11b (Asselin-Paturel et al., 
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2001;Bjorck, 2001;Nakano et al., 2001). Mouse pDC are similar to human pDC in 
morphology, activation by CpG and secretion of type-I IFN following detection of 
RNA and DNA viruses (Nakano et al., 2001;Asselin-Paturel et al., 2001;Bjorck, 
2001). Mouse pDC secrete type-I IFN and other cytokines following detection of 
influenza or murine cytomegalovirus (MCMV) via TLR-7 or TLR-9 respectively 
(Dalod et al., 2002;Krug et al., 2002;Asselin-Paturel et al., 2003;Krug et al., 
2004;Diebold et al., 2004). The role of DC during alphavirus infection is poorly 
understood, as described in 1.4.10. 
  
1.4.9 Inverse interference (Table 1.3). 
All viruses studied to date have evolved mechanisms to control the type-I IFN 
response (Randall & Goodbourn, 2008), which is termed inverse interference. 
Inverse interference has been detected throughout the type-I IFN pathway and can be 
divided into (i) global shutoff of cellular transcription and translation, (ii) inhibition 
of IFN-β production, (iii) inhibition of IFNAR signalling and (iv) inhibition of 
specific ISG products. These areas will be described below with examples of RNA 
viruses which employ them. 
 
Global transcription and translation shutoff 
Several virus families, such as Togaviridae, Bunyaviridae and Picornaviridae, 
induce global transcription and translation shutoff within infected cells. This process 
promotes virus infection by inhibiting the production of type-I IFN and ISGs. 
However, these cells rapidly die following shutoff of host protein synthesis and, 
therefore, a persistent infection cannot be established. Global shutoff of host 
transcription and translation has been observed in infections with the Old World 
alphaviruses SFV and SINV and the New World alphaviruses VEEV and EEV at 2 
to 4 h post-infection (Frolov & Schlesinger, 1994;Kedersha et al., 1999). For Old 
World viruses, nsP2 is associated with inhibition of the IFN response (Frolova et al., 
2002;Garmashova et al., 2006;Breakwell et al., 2007) through mechanisms not yet 
understood, while in New World viruses capsid is associated with this process 
(Aguilar et al., 2007;Garmashova et al., 2007a;Garmashova et al., 2007b). The 
alphavirus sg ORF contains a translational enhancer, which enables the translation of 
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the structural polyprotein independent of eIF-2α (Frolov & Schlesinger, 
1994;Sjoberg et al., 1994;Ventoso et al., 2006). Therefore, the structural proteins are 
produced later in infection when the host proteins are no longer being produced and 
are unaffected by the shutoff of host protein synthesis through phosphorylation of 
eIF2α.   
 The bunyavirus Bunyamwera virus expresses NSs protein that inhibits 
cellular RNA polymerase II and, therefore, prevents cellular mRNA transcription 
(Thomas et al., 2004). Similarly, Rift Valley fever virus (RFVF) expresses NSs 
protein which inhibits cellular mRNA transcription. However, RVFV NSs protein 
targets and inhibits the transcription factor TFIIH (Billecocq et al., 2004;Le et al., 
2004). 
 The picornaviruses poliovirus (PV) and FMDV express proteases that cleave 
cellular proteins that are essential for cellular transcription (Etchison et al., 
1982;Devaney et al., 1988;Kirchweger et al., 1994;Belsham & Sonenberg, 2000). 
Finally, the picornavirus EMCV limits the translation of cellular mRNA by 
disrupting nucleocytoplasmic transportation of mRNA (Porter et al., 2006). 
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Inhibition of IFN-β induction 
Viruses can inhibit the production of IFN-β by (i) limiting and/or hiding dsRNA 
synthesis, (ii) inhibiting the PRR and/or the PRR signalling pathway (iii) inhibiting 
IRF-3, (iv) inhibiting NF-KB and/or (v) disrupting the IFN-β promoter. The 
othomyxoviruses express NS1 that binds RIG-I and limits the induction of IFN-β. In 
addition, influenza A inhibits IRF-3 activity (Talon et al., 2000;Wang et al., 
2000;Mibayashi et al., 2007;Guo et al., 2007;Opitz et al., 2007). 
 The paramyxoviruses SeV, mumps virus, PIV5 (previously known as simian 
virus 5, SV5), human parainfluenza virus 2 and Hendra virus (HeV) bind mda-5 via 
the virus V protein. The C-terminal domain of the V protein binds and inhibits mda-5 
and, therefore, prevents PRR signalling (Andrejeva et al., 2004). In contrast, the 
flavivirus HCV inhibits PRR downstream of RIG-I and mda-5. RIG-I and mda-5 
converge and signal through IPS-1. HCV expresses NS3/4A protease that cleaves 
both IPS-1 and the adaptor protein for TLR-3 and TLR-4 TRIF that prevents IFN-β  
induction (Foy et al., 2005;Li et al., 2005;Ferreon et al., 2005).  
 Inoculation of adult mice with alphaviruses drives the production of IFN-β 
(Klimstra et al., 1999;Ryman et al., 2000;White et al., 2001). However, in cell 
culture alphaviruses seem to limit the induction of type-I IFN. In MEFs and mouse 
fibroblast L929 cells, SFV induces less type-I IFN than an SFV derivative with a 
mutation in nsP2 (Breakwell et al., 2007), while CHIKV, SINV, VEEV and EEEV 
induced less type-I IFN than a parallel infection with SeV (Burke et al., 2009). To 
date, a mechanism by which alphaviruses directly inhibit the induction of IFN-β has 
not been described. However, this apparent inhibition of IFN-β production has been 
associated with global shutoff of transcription and translation, nsP2, capsid and 
reduced phosphorylation of STAT1, which are listed with references in table 1.3. 
 
Inhibition of IFNAR signalling 
Many viruses antagonise the type-I IFN response by targeting the signalling 
components, including JAK, STAT and IRF-9 (Randall & Goodbourn, 2008;Najjar 
& Fagard, 2010). Two recent studies have demonstrated that SINV and CHIKV both 
limit the phosphorylation of STAT1 in cell culture (Fros et al., 2010;Simmons et al., 
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2010). For SINV, nsP1 may facilitate this process (Simmons et al., 2010), while for 
CHIKV nsP2 has been associated with this function (Fros et al., 2010). 
The flaviviruses WNV (Guo et al., 2005), JEV (Lin et al., 2004), Langat 
virus (Best et al., 2005), DENV (Ho et al., 2005) and HCV (Lin et al., 2006) inhibit 
STAT1 phosphorylation and IFN signalling via NS5 protein disruption of the IFNAR 
complex. During JEV infection, NS5 limits Tyk2 activation in IFNAR (Lin et al., 
2004). During DENV infection, NS5 protein binds and sequesters STAT1 and 
STAT2 for degradation (Ashour et al., 2009). In addition, DENV protein NS4B 
inhibits the phosphorylation of STAT1 (Munoz-Jordan et al., 2003). Studies have 
demonstrated that HCV inhibits the type-I IFN signalling pathway by inducing 
cellular protein phosphatase 2A (PP2A) and SOCS3 (Heim et al., 1999;Bode et al., 
2003;Duong et al., 2004). PP2A is implicated in several cellular processes, including 
regulation of the JAK/STAT pathway (Zhang et al., 1995). SOCS3 is reported to 
bind STAT1 and prevent downstream signalling, which is described in 1.4.5. 
 Several studies have demonstrated that paramyxoviruses reduce the half-life 
of STAT1 and STAT2 via the virus V protein. However, the mechanism by which 
the V protein inhibits type-I IFN signalling varies between the different 
paramyxovirus family members. In PIV5 infection, the V protein facilitates the 
polyubiquitination of STAT1 and targets it for proteasomal degradation (Young et 
al., 2000;Andrejeva et al., 2002;Parisien et al., 2002;Ulane & Horvath, 2002). In 
contrast, Nipah virus (NiV) and MeV sequester STAT1 into high molecular weight 
complexes in the cytoplasm (Rodriguez et al., 2002;Rodriguez et al., 2003). In NiV 
infection, the V protein forms a complex with STAT2 (Rodriguez et al., 2002), while 
MeV V protein forms a high molecular weight complex comprising STAT1, STAT2 
and IRF-9 (Palosaari et al., 2003). SeV inhibits type-I IFN signalling by sequestering 
STAT1 and also disrupting STAT1 phosphorylation (Didcock et al., 1999;Garcin et 
al., 2002). 
 The coronavirus SARS-CoV antagonises type-I IFN signalling via the virus 
protein ORF6. ORF6 prevents the nuclear translocation of STAT1 by binding the 
nuclear transport protein karyopherin α2 (Frieman et al., 2007). 
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Inhibition of ISG products  
Several studies have demonstrated that viruses can inhibit ISG, including PKR, 
OAS/RNase L, ISG15 and PML nuclear bodies (Randall & Goodbourn, 2008). 
Examples of RNA viruses that can inhibit PKR and/or OAS/RNase L will be 
described here. Latent cytoplasmic PKR binds dsRNA, homodimerises and prevents 
cellular translation, as described in 1.4.7. OAS/RNase L is activated by binding 
dsRNA and then cleaves both mRNA and viral RNA at specific sequence motifs, as 
described in 1.4.7. Influenza expresses NS1 that sequesters dsRNA (Chien et al., 
2004) and prevents the activation of PKR (Lu et al., 1995). The genome of HCV 
contains an IRES structure that competes with dsRNA for binding to PKR (Vyas et 
al., 2003). In addition, HCV expresses NS5A and E2 proteins that directly bind and 
inhibit PKR (Taylor et al., 1999;Noguchi et al., 2001;Gimenez-Barcons et al., 2005). 
In contrast, the PV infection promotes the degradation of PKR (Black et al., 1993). 
The retrovirus HIV-1 expresses Tat during infection, which binds active PKR and, 
therefore, prevents PKR binding to eIF2α (McMillan et al., 1995;Brand et al., 1997). 
 In addition to inhibiting PKR, HCV and HIV-1 can also inhibit the 
OAS/RNase-L pathway (Martinand et al., 1999;Sumpter, Jr. et al., 2004;Taguchi et 
al., 2004). One study reports that HCV genomes generally contain very few RNase-L 
target motifs (Han et al., 2004). HIV-1 induces the expression of the cellular RNase 
L inhibitor (RLI) (Martinand et al., 1999). Similarly, the paramyxovirus EMCV also 
induces RLI activity (Martinand et al., 1998). 
 To date, no studies report the ability of alphaviruses to inhibit PKR or 
OAS/RNase L activity. This may be due to the limited affect of PKR and 
OAS/RNase L on alphavirus replication. In mice deficient in PKR, RNase L and the 
ISG myxovirus resistance-1, SINV only produces a subclinical infection (Ryman et 
al., 2002). In mice lacking the PKR gene, SFV4 replication increases relative to in 
WT mice, but the infection remains avirulent (Barry et al., 2009). In dendritic cells 
OAS/RNase L does not control alphavirus replication (Ryman et al., 2005). 
However, in HeLa cells OAS3 was implicated in controlling CHIKV replication 
(Brehin et al., 2009). 
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Table 1.2: Examples of RNA viruses that inhibit the type-I interferon 
response. 










  VEEV, EEEV Capsid facilitates 
shutoff 
(Aguilar et al., 
2007;Garmashova 
et al., 2007a). 
 Bunyaviridae BUNV NSs inhibits cellular 
RNA polymerase II 
(Thomas et al., 
2004). 
  RVFV NSs protein inhibits 
transcription factor 
TFIIH 
(Billecocq et al., 
2004;Le et al., 
2004). 




(Etchison et al., 
1982); (Clark et 
al., 1993;Das & 
Dasgupta, 1993). 
  FMDV Virus protease cleaves 
eIF4-G and eIF4A 





2000;Li et al., 
2001) 








Togaviridae SFV, SINV, 
CHIKV, 
VEEV, EEEV 
Unknown. (Breakwell et al., 
2007;Burke et al., 
2009). 
 Flaviviridae HCV NS3/4A protease 
cleaves TRIF (adaptor 
protein for TLR-3 and -
4) and IPS-1 (adaptor 
protein for RIG-I).  
 
(Foy et al., 
2005;Ferreon et 
al., 2005;Li et al., 
2005). 




virus 2, HeV 
V protein binds mda-5 
and prevents its activity 
(Andrejeva et al., 
2004). 
 Orthomyxoviridae Influenza A NS1 binds RIG-I and 
IRF-3 and prevents 
their activity 
(Talon et al., 
2000;Wang et al., 
2000;Mibayashi 
et al., 2007;Guo 
et al., 2007;Opitz 
et al., 2007). 




Togaviridae SINV Limits STAT1 
phosphorylation, 
(Simmons et al., 
2010). 
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signalling associated with nsP1 
  CHIKV Limits STAT1 
phosphorylation, 
associated with nsP2 
(Fros et al., 
2010). 
 Flaviridae WNV NS5 limits STAT1 
phosphorylation 
(Guo et al., 2005) 
  JEV NS5 limits STAT1 
phosphorylation 
(Lin et al., 2004). 
  DENV NS5 limits STAT1 
phosphorylation and 
sequesters STAT2 for 




al., 2003;Ho et 
al., 2005;Ashour 
et al., 2009). 
  Langat virus NS5 limits STAT1 
phosphorylation 
(Best et al., 
2005). 
  HCV NS5A protein inhibits 
the phosphorylation of 
tyrosine 701 on 
STAT1. Induces 
cellular protein 
phosphatase 2A and 
SOCS3, which inhibits 
the JAK/STAT 
pathway 
(Heim et al., 
1999;Bode et al., 
2003;Duong et 
al., 2004). 
 Paramyxoviridae PIV5 V protein induces the 
polyubiquitylation of 
STAT1 that triggers 
proteasomal 
degradation.  
(Didcock et al., 
1999;Andrejeva et 




  SeV V protein induces the 
degradation of STAT1 
(Didcock et al., 
1999;Garcin et 
al., 2002). 
  NiV V protein sequesters 
STAT1 and STAT2 
into high molecular 
weight complexes 
(Rodriguez et al., 
2002). 
  HeV V protein sequesters 
STAT1 into high 
molecular weight 
complexes 
(Rodriguez et al., 
2003). 
  MV V protein sequesters 
STAT1, STAT2 and 
IRF-9 into high 
molecular weight 
complexes 
(Palosaari et al., 
2003). 
 Coronaviridae SARS-CoV ORF6 by binds the 
nuclear transport 
protein karyopherin α2 
and prevents the 
nuclear translocation of 
STAT1 




Flaviviridae HCV Virus RNA contains an 
IRES structure that 
binds PKR. Virus 
proteins NS5a and E2 
(Taylor et al., 
1999;Noguchi et 
al., 2001;Vyas et 
al., 
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directly bind and 
inhibits PKR 
2003;Gimenez-
Barcons et al., 
2005). 
 Picornaviridae PV Induces degradation of 
PKR 
(Black et al., 
1993) 
 Orthomyxoviridae Influenza Virus protein NS1 
sequesters dsRNA that 
prevents PKR 
activation 
(Lu et al., 
1995;Chien et al., 
2004). 
 Retroviridae HIV Virus protein Tat binds 
PKR and is a 
pseudosubstrate for 
eIF2α 
(McMillan et al., 
1995;Brand et al., 
1997). 
OAS/RNase L Retroviridae HIV-1 Induces the expression 
of the cellular RNase L 
inhibitor (RLI) 
(Martinand et al., 
1999) 
 Paramyxoviridae EMCV Induces the expression 
of the cellular RLI 
(Martinand et al., 
1998) 
 
1.4.10 Semliki Forest virus and the type-I interferon 
response 
Inoculation of Random−Βred Porton mice or inbred A2G, C57 and C3H mice with 
SFV L10 or SFV A7(74) drives the production of functional IFN; IFN levels increase 
as the blood viraemia titres increase, peak at 2 to 3 days post-infection and then 
decrease (Bradish et al., 1975). Type-I IFN is protective against SFV infection in cell 
culture and in adult mice. Administration of type-I IFN prior to inoculation with SFV 
(strain not reported) protected mice (strain not reported) from disease, depending on 
the time of administration and dose of IFN (Finter, 1966). In plaque assays on mouse 
fibroblast L-cells, addition of anti-IFN antibodies enhanced SFV spread (strain not 
reported), as demonstrated by an increase in plaque size (Fauconnier, 1969). 
Similarly, administration of anti-IFN antibodies immediately after inoculation of 
mice with SFV (strain not reported) enhanced brain viraemia titres and mortality 
rates (Fauconnier, 1971).  
Administration of type-I IFN or poly(I:C) to adult A2G and BALB/c mice 
prior to inoculation with SFV A7 or SFV L10 reduces virus replication, although 
SFV L10 remains virulent (Bradish & Titmuss, 1981). In adult mice inoculated first 
with SFV A7(74) and then with SFV L10 3 h later, SFV L10 was rendered avirulent 
(Oliver et al., 1997). Similarly, in adult Porton-white mice inoculated with SFV A7 
prior to infection with SFV V13, SFV V13 became avirulent (Smillie et al., 1973).  
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In mice lacking IFN receptors (IFNAR-/-) SFV A7(74), SFV4 and SFV4 
mutants spread efficiently and are virulent, unlike in WT mice (Muller et al., 
1994;Fazakerley et al., 2002;Fragkoudis et al., 2007). Studies using other mutant 
mouse models demonstrated that the type-I IFN response is essential for controlling 
the virulence of SFV infection, but the adaptive immune response is required for 
clearance of SFV from the brain; SFV A7(74) is avirulent and cleared from WT 
mice, but is virulent in adult IFNAR-/- mice and establishes a persistent infection in 
adult athymic nu/nu mice (Amor et al., 1996;Fragkoudis et al., 2007).  
Studies in MEFs and L929 cells demonstrated that SFV4 infection inhibits 
the induction of type-I IFN; WT SFV4 induces less functional IFN than SFV4 with a 
mutation in the NLS of nsP2, termed SFV4-RDR (Breakwell et al., 2007). During 
SFV4 infection, the majority of nsP2 translocates to the nucleus by 5 h post-infection 
(Rikkonen et al., 1992). In contrast, during SFV4-RDR infection, nsP2 is largely 
restricted to the cytoplasm (Rikkonen et al., 1992). In mice, SFV4-RDR infection is 
restricted to foci around the inoculation site, whereas SFV4 spreads throughout the 
brain (Fazakerley et al., 2002). In contrast, ic inoculation of IFNAR-/- mice with 
SFV4-RDR produces a widespread and fatal infection, similar to SFV4 (Fazakerley 
et al., 2002). In cell culture, SFV4-RDR replicates less efficiently than SFV4, unless 
the IFN system is compromised (Rikkonen et al., 1992;Breakwell et al., 2007). In 
MEFs, SFV4-RDR infection induces more IFN-β transcripts and functional IFN than 
SFV4 (Breakwell et al., 2007). However, both SFV4 and SFV4-RDR induce 
shutdown of host protein synthesis and the transcription factors NF-KB and IRF-3 
both translocate to the cell nucleus (Breakwell et al., 2007). Taken together, these 
results strongly suggest a role for nsP2 and, in particular, the NLS in controlling the 
IFN responses. Possible explanations include (i) nsP2 functions in the nucleus to 
prevent IFN production through an unknown mechanism, (ii) nsP2 interacts with 
protein(s) in the cytoplasm to inhibit the IFN pathway, which is prevented by 
mutation of the NLS containing domain and/or (iii) SFV4nsP2RDR replicates less 
efficiently than SFV4 and, therefore, there are fewer virus proteins to inhibit the IFN 
pathway.   
DCs, particularly the pDCs, produce type-I IFN following virus infection 
(Cella et al., 1999; Siegal et al., 1999). The interaction of SFV with specific subsets 
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of DCs during infection is largely unknown. SFV infection induces Langerhan’s cells 
(LC) functional maturation in vitro and in vivo (Johnston et al., 1996). In adult CD-1, 
C57BL/6 or BALB/C mice subcutaneously (sc) inoculated with SFV, large numbers 
of mature LC were detected in the LN (MacDonald & Johnston, 2000;Johnston et al., 
2000). Other DC studies have focused on VEEV and CHIKV. Studies demonstrate 
that VEEV can infect human immature DC in vitro and induce the secretion of IFN-
α, TNF-α and IL-6 in vitro (Moran et al., 2005). In mice, pDCs are required for 
VEEV to enter the LN and, also, for detection of cytokine expression in the sera 
(Tonkin et al., 2012). The role of DCs and, indeed, macrophages during CHIKV 
infection is controversial with conflicting data and variation in clinical cases 
depending on the age of patient and strain of CHIKV (Dupuis-Maguiraga et al., 
2012).  
In conclusion, these studies suggest that strains of SFV are sensitive to type-I 
IFN pre-treatment and the antiviral state. The report that SFV L10 is virulent in adult 
mice despite the production of type-I IFN, while SFV A7(74) is avirulent (Bradish et 
al., 1975) could indicate that SFV L10 and SFV A7(74) vary in sensitivity to the 
type-I IFN response. Indeed, one study reported that virulent SFV L10 and avirulent 
V42 differ in sensitivity to the type-I IFN response; SFV L10 replicates more 
efficiently in the presence of type-I IFN than SFV V42 (Deuber & Pavlovic, 2007). 
In addition, it remains unclear (i) which PRR(s) detect SFV infection in cell culture, 
(ii) if SFV inhibits the type-I IFN response and, if so, (iii) the cellular targets and the 
virus proteins involved in inhibiting the type-I IFN response and (iv) the role of DCs 
in secreting type-I IFN during SFV infection in vivo. 
 
1.5 Hypotheses and aims 
This project has three hypotheses: 
1) SFV infection induces autophagy in cell culture and utilises this response to 
enhance virus replication. 
2) The quality, quantity and/or the protective efficacy of the IFN response differ 
between strains of SFV and between human and murine cells. 
3) The replicase proteins nsP2 and/or nsP3 antagonise the IFN response. 
Questions to be addressed: 
Chapter 1  Introduction 
53 
 
1) Does SFV induce autophagy and, if so, does this enhance virus 
replication? 
SINV and CHIKV both induce the accumulation of autophagosomes. In SINV 
infection autophagy degrades capsid (Orvedahl et al., 2010), while with CHIKV 
autophagy enhances virus replication (Krejbich-Trotot et al., 2011). At the start of 
this thesis there were no studies on the role of autophagy in SFV infection. 
2) Do strains of SFV differ in induction of or sensitivity to the type-I IFN 
response?  
There are several strains of SFV that can be divided into two groups based on their 
virulence in adult mice; SFV L10 is virulent, while SFV4 and SFV A7(74) are 
avirulent. One study reports that strains of SFV differ in their sensitivity to type-I 
IFN and this may dictate virulence in adult mice (Deuber & Pavlovic, 2007). The 
ability of strains of SFV to induce type-I IFN and their sensitivity to type-I IFN has 
not been investigated. 
3) Is SFV more sensitive to human IFN than mouse IFN and can SFV evade 
and/or inhibit the mouse IFN response better than the human IFN 
response? 
In humans, SFV infection only causes a mild or subclinical disease (Mathiot et al., 
1990), while CHIKV is currently causing debilitating disease in millions of humans 
worldwide (Enserink, 2007). In contrast, in adult mice SFV can induce a fatal 
panencephalitis (Bradish et al., 1975), while CHIKV is avirulent unless the mice are 
deficient in the type-I IFN system (Couderc et al., 2008). This data could be 
explained by SFV inducing more or being more sensitive to human type-I IFN than 
mouse type-I IFN. Comparison of the interaction of SFV with the mouse and human 
type-I IFN response has not been investigated. 
4) Do strains of SFV antagonise the type-I IFN response? 
In MEFs and L929 cells, SFV4 induces less functional IFN than SFV4 with a 
mutation in nsP2, SFV4-RDR (Breakwell et al., 2007). The mechanism(s) by which 
SFV4 antagonises the type-I IFN response and the role(s) of nsP2 within this has not 
been delineated. 
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5) Do nsP2 and/or nsP3 antagonise the IFN response? 
In MEFs and L929 cells, SFV4 with a mutation in nsP2, SFV4-RDR, induces greater 
amounts of functional IFN and IFN-β transcripts than WT SFV4 (Breakwell et al., 
2007). In cell culture, 50 % of nsP2 translocates to the nucleus by 5 h post-infection 
during SFV4 infection, while in SFV4-RDR infection nsP2RDR is largely restricted 
to the cytoplasm (Rikkonen et al., 1992). The mechanism by which nsP2 and 
nsP2RDR interacts with the IFN response remains unclear. NsP3 is the least well-
characterised of the nsPs. NsP3 is a virulence determinant (Tuittila et al., 
2000;Tuittila & Hinkkanen, 2003). However, the potential interaction of nsP3 with 
the IFN response has not been investigated.   
6) Where are the differences in the genetic sequence of SFV L10, SFV 
A7(74) and SFV4? 
SFV4 was derived from Prototype virus, which is closely related to SFV L10 
(Liljestrom et al., 1991). However, SFV L10 is virulent in adult mice, while SFV4 is 
avirulent unless inoculated ic, in or at a high dose (Glasgow et al., 1991;Fazakerley, 
2002). Previous studies identified several amino acid substitutions between SFV 
A7(74) and SFV4, which mainly mapped to nsP3 (Tuittila et al., 2000). The genetic 
sequences for the strains SFV L10 and SFV A7(74) held at the University of 
Edinburgh have not been determined or compared to SFV4.  
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2.1 Cell Lines 
All cell lines were maintained in sterile plastic ware (Nunc) at 37oC in a humidified 
incubator with an atmosphere of 5 % CO2. Table 2.1 describes the cell lines used in 
this project. 
 Baby Hamster Kidney-21 (BHK-21) cells were grown in Glasgow’s modified 
Eagles medium (GMEM, Gibco), supplemented with 10 % (volume/volume (v/v)) 
newborn calf serum (NBCS, Biosera), 10 % v/v tryptose phosphate broth (TPB, 
Invitrogen) and penicillin/streptomycin (100 U/ml and 100 µg/ml respectively, 
Gibco) (10 % NBCS GMEM).  
 Mouse L929 and NIH 3T3 fibroblast cells were maintained in Dulbeccos 
modified Eagles medium (DMEM, Gibco), supplemented with 10 % v/v foetal calf 
serum (FCS, Biosera) and penicillin/streptomycin as above (10 % FCS DMEM). 
 Human 2fTGH, Hs 633T, Huh7, MRC5 and U4C cells were maintained in 
DMEM supplemented with FCS and penicillin/streptomycin as above.  
 Human A549-NPro cells were maintained in DMEM supplemented with 10 % 
FCS and Puromycin (1 µg/ml, Invivogen). 
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Table 2.1: Cell lines used in this project 
Name Cell type Additional information 
Hamster   
BHK-21 Fibroblast IFN incompetent cell  line 
Mouse   
L929  Fibroblast IFN competent cell line 
NIH 3T3  Fibroblast IFN competent cell line 
Human   
2fTGH  Fibroblast IFN competent cell line 
A549-NPro Epithelial IFN incompetent cell line. A549 cells stably expressing the NPro 
protein of the Bovine viral diarrhoea virus (Pe515strain) with an N-
terminal V5 tag (Jackson et al., 2010). NPro targets the transcription 
factor IRF-3 and prevents it from binding to DNA and instead targets 
IRF-3 for polyubiquitination and destruction (Hilton et al., 2006). 
Therefore, A549-NPro cells can respond to IFN, but cannot produce 
IFN. 
Hs 633T  Fibroblast IFN competent cell line 
Huh7  Hepatocyte IFN competent cell line 
MRC5 Fibroblast IFN competent cell line 
U4C  Fibroblast IFN incompetent cell line. Derivative of 2fTGH that were mutated to 
express the drug-selectable gpt (guanine/hypoxanthine phorphoribosyl 
tranferase) controlled by an IFN-α/β-inducible promoter. Cells 
resistant to IFN were selected. These cells, called U4C cells, lacked the 
JAK1 protein and contained a truncated JAK1 messenger RNA. JAK1 
is essential for IFN signalling. Therefore, U4C cells are defective in 
the IFN response (Muller et al., 1993). 
 
2.1.1 Passaging and counting cell lines 
The same procedure was used to passage and count all the cell lines used in this 
project. When cells were 80% confluent the medium was removed and the 
monolayer was washed with 5 ml of phosphate buffered saline (PBS). The PBS was 
replaced with 5 ml of trypsin/EDTA (0.05% trypsin, 0.53 mM EDTA, Gibco) and the 
cells were incubated at 37oC. When the cells had detached, 5 ml of medium was 
added to neutralise the trypsin and the cells were pelleted by centrifuging for 5 
minutes at 450 x g. The supernatant was discarded and the cell pellet was re-
suspended in 10 ml of 10 % media. A 10 µl aliquot of the cell suspension was diluted 
in 90 µl of PBS and the cells were counted on a haemocytometer. The mean number 
of cells present in the 10 ml cell suspension was calculated using the following 
formula:  
Mean number of cells in 10 ml = mean number of cells per square of the 
haemocytometer x 106. 
The required number of cells were then seeded into a fresh flask with 10 % 
medium and incubated at 37oC. BHK-21 cells and MRC5 cells were passaged 
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approximately 30 times after which their growth significantly slowed and they were 
replaced with fresh stocks from liquid nitrogen stocks (2.1.2). The other cell lines 
were replaced at passage 60 – 70 with lower passage number cells from liquid 
nitrogen.  
 
2.1.2 Freezing and resurrecting cell lines 
Cells were frozen during the growth phase while still <80 % confluent. The cells 
were harvested and counted. Cells were centrifuged at 478 x g for 5 minutes and re-
suspended in freezing medium (90 % FCS and 10 % dimethylsulfoxide (DMSO)) to 
produce 5x106 cells per ml, the optimal concentration of cells for freezing. Aliquots 
of 1 ml of cell suspension were transferred to Nunc cryovials and placed in an 
isopropanol box at -80oC overnight to gradually freeze the cells. The frozen cells 
were stored in the vapour phase of a liquid nitrogen refrigerator at below -130oC. 
To thaw the cell lines, cryovials were removed from the liquid nitrogen 
refrigerator and transported to the laboratory on dry ice. The cells were rapidly 
thawed in a 37oC water bath and 1 ml of pre-warmed 10% media was gradually 
added to the cryovial. The cell suspension was transferred into a 25 cm2 flask 
containing 8 ml of warm 10 % media and then incubated at 37oC. After 24 h the cells 
were passaged if confluent. Alternatively, the medium was replaced at 24 h with 
fresh 10 % media to remove all traces of DMSO and the cells were passaged once 
confluent. 
 
2.2 Viruses and Virus Replicon Particles (VRPs) 
Table 2.2 and Fig. 2.1 describe the viruses and virus replicon particles (VRPs) used 
in this project.  
 
2.2.1 Propagation of wild-type SFV 
Strains of WT SFV (SFV L10 and A7(74)) were propagated from the original stocks 
(Prof. John Fazakerley, The Roslin Institute, University of Edinburgh). BHK-21 cells 
were seeded into ten 175 cm2 with 10 % NBCS GMEM. Once confluent, the medium 
was removed and the BHK-21 cells were infected with virus at a MOI of 0.01 in 5 ml 
of PBS supplemented with 0.75% bovine serum albumin (BSA, Sigma) (PBSA) for 1 
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hour at room temperature with constant rocking. Following incubation, the virus 
suspension was replaced with 20 ml of 10 % NBCS GMEM and the cells were 
incubated until cyptopathic effect (CPE) was observed, usually after 24 h. The 
supernatant was collected, centrifuged at 27,200 g for 30 minutes to remove cell 
debris and stored at -80oC until the virus was purified. 
 
2.2.2 Production of VRPs 
VRPs were produced from DNA plasmids, which were kindly provided by Prof. 
Andres Merits, Institute of Technology, University of Tartu, Estonia. The method 
used has been previously described (Smerdou & Liljestrom, 1999). Briefly, two 
plasmids (1 µg each) were linearised with Spe I (New England Biolabs) and in vitro-
transcribed to produce RNA. One plasmid encoded the SFV4 non-structural proteins 
and a foreign gene insert and the second plasmid encoded the SFV4 structural 
proteins. The RNA from both plasmids was electroporated into BHK-21 cells using 
the BioRad Gene Pulser Xcell electroporator. BHK-21 flasks were trypsinised, the 
cells counted, and re-suspended in chilled PBS to give a final concentration of 6x106 
cells per ml. A 400 µl aliquot of the cell/nucleic acid mix was added to a 0.4 cm 
electroporation curvette and then pulsed twice using a square wave of 140 volts (V) 
for 25 mseconds. The cells were carefully transferred into a 175 cm2 flask with 20 ml 
of 10 % NBCS GMEM and incubated at 37oC. The supernatant was collected 24 – 
48 h later when CPE was observed, clarified by centrifugation at 27,200 g for 30 
minutes and then stored at -80oC. 
SFV4 was produced in the same way using a single plasmid that encoded the 
whole SFV4 genome and, in some cases, a foreign gene insert. This technique 
produced viable SFV4.  
 
2.2.3 Purification of Viruses and VRPs 
The viruses and VRPs were purified from the BHK-21 cell supernatant by 
ultracentrifugation through a 20 % sucrose cushion. The sucrose cushion contained 
20 % (w / v) sucrose (Sigma) and 80 % TNE buffer pH 7.4 (50 mM Tris-HCl pH 7.4, 
100 mM NaCl (Sigma) and 0.1 mM EDTA pH 8.0 (Sigma)). The supernatant was 
poured into an ultracentrifugation tube and 10 ml of the 20 % sucrose cushion was 
Chapter 2  Materials and Methods 
61 
 
added below the supernatant using a 10 ml pipette. The supernatant was 
ultracentrifuged at 82,700 x g for 1.5 h to pellet the virus or VRPs. The supernatant 
was carefully removed and the pellet was re-suspended in 100 µl of TNE buffer pH 
7.4. The re-suspended viruses and VRPs were stored at -80oC. 
 
2.2.4 Restriction Digest of DNA Plasmids  
Linearisation of DNA plasmids was carried out using the restriction endonuclease 
Spe I (New England Biolabs). The plasmid DNA was mixed with the restriction 
digest mixture, which contained 6 µl of 10x acetylated BSA  (New England Biolabs), 
6 µl of 10x restriction enzyme buffer (New England Biolabs), 2 µl of Spe I and was 
made up to 60 µl with nuclease free water. This was incubated at the manufacturer’s 
recommended temperature for 2 – 4 h. The DNA was purified using the High Pure 
PCR Product Purification Kit (Roche) and the results were checked by agarose gel 
electrophoresis (2.2.6 and 2.2.7).  
 
2.2.5 In vitro transcription 
Spe I linearised plasmid DNA (2.2.4) was transcribed into mRNA using the 
MegaScript SP6 kit (Ambion). Following the manufacturer’s instructions a 20 µl 
reaction mixture was prepared, which contained 2 µl of ATP, 2 µl of UTP, 2 µl of 
CTP, 2 µl of GTP (diluted 1 in 5), 2 µl of 10x SP6 reaction buffer, 2 µl of the 
enzyme polymerase mixture, 2 µl of 10 mM M7G (5’)ppp (5’) G (cap) (GE 
Healthcare), 1 µg of linearised plasmid DNA and nuclease free water. The reaction 
mixture was incubated in a water bath at 37oC for 5 h. The products were checked by 
agarose gel electrophoresis (2.2.6). 
 
2.2.6 Agarose gel electrophoresis 
Agarose (Sigma) was added to Tris-acetate-EDTA (TAE) buffer and heated until the 
agarose dissolved. The percentage of agarose and the volume of TAE buffer 
depended on the size of gel and speed of nucleotide movement desired. On cooling, 
ethidium bromide was added to the agarose mix to give a final concentration of 0.5 
µg/ml. The solution was mixed and poured into a plastic frame with a comb. On 
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solidifying, the gel was moved to a tank, the comb removed and the gel was covered 
with TAE buffer. Samples were loaded with loading buffer (Promega). A 100 bp or 
1000 bp DNA ladder (Promega) was run in lane 1. Gels were normally run at 90 V 
for 45 minutes. The products were visualised using a UV transilluminator. 
 
2.2.7 DNA purification  
DNA was purified from a restriction digest or from an agarose gel using the High 
Pure PCR Product Purification Kit (Roche) according to the manufacturer’s 
instructions. For the restriction digest, the sample was adjusted to 100 µl using 
nuclease free water and 500 µl of binding buffer 1 added. For the gel extraction, the 
DNA band was visualised by placing the gel on a ultra-violet light box, then cutting 
out the band using a scalpel and dissolving it in 700 µl of binding buffer at 56oC. A 
High Pure Filter Tube was inserted into a Collection Tube and the digest or the gel 
mixture was added to this, centrifuged at 6,800 g for 1 minute and the flow-through 
discarded. The filter was washed with 700 µl of buffer 2, centrifuged at 6,800 g for 1 
minute and the flow-through discarded. The wash and centrifugation was repeated 
with 200 µl of buffer 2. To elute the DNA, the tube was inserted into a fresh 
eppendorf tube and 50 µl of elution buffer 3 was added for 1 minute at room 
temperature. The eppendorf tube was centrifuged at 6,800 g for 1 minute and the 
eluted DNA was stored at -20oC. The concentration of DNA was measured using a 
NanoDrop Spectrophotometer. 
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Table 2.2: Viruses and VRPs used in this project 
Virus Strain Backbone Modification 
SFV L10 n/a Wild type – isolated originally as a naturally 
occurring strain.  
SFV A7(74) n/a Wild type – isolated originally as a naturally 
occurring strain.  
SFV4 n/a Prototype.  
SFV4-RDR SFV4 SFV4 with a point mutation in the nuclear 
localisation signal of nsP2 (RRR is changed 
to RDR).  
SFV4nsP3∆50 SFV4 SFV4 with 50 amino acids deleted in the C’-
terminus of nsP3 (amino acids between 
positions 318-369).  
SFV4(3H)RLuc SFV4 The gene encoding Renilla luciferase (RLuc) 
is inserted at the 3’ end of the nsP3 gene. 
RLuc is translated and released during 
replication of the SFV4 genome. The amount 
of RLuc produced is used as an indirect 
measure of virus replication.  
SFV4(3F)-ZsGreen SFV4 The gene encoding ZsGreen is fused to the 3’ 
terminus of the nsP3 gene. During the 
replication of SFV4(3F)-ZsGreen, nsP3 is 
produced fused to ZsGreen, which highlights 
the location of nsP3. 
SFV1-d1eGFP VRP SFV4 SFV1 VRP expressing the enhanced green 
fluorescent protein (eGFP) under the control 
of the subgenomic promoter. 
Sendai virus (Cantell 
strain) 
n/a Negative ssRNA virus (Paramyoxviridae). 




n/a Positive ssRNA virus (Picornaviridae).  
 




Figure 2.1: Schematic representation of the viruses and VRPs used in 
this project 
Blue boxes correspond to the nsPs 1 – 4 and yellow boxes correspond to the 
structural proteins: capsid protein (C), the envelope glycoproteins (E1 – 3) and the 
6K protein. SFV4-RDR has a point mutation in nsP2 at amino acid position 649, 
arginine (R) to aspartic acid (D). SFV4nsP3∆50 has a deletion of 50 amino acids 
between positions 318 – 369. RLuc is inserted into SFV4(3H)RLuc at the 3’ end of 
nsP3 between duplicated nsP2 cleavage sites (*). ZsGreen is inserted into SFV4(3F)-
ZsGreen at the 3’ terminus of nsP3. SFV1-d1eGFP expresses eGFP under the control 
of the subgenomic promoter instead of structural proteins. 
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2.2.8 Infection of cells in vitro with virus or VRPs 
To infect cells in a 6-well plate, cells were seeded at a concentration of 3x105 per 
well and incubated overnight. The medium was removed from the wells and the 
required amount of virus or VRP diluted in 400 µl of PBSA was added. The plates 
were placed on a rocker at room temperature for 1 hour. After incubation, the virus 
mixture was replaced with 1 ml of fresh medium and the plates incubated at 37oC. In 
a 24-well plate, the virus or the VRP was added in 100 µl volumes to each well. In a 
96-well plate, the virus or the VRP was added in 30 µl volumes to each well. Time 
zero in all experiments was considered to be the time at which virus was added to the 
cells. 
 
2.2.9 Titration of virus by standard plaque assay 
Generally, infectious virus was titrated by standard plaque assay in BHK-21 cells. 
BHK-21 cells were seeded in 6-well plates at a concentration of 3x105 cells per well 
and incubated overnight. The virus was serially diluted 10-fold in PBSA. The 
medium was removed from the wells and 400 µl of each dilution was added to two 
wells of the 6-well plate. The cells were incubated for 1 hour at room temperature 
with gentle rotation. After incubation, molten agar (4 g of Bacto agar per 100 ml PBS 
sterilised by autoclave) mixed with GMEM supplemented with 2 % NBCS (2% 
NBCS GMEM) at a ratio of 10:3 was used to overlay the cells. The cells were 
incubated for 2-3 days and then fixed by covering the agar with 10 % 
paraformaldehyde (PFA) (Surgipath) for 1 hour. The PFA and the agar were 
removed and the monolayer was stained with approximately 1 ml of 0.1% toludine 
blue. The plates were placed on the rocker for 30 minutes and then rinsed with tap 
water. Round areas of dead cells unstained by the dye were considered to be plaques. 
Plaques were counted and the titre of the virus stock determined using the following 
formula: 
Virus titre in plaque forming units (PFU) per ml = average number of plaques in two 
wells / amount of inoculum x dilution factor  
In experiments analysing plaque phenotype the BHK-21 cells were replaced 
by other cell lines. The rest of the experimental procedure was identical.  
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2.2.10 Titration of VRPs  
The standard plaque assay could not be used to titrate VRPs because VRPs do not 
produce progeny virus after infection and therefore plaques of dead cells are not 
formed. Instead, virus infection was visualised by immunostaining. In some cases, 
the VRP expressed its own marker gene, e.g. ZsGreen and could be visualised 
directly. BHK-21 cells were seeded on 20 x 20 mm glass coverslips (Menzel Glaser) 
in 6-well plates at a concentration of 3x105 cells per well and incubated overnight. 
Next day, a 10-fold serial dilution of the VRP was prepared in PBSA. The medium 
was removed from the wells and 400 µl of each dilution was added to two wells of 
the 6-well plate). The cells were incubated for 1 hour at room temperature with 
gentle rotation. After incubation, the PBSA was replaced by 2 ml of medium and the 
cells were incubated for 20 h. The cells were fixed with PFA for 1 hour and then 
immunostained as described in section 2.3.1 or viewed immediately, if cells 
expressed a marker gene. The coverslips were mounted using Vectashield Aqueous 
Mounting Medium (Vector Laboratories), dried for 30 minutes at room temperature 
and the edges of the coverslip sealed with nail varnish. The results were viewed 
using a Zeiss Axioskop 2 microscope. Fifteen fields were examined for presence of 
virus, indicated by red fluorescent immunostaining for SFV non-structural protein 3. 
The average number of infected cells was calculated and this was used to find the 
titre of the VRP using the following formula:  
VRP concentration per ml = Mean number of VRPs x microscope constant / volume 
of inoculum. 
Throughout this project the MOI was calculated based on the titre of the virus 
or the VRP in BHK-21 cells.  
 
2.3 Immunostaining 
2.3.1 Detection of target by immunofluorescence 
The antibodies used in this project and the corresponding dilutions are listed in Table 
2.3. Cells were seeded on 20 x 20 mm glass coverslips in 6-well plates at a density of 
3x105 cells per well overnight. The cells were infected, incubated and fixed using 
PFA for 1 hour at room temperature as described above in section 2.2.9. The PFA 
was removed and the cells were washed with PBS (3 x 5 minutes). The PBS was 
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replaced with 2 ml of PBS with 0.3% Triton-X100 and the cells were placed on the 
rocker for 20 minutes at room temperature to permeabilise the cell membranes. The 
cells were washed with PBS (3 x 5 minutes) and covered with 700 µl of Cas-block 
(Zymed) for 20 minutes at room temperature. The Cas-block was replaced with 700 
µl of the primary antibody diluted in Cas-block and incubated for 2 h at room 
temperature. The cells were washed with PBS (3 x 10 minutes), covered with 700 µl 
of the secondary antibody diluted in Cas-block and incubated for 1 hour at room 
temperature. The cells were washed again with PBS (3 x 10 minutes), covered with 
700 µl of the tertiary antibody diluted in distilled water and incubated for 45 minutes 
in darkened conditions. The cells were washed with PBS (3 x 10 minutes), then 
rinsed with distilled water and mounted using Vectashield Aqueous Mounting 
Medium. On certain occasions, the Vectamount contained 4’, 6-diamidino-2-
phenylindole (DapI) that stains DNA. Results were viewed using the Zeiss AxioSkop 
2 microscope or a Zeiss AxioObserver D1 microscope with Colibri filters for the 
visualisation of eGFP, ZsGreen, Alexa Fluor 594 (red) and DapI. For visualisation 
using confocal microscopy, the cell nuclei were stained using To-Pro-3 (Invitrogen) 
diluted 1 in 10 with water and incubated for 10 minutes at room temperature. The 
coverslips were then mounted using Vectashield Aqueous Mounting Medium and the 
results were viewed using a Zeiss-LSMpascal microscope with lasers suitable for 
viewing eGFP, ZsGreen, Alexa Fluor 594 (red) and To-Pro-3 (blue). 
 
2.3.2 Detection of target by 3,3’-Diaminobenzide 
SIGMAFAST 3,3’-Diaminobenzide (Dab) tablets were used to detect peroxidise 
activity. Immunostaining using Dab was carried out in the same way as 
immunostaining using fluorescent antibodies. However, the tertiary antibody was 
replaced with 1 ml of the Dab mix (1 Dab tablet and 1 Urea tablet dissolved in 5 ml 
of distilled water) and incubated for 5 minutes at room temperature under darkened 
conditions. Slides were washed with water and mounted using VectaMount  Aqueous 
Mounting Medium. Results were visualised using the Zeiss Axioskop 2 microscope 
with brightfield settings.  
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Table 2.3: List of antibodies used for immunostaining 
* Reagent kindly provided by Dr. Tero Ahola, University of Helsinki, Finland. 
**Reagent kindly supplied by Prof. Andres Merits, Institute of Technology, 
University of Tartu, Estonia.  
Target Source Host Isotype Feature Dilution Incubation 
time 




- 1 in 800 2 h 
SFV nsP1 Andres 
Merits** 






Rabbit Polyclonal - 1 in 800 2 h 
dsRNA Scicons Mouse Monoclonal 
IgG1 
- 1 in 500 2 h 




Biotinylated 1 in 750 1 hour 
Mouse IgG  Sheep Monoclonal 
IgG 
Biotinylated 1 in 750 1 hour 
Rabbit IgG Sigma Goat Monoclonal 
 
Peroxidase 1 in 750 1 hour 
SA Alexa 
Fluor 594 
Invitrogen Goat Monoclonal 
IgG 




2.4 Interferon bioassay 
2.4.1 Infection of cells for the interferon bioassay 
Cells were seeded in four wells of a 6-well plate at 3x105 cells per well and 
incubated for 24 h or until 100 % confluent. The supernatant was removed from the 
wells and the cells were infected with virus at MOI 5 in 400 µl of PBSA. After 1 
hour the PBSA was replaced with 1 ml of 2 % FCS DMEM and incubated for 24 h. 
After incubation, the supernatant from the four wells was combined and centrifuged 
at 478 g for 5 minutes to remove any cell debris. 2 ml of the supernatant was 
collected for plaque assay and 2 ml was collected for the IFN bioassay.  
 
2.4.2 Preparation of samples for the interferon bioassay 
UV light was used to inactivate virus in the supernatant as follows. The supernatant 
was divided equally between four wells of a 24-well plate and placed in the 
Stratalinker 1800 UV cross linker. The plate was placed 5 cm from the UV light bulb 
with the lid removed and exposed to UV light for 30 minutes. To determine if the 
virus was inactivated, a plaque assay was subsequently carried out on BHK-21 cells 
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using an aliquot of the supernatant. The remaining supernatant was stored at -80oC 
until used. 
 
2.4.3 Mouse interferon bioassay 
The mouse IFN bioassay was used to measure the amount of IFN in the supernatant. 
In a 96-well plate, 2x104 L929 cells were seeded per well in 0.1 ml of 10 % FCS 
DMEM and incubated for 24 h. In a separate 96-well plate, 2-fold serial dilutions of 
the supernatant samples were prepared (Fig. 2.2). To each well in column 1, 200 µl 
of neat sample was added. To each well in column 2 – 12 100 µl of 2 % FCS DMEM 
was added. A 2-fold serial dilution was created by transferring 100 µl of column 1 to 
column 2 and repeating this across the plate. All samples were run in duplicate to 
control for experimental error. 
On one plate, a negative control (cells with medium only) was included in 
three wells of row H and a positive control (cells with challenge virus SFV A7(74)) 
were also included. A mouse IFN international standard (Stratech Scientific Ltd) was 
included on one plate to allow quantification of IFN. For the international standard, 
90 µl of 2 % FCS DMEM was added to row A. To well A1, 10 µl of the mouse IFN 
international standard was added giving a final concentration of 100 U/ml. A 10-fold 
serial dilution was created by adding 10 µl of well A1 to well A2 and repeating this 
across the plate.  
The medium on the L929 cells was replaced with the prepared dilutions and 
then incubated for a further 24 h. After incubation, the dilutions were removed and 
replaced with 100 µl of the challenge virus suspension containing SFV A7(74) 
diluted in 2 % FCS DMEM at MOI 0.1. The negative control wells were replaced 
with fresh medium instead of the challenge virus suspension.  
The cells were incubated until complete CPE was observed in the positive 
control, which was normally after 48 h. The cells were fixed by adding 100 µl of 
PFA for 1 hour and stained by removing the PFA and adding 100 µl of 0.1 % 
toludine blue. The plates were placed on a rocker for 30 minutes and then washed 
with water. The endpoint was determined as the dilution which protected 50 % of the 
monolayer.  
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To determine the amount of IFN within a sample, the endpoint of the IFN 
standard was determined and the concentration of IFN at this dilution was calculated. 
This concentration was the amount of IFN required to protect 50 % of the cell 
monolayer from virus challenge in this experiment. For each dilution series, the 
concentration of IFN at the endpoint, as determined by the international standard, 
was multiplied by the dilution factor protecting 50 % of the monolayer to calculate 
the amount of IFN per ml of the test sample. 
 
2.4.4 Human interferon bioassay 
The human IFN bioassay was carried out in the same way as the mouse IFN bioassay 
with some modifications. The mouse L929 cells were replaced with human A549-
NPro cells. These were grown in 10 % FCS DMEM supplemented with Puromycin. 
A human international IFN standard (NIBSC) was used instead of the mouse 
standard. The virus challenge suspension contained EMCV at MOI 0.1 in 2 % FCS 
DMEM instead of SFV A7(74). 100 µl of the suspension was added to each well and 
the cells were incubated until complete CPE was observed in the positive control, 
usually after 24 h.  
Figure 2.2: IFN bioassay plate design 
The numbers in the wells indicate the reciprocal dilution of the two-fold serial 
dilution. Samples were run in duplicate such that rows A and B contained the same 
sample. NC indicates the negative control and PC indicates the positive control, 
which were included on one plate in each experiment. Where standards were 
included on a plate, one sample was replaced with the 100 U/ml of the International 
IFN standard diluted 1 in 10 across the plate.  
 
2.5 Interferon sensitivity assay 
The IFN sensitivity assay was used to measure the effect of IFN pre-treatment on 
SFV replication. In a 96-well plate, 2x104 2fTGH, Hs 633T, L929 or NIH 3T3 cells 
 1 2 3 4 5 6 7 8 9 10 11 12 
A  1 2 4 8 16 32 64 128 256 512 1024 2048 
B  1 2 4 8 16 32 64 128 256 512 1024 2048 
C  1 2 4 8 16 32 64 128 256 512 1024 2048 
D  1 2 4 8 16 32 64 128 256 512 1024 2048 
E  1 2 4 8 16 32 64 128 256 512 1024 2048 
F  1 2 4 8 16 32 64 128 256 512 1024 2048 
G                         
H  NC NC NC           PC PC PC 
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were seeded per well in 0.1 ml of 10 % FCS DMEM and incubated for 24 h. 
Following incubation, the media was replaced with 10 U/ml of human IFN or mouse 
IFN in 100 µl of 10% FCS DMEM and incubated for 16 h. Following incubation, the 
IFN mixture was replaced with virus in 30 µl of PBSA at MOI 5. Three wells were 
included as a mock infected control and were treated with 30 µl of PBSA. Cells were 
incubated for 1 hour at 37oC and then 100 µl of 2% FCS DMEM was added to each 
well. At the desired time post-infection, the cells were analysed for fluorescence or 
the supernatant was collected for measuring virus titre by plaque assay (2.2.9). 
 
2.6 Western Blot 
2.6.1 Sample preparation for sodium dodecyl sulphate – 
polyacrylamide gel electrophoresis (SDS-PAGE) 
The lysis buffer consisted of 20 mM Tris-HCl (pH 8), 137 mM NaCl (Sigma), 10% 
glycerol (Sigma), 1 % Nonidet-P40 (Fluka) and 2 mM EDTA (Sigma) plus 1X 
phosphatase inhibitor cocktail (Calbiochem) and 1X Halt Protease Inhibitor Cocktail 
(Thermo Scientific). Cells in one well of a 6-well plate were lysed by removing the 
medium from the well, adding 300 µl of lysis buffer and incubating on ice for 20 
minutes with continuous rotation. Following incubation, 100 µl of the mixture was 
collected for measuring protein concentration and 200 µl was collected for SDS-
PAGE. The sample for SDS–PAGE was mixed with 200 µl of Laemmli buffer (950 
µl of Laemmli buffer (Bio-Rad) mixed with 50 µl of β-mercaptoethanol (Sigma)) 
and boiled for 10 minutes at 100oC. The samples were stored at -20oC until required.  
 
2.6.2 Measurement of protein concentration 
Protein concentration in the lysed samples was measured using the Pierce BCA 
Protein Assay Kit (Thermo Scientific) according to the manufacturer’s instructions. 
Following the microplate protocol, the working reagent was prepared, which 
contained 50 parts of reagent A mixed with 1 part of reagent B to give 200 µl per 
well. The BSA standard was diluted following the manufacturer’s instructions. Into 
wells of a 96-well plate, 25 µl aliquots of the standard or the samples were added in 
duplicate, 200 µl of the working reagent was added to each well and mixed. The 
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plate was incubated for 30 minutes at 37oC and protein concentration was measured 
spectrophotometrically at 750 nm. 
 
2.6.3 SDS-PAGE preparation 
A 12 % gel consisted of two parts: a resolving gel and a stacking gel. The resolving 
gel was made with 30 ml of 40 % acrylamide (Sigma), 25 ml 1.5M Tris-Base pH8.8 
(Sigma), 1 ml of 10 % sodium dodecyl sulphate (SDS) (Sigma) and 43 ml of distilled 
water. Just before use, 10 µl of tetramethylethylenediamine (TEMED, Sigma) and 
100 µl of ammonium persulphate (APS, Sigma) were added to 10 ml of the resolving 
gel solution and it was poured between two glass plates. A space of approximately 2 
cm was left at the top of the gel and this was filled with isobutanol (Sigma) to level 
the gel. The stacking gel was made with 10 ml of 40 % acrylamide, 25 ml of 0.5 M 
Tris-Base pH 6.8 (Sigma), 1 ml of 10 % SDS and 64 ml of distilled water. Just 
before use, 5 µl of TEMED and 50 µl APS were added to 5 ml of the stacking gel 
solution. Once the resolving gel had set, the isobutanol was removed and the stacking 
gel was added. A 0.75 mm comb was immediately inserted into the stacking gel to 
create the lanes. The gel was left until solid and then used. 
 
2.6.4 SDS-PAGE and protein transfer 
The 12 % gel was placed into an electrophoresis tank and the tank was filled with 1 
X running buffer. The 5X running buffer contained 15.1 g of Tris-Base (Sigma), 94 g 
of glycine (Sigma) dissolved in 900 ml of distilled water and made up to 1000 ml 
with 10 % SDS. This was diluted to 1X with distilled water for use. The samples in 
Laemmli buffer (2.6.1) were thawed and aliquots of each sample containing 200 µg 
of protein were loaded into separate wells. The first well contained 10 µl of 
Hyperpage Pre-strained Protein Marker (Bioline). The SDS gel was run at 140 V 
until the blue dye band reached the bottom of the gel. The gel was removed from 
between the glass plates and the stacking gel was discarded. Hybond ECL 
nitrocellulose paper (GE Healthcare), extra thick Western blot filter paper (Thermo 
Scientific) and sponges were soaked in transfer buffer before use. The transfer buffer 
comprised 3.03 g Tris-Base (Sigma), 14.4 g of glycine (Sigma), 200 ml of methanol 
(Sigma) and 800 ml of distilled water. The transfer cassette was opened and a sponge 
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placed on the bottom followed by one piece of filter paper, the gel, the Hybond ECL 
nitrocellulose paper and another piece of filter paper. The cassette was rolled to 
remove any air bubbles and a wet sponge was added on top. The cassette was closed 
and placed into the electrophoresis tank in the orientation that would allow the 
proteins to transfer from the gel onto the Hybond ECL nitrocellulose paper. An ice 
pack was added to the tank and the tank was filled with transfer buffer. The 
electricity was turned on at 30 V for 30 minutes followed by 60 V for 60 minutes. 
The nitrocellulose paper was removed from the cassette and placed in PBS with 0.1 
% Tween-20 (Sigma) (PBS-T), until probed.   
 
2.6.5 Detection of cellular proteins using antibodies (Western 
blot) 
The nitrocellulose paper was probed using the antibodies shown in Table 2.4. The 
primary antibodies were diluted in blocking buffer (0.3 g blocking powder (GE 
Healthcare) in 5 ml of PBS-T) and incubated for the time shown in Table 2.4. After 
incubation, the nitrocellulose paper was washed with PBS-T (3 x 5 minutes), 
immersed in blocking solution containing the secondary antibody for 1–3 h at room 
temperature and then re-washed with PBS-T (3 x 5 minutes). To detect the secondary 
antibody, the ECL Advance Western Blotting Detection Kit (Amersham) or the 
Pierce Fast Western Blot kit ECL substrate (Thermo Scientific) were used. The ECL 
kit was used with blots for phosphorylated STAT1 and the Pierce kit was used with 
blots for total STAT1 or β-actin. To use either kit, the nitrocellulose paper was 
immersed in 1 ml of reagent 1 or A mixed with 1 ml of reagent 2 or B for 5 minutes. 
After the incubation the bands were visualised using the G:Box Imaging System.  
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Table 2.4: List of antibodies used for Western blot 
Target Source Host Isotype Dilution Incubation 
time 
Temp. 
Human STAT1 Cell 
signaling 






Rabbit Polyclonal 1 in 500 24 h 4oC 
Human β-actin Cell 
signaling 
Rabbit Polyclonal 1 in 750 1 hour Room 
temp. 





1 – 3 h Room 
temp. 
 
2.6.6 Quantification of Western blot bands 
To quantify protein bands detected by Western blot, ImageJ 
(http://rsbweb.nih.gov/ij/) was used. ImageJ enabled the quantification of the bands 
detected relative to β-actin bands.  
 
2.7 Cell viability assay 
Cell viability was measured using the Wst-1 assay (Roche), according to the 
manufacturer’s instructions. The Wst-1 assay measures mitochondrial activity by 
providing formazan dye that the mitochondrial dehydrogenases cleave to produce a 
product that can be measured spectrophotometrically. 96-well plates were seeded 
with cells at a density of 9000 cells per well and the experiment carried out. At the 
termination of the experiment, 10 µl of Wst-1 was added to each well containing 100 
µl of media. Plates were incubated for 1 hour and measured the optical density at 450 
nm using the Promega GloMax Multi-Detection System.  
 
2.8 Cell transfection 
2.8.1 Cell transfection using Lipofectamine 2000 
Cells were seeded in 24 or 96-well plates at a concentration of 7x104 or 3x105 cells 
per well respectively and incubated overnight. In a polystyrene tube, 1 µl of 
Lipofectamine 2000 (Invitrogen) per well was mixed with 50 µl of Optimem 
(Invitrogen) and incubated at room temperature for 5 minutes. In a separate tube, the 
plasmid or RNA to be transfected was mixed with Optimem to give a final volume of 
Chapter 2  Materials and Methods 
75 
 
50 µl per well. The total volume of the plasmid/siRNA mix was transferred to the 
tube containing the Lipofectamine 2000 mix and incubated at room temperature for 
20 minutes. During this time, the medium in the wells was replaced with fresh 2 % 
FCS DMEM (900 µl per well of a 6-well plate and 400 µl per well of a 24-well 
plate). 100 µl of the Lipofectamine 2000 mix was then added to each well and the 
plates were incubated. After 5 h, the transfection mix was replaced with fresh 
medium and the cells were incubated for a further 24 – 48 h. 
In certain experiments cells were seeded and transfected simultaneously. 
Briefly, the Lipofectamine 2000, Optimem and siRNA mix was prepared and 
incubated for 20 minutes. During the incubation, a 175 cm2 flask of cells was 
trypsinised, counted, centrifuged again and re-suspended in medium to produce the 
desired number of cells for seeding. The cells were seeded into 24-well plates or 6-
well plates and 100 µl of the Lipofectamine 2000 mix was added to each well. Cells 
were incubated for 24 – 48 h. 
 
2.8.2 Dual-Glo Luciferase Assay 
The Dual-Glo Luciferase Assay (Promega) was used to measure both firefly and 
Renilla luciferase. The lysis buffer was comprised of passive lysis buffer diluted 1 in 
5 with distilled water. The cells to be assayed were lysed by removing the medium in 
a 24-well plate, adding 100 µl of diluted lysis buffer and placing on a fast rocker 
until the cells detached. 30 µl from each well was then aliquotted into a white plastic 
96-well plate suitable for the Promega GloMax Multi-Detection System. 70 µl per 
well of luciferase assay reagent was placed in a universal container. To a separate 
universal container 70 µl per well of stop-glo was added (diluted 1 in 50 in distilled 
water). An additional 900 µl of both the luciferase reagent and the stop-glo reagent 
were added to prime the detection system. Firefly and Renilla luciferase were 
measured using the Dual-Luciferase two injector programme in the Promega 
GloMax Multi-Detection System.  
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2.9 Polymerase Chain Reaction 
2.9.1 RNA extraction 
RNA extraction was carried out using the RNeasy Kit (Qiagen) according to the 
manufacturer’s instructions. The cells in 4 wells of a 6-well plate were lysed by 
removing the medium and adding 600 µl of RLT buffer containing 1 % β-
mercaptoethanol. The cell lysate was homogenised by passing it through a 20-gauge 
needle five times. The lysate was collected, 70 µl of 70 % ethanol was added and the 
lysate was transferred to an RNeasy spin column. The column was centrifuged at 
8,000 g for 15 seconds and the flow-through discarded. 350 µl of buffer RW1 was 
added to the column, the centrifugation was repeated and the flow-through discarded. 
80 µl of DNase I stock in buffer RDD (10 µl and 70 µl respectively) was added to 
the filter and incubated at room temperature for 15 minutes to remove any residual 
DNases. The filter was washed with 350 µl of buffer RW1, centrifuged at 8,000 g for 
15 seconds and the flow-through discarded. To remove any residual ethanol that 
would affect purity of the RNA the filter was washed with 500 µl of buffer RPE, 
centrifuged at 8,000 g for 15 seconds and the flow-through discarded. An additional 
200 µl of buffer RPE wash was added, centrifuged at 8,000 g for 2 minutes and the 
flow-through discarded. RNA was eluted into a 1.5 ml collection tube by adding 30 
µl οf RNase-free water and centrifuging at 8,000 g for 1 minute. The RNA 
concentration was measured using a NanoDrop Spectrophotometer. The RNA was 
then stored at -80oC until use. 
 
2.9.2 Reverse transcription PCR 
Reverse transcription PCR converted RNA into cDNA. Five µg of total RNA was 
combined with 1 µl of 50 µM oligo(dT)15 (Promega), 1 µl of 10 mM dNTP Mix 
(Promega) and made up to 13 µl with RNase-free water. The RNA mix was 
incubated at 65oC for 5 minutes and placed on ice for 1 minute. The cDNA synthesis 
mix was prepared with 4 µl of 10X RT buffer (Invitrogen), 1 µl of 0.1 M DTT 
(Invitrogen), 1 µl of RNasein Ribonuclease Inhibitor (Promega) and 1 µl of 
SuperScript III (Invitrogen) and 7 µl of this was added to each RNA reaction. The 
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total RNA was incubated at 50oC for 1 hour, inactivated by heating at 70oC for 15 
minutes and stored at -20oC until use. 
 
2.9.3 Polymerase Chain Reaction 
Several Polymerase Chain Reaction (PCR) programmes were used in this project. 
The primer sets and the corresponding annealing temperatures are shown below. The 
reactions used either Taq polymerase (Promega) or Vent DNA Polymerase (New 
England Biolabs). The PCR reaction mix for Taq polymerase contained 5 µl of 10X 
PCR buffer with MgCl2 (Promega), 1 µl of 10 mM dNTP Mix (Promega), 1 µl of the 
forward primer (50 pM, Sigma), 1 µl of the reverse primer (50 pM, Sigma), 
nuclease-free water, DNA and 0.4 µl of Taq polymerase. In PCR reactions using 
Vent DNA Polymerase, the 10X PCR buffer was replaced with Thermo Pol reaction 
Buffer (New England Biolabs) and the Taq polymerase was replaced with Vent DNA 
Polymerase (New England Biolabs). The results were checked by agarose gel 
electrophoresis (2.2.6). 
nsP2 
The PCR was carried out using Vent DNA Polymerase 
95oC 5 minutes, (95oC 1 minute, 56oC 2 minutes, 72oC 4 minutes) x 30, 72oC 8 
minutes. The primers used were: 
For 5’ GAGGCCGAGCTGACTAGAGA; Rev 5’ TCATTGAGCAACTCCACAGC 
nsP3 
The PCR was carried out using Vent DNA Polymerase 
95oC 5 minutes, (95oC 1 minute, 56oC 2 minutes, 72oC 4 minutes) x 30, 72oC 8 
minutes. The primers used were: 
For 5’ AGGGTCACTTGGTTGTCACC; Rev 5’ TACATCGGGGCTTGAGAATC 
β-actin (human) 
The PCR was carried out using Taq polymerase. 
95oC 5 minutes, (95oC 30 seconds 56oC 20 seconds, 72oC 30 seconds) x 30, 72oC 15 
minutes. 
For 5’ AGAAAATCTGGCACCACACC; Rev 5’ 
AACGGCAGAAGAGAGAACCA 
Beclin-1 (human) 
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The PCR was carried out using Taq polymerase. 
95oC 5 minutes, (95oC 30 seconds 56oC 20 seconds, 72oC 30 seconds) x 28, 72oC 15 
minutes. The primers used were: 
For 5’ GAGTGCTAGGAGGGCAACAG; Rev 5’ TTTCATATCCGGCCACTCTC 
 
2.10 Autophagy assays 
2.10.1 Assay to determine autophagic cells 
Cells were seeded on glass coverslips with a 13 mm diameter in 24-well plates at a 
density of 7x104 cells per well overnight. The cells were transfected with 0.5 µg of 
GFP-LC3 plasmid (AddGene) per well using Lipofectamine 2000, according to the 
manufacturer’s instructions (Section 2.7.1). LC3 in this plasmid was produced from 
the gene MAP1LC3B, which is also known as ATG8F, LC3B, MAP1A/1BLC3, 
MAP1LC3B-a. 24 h later, the cells were treated with chemicals (2.10.2), virus/VRPs 
or PBSA alone and then fixed with PFA. The coverslips were washed with water, 
mounted using Vectamount Aqueous Mounting Medium containing DapI and then 
viewed using the Zeiss Axioskop 2 microscope. Fifteen fields were examined for 
autophagic cells. An autophagic cell was defined as transfected cells expressing two 
or more eGFP foci (puncta). The average percentage of autophagic cells in the cell 
monolayer was calculated using the following formula:  
Mean number of autophagic cells (%) = mean number of autophagic cells / total 
number of transfected cells x 100 
 
2.10.2 Chemical activation or inhibition of autophagy 
Cells were seeded in 24-well plates and transfected with the GFP-LC3 plasmid. To 
induce autophagy, the medium was removed from the wells and replaced with 500 µl 
of 2 µM of rapamycin (Sigma) diluted in 10% FCS DMEM for 3 h. To inhibit 
autophagy, the medium was removed from the wells and replaced with 500 µl of 10 
mM of 3-methyladenine (Sigma) diluted in 10% FCS DMEM for 3 h.  
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2.11 DNA transformation and amplification using bacteria 
2.11.1 Preparation of agar plates 
SURE 2 Supercompetent bacteria cells (Stratagene) or chemically competent 
Escherichia coli strain DH5α cells (Promega) were grown on Luria-Bertani (LB) 
agar plates or Soya agar plates. LB plates were prepared by mixing 7.5 g agar with 
500 ml LB and then autoclaving.  Ampicillin or kanamycin was added to give a final 
concentration of 100 µg/ml and the liquid was poured into 10 cm diameter petri 
dishes. The antibiotic selected depended on the resistance gene encoded by the 
plasmid. Soya broth plates were prepared by mixing 15 g soya broth (Oxoid) with 
7.5 g agar and 500 ml LB. The soya broth was autoclaved, ampicillin or kanamycin 
was added (final concentration 50 µg/ml) and the liquid was poured into petri dishes. 
The plates were stored at -20oC until use. 
 
2.11.2 Bacterial cell transformation  
Bacterial cell transformation was carried out using SURE 2 Supercompetent bacteria 
cells (Stratagene) or chemically competent Escherichia coli strain DH5α cells 
(Promega), according to the manufacturer’s instructions. Cells were thawed on ice 
and 100 µl was added to a fresh tube. The SURE 2 Supercompetent bacteria cells 
were mixed with 2 µl of β-mercaptoethanol and incubated on ice for 10 minutes with 
swirling every 2 minutes. After incubation, 1 µl of plasmid DNA (0.1 – 50 ng) was 
added to the cells and placed on ice for 30 minutes. The cells were then heat-shocked 
for approximately 30 seconds in a 42oC water bath, then immediately chilled on ice 
for 2 minutes to induce plasmid uptake. 900 µl of pre-warmed SOC media 
(Invitrogen) was added to the cells and the suspension was incubated at 37oC with 
shaking at 225-250 rpm. One hour later, a 50 µl or 100 µl volume of the cell 
suspension was added to the LB or Soya plates and incubated for 16 h at 37oC. The 
plates used depended on the plasmid to be amplified. Cells transformed with the 
plasmid were resistant to the antibiotic and formed colonies on the surface of the 
agar. These colonies were amplified by Miniprep (2.11.3) or Maxiprep (2.11.4). 




2.11.3 Miniprep  
DNA plasmids were amplified on a small scale using the QIAprep Miniprep kit 
(Qiagen), according to the manufacturer’s instructions. One colony of transformed 
cells was selected and added to 5 ml of LB broth supplemented with ampicillin or 
kanamycin (100 µg/ml). Alternatively, the colony was added to 5 ml of Soya broth 
supplemented with ampicillin or kanamycin (50 µg/ml). The broths were incubated 
at 37oC with shaking at 225-250 rpm. After 16 h, the broths were centrifuged at 
6,800 g for 5 min at room temperature to pellet the cells. Each pellet was re-
suspended in 250 µl of chilled buffer P1, lysed using 250 µl of buffer P2 and 
neutralised with 350 µl of buffer N3. The cell lysate was centrifuged at 17,900 g for 
10 min and the supernatant that contained the DNA was transferred to a QIAprep 
spin column. The spin column was centrifuged at 17,900 g for 1 minute and the flow-
through discarded. The filter was washed by adding 500 µl buffer PB, centrifuging at 
17,900 g for 1 minute and discarding the flow-through. The wash was repeated with 
750 µl of buffer PE. The filter was dried by centrifuging at 17,900 g for 1 minute. To 
elute the DNA 50 µl of buffer EB was added to the filter for 1 minute and 
centrifuged at 17,900 g for 1 minute. The concentration of the DNA was measured 
using a NanoDrop Spectrophotometer and the DNA was stored at -20oC. 
 
2.11.4 Maxiprep 
To amplify large quantities of plasmid DNA, the EndoFree Plasmid Purification kit 
(Qiagen) was used according to the manufacturer’s instructions. One colony of 
transformed bacteria was selected and added to a 5 ml starter culture containing LB 
broth with 100 µg/ml ampicillin or kanamycin. Alternatively, the colony was added 
to a 5 ml starter culture containing Soya broth with 50 µg/ml ampicillin or 
kanamycin. The broth was incubated at 37oC for 6-8 h with shaking at 225-250 rpm. 
After incubation, 100 µl of starter culture was added to a 2 L conical flask containing 
200 ml of LB or Soya broth supplemented with ampicillin or kanamycin. The 
antibiotics were added to the LB to give a final concentration of 100 µg/ml and to 
soya broth to give a final concentration of 50 µg/ml. The broth was incubated for 16 
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h at 37oC with shaking at 225 – 250 rpm. After incubation, the cells were pelleted by 
centrifuging at 6,000 g for 15 min at 4oC. The pellet was re-suspended in 10 ml of 
chilled buffer P1 and lysed by adding 10 ml of buffer P2 for 5 min at room 
temperature. The buffer was neutralised by adding 10 ml of chilled buffer P3 and the 
lysate was poured into the QIAfilter Maxi Cartridge. The cartridge was incubated for 
10 minutes at room temperature to allow the cell debris to settle at the top of the 
cartridge and the lysate at the bottom. The lysate was pushed through into a 50 ml 
centrifuge tube (Falcon), 2.5 ml of buffer ER was added and the lysate was incubated 
on ice for 30 minutes. During this time the QIAGEN-tip 500 was equilibrated by 
allowing 10 ml of buffer QBT to flow through. The lysate was poured into the 
QIAGEN-tip 500 and allowed to flow through. The filter was washed twice with 60 
ml of buffer QC and the DNA was then eluted into a fresh 50ml centrifuge tube by 
adding 15 ml of buffer QN. 10.5 ml of isopropanol was added to precipitate the DNA 
and the tube was centrifuged at 15,000 g for 10 min. The DNA pellet was washed 
with 5 ml of 70% ethanol and centrifuged at 15,000 g for 10 min to remove all traces 
of isopropanol. The ethanol was carefully removed and the pellet was air-dried. 300 
µl of endotoxin free buffer TE was added to resuspend the pellet. The concentration 
of the plasmid DNA was measured using the NanoDrop Spectrophotometer and the 
DNA was then stored at -20oC 
 
2.12 Statistical analysis 
All statistical analysis was carried out using Microsoft Excel or Graphpad Prism. 
Viral titre, IFN production and autophagy activation were analysed with the non-
parametric Mann-Whitney test. 
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2.13 Sequencing  
2.13.1 Standard PCR Sequencing  
DNA sequencing was performed using specific primers by DNA Sequencing & 
Services (MRCPPU, College of Life Sciences, University of Dundee, 
Scotland, www.dnaseq.co.uk) using Applied Biosystems Big-Dye Ver 3.1 chemistry 
on an Applied Biosystems model 3730 automated capillary DNA sequencer. The 
primers used in this project are shown below: 
nsP2 set 1 
For 5’: GAGGCCGAGCTGACTAGAGA 
Rev 5’: GGTCTCCGCATAACACCACT 
nsP2 set 2 
For 5’: CCGACGAGGAGAACTACGAG 
Rev 5’: CGTTTTCCACACCAGCCTAT 
nsP2 set 3 
For 5’: CGGAGCACGTGAATGTACTG 
Rev 5’: TTATCGGCGTATCCGTAAGC 
nsP2 set 4 
For 5’: AGGGTCACTTGGTTGTCACC 
Rev 5’: TCATTGAGCAACTCCACAGC 
nsP3 set 1 
For 5’: AGGGTCACTTGGTTGTCACC 
Rev 5’: TCATTGAGCAACTCCACAGC 
nsP3 set 2 
For 5’: CTGTCACTGAGCAGCGTAGC 
Rev 5’: GTTCTCGAGGTCCACATGGT 
nsP3 set 3 
For 5’: TGCGAGAAGGTTCTCCTGTT 
Rev 5’: TACATCGGGGCTTGAGAATC 
The results were returned as sequence files. These were aligned using the programme 
APE (http://biologylabs.utah.edu/jorgensen/wayned/ape/) to determine the final 
sequence. 




2.13.2 Solexa (Illumina) sequencing 
Solexa (Illumina) sequencing was carried out to determine the complete genome 
sequence of SFV L10 and SFV A7(74) as follows. 
 
Sample preparation for Solexa (Illumina) sequencing 
In 6-well plates, NIH 3T3 cells were seeded at a density of 3x105 cells per well in 10 
% FCS DMEM and incubated overnight. The cells were infected with SFV L10 or 
SFV A7(74) at MOI 10 in 400 µl of PBSA for 1 hour at room temperature. A high 
MOI was used to ensure that all cells were infected. After incubation, the PBSA was 
replaced with 2 ml of 2 % FCS DMEM. The plates were incubated for 8 h and then 
the total RNA was extracted using the RNeasy kit (Qiagen), according to the 
manufacturer’s instructions. 
RNA integrity and concentration were measured by the RNA 6000 Nano 
Assay (Agilent Technologies). 10 µg of RNA was sent to ArkGenomics, Roslin 
Institute, Edinburgh for Solexa (Illumina) sequencing. 
 
Solexa Genome Analyzer (Illumina) sequencing  
Solexa (Illumina) sequencing was carried out by Sarah Smith at ArkGenomics, the 
Roslin Institute, Edinburgh. Illumina kits were used to make the DNA, according to 
the manufacturer’s instructions and the DNA was run on the Solexa Illumina 
machine with RTA Software 1.5 and Pipeline Software 1.6 to give 36 reads and to 
generate raw intensity files. The sequence tag preparation was carried out using the 
Illumina's Digital Gene Expression Tag Profiling Kit, according to the 
manufacturer's protocol, to purify cDNA tags. The cDNA tags were sequenced on 
the Illumina Cluster Station and Genome Analyzer. Image recognition and base 
calling were performed using the Illumina Pipeline. 
 
Image analysis and De Novo alignment 
Image analysis and de novo alignment was carried out by Mark Fell at 
ArkGenomics, the Roslin Institute, Edinburgh. Briefly, the raw intensity files 
generated by the Solexa Genome Analyzer were input into ‘Firecrest’. This 
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generated image data in txt form. This data was put into the program ‘Bustard’ which 
determined the sequence and quality of the data. The data was then run through the 
program ‘Velvet’ to generate high quality contigs. These contigs were run through 
the programs ‘Generation of Recursive Analysis Linked by Dependency’ and ‘SGA’ 
as further quality controls. The final contigs generated were of high quality and could 
be analysed with confidence. 
 
Comparative sequence alignment 
Comparative sequence alignment was carried out by Dr. Karen Sherwood, Roslin 
Institute, University of Edinburgh.  The contigs were aligned to previously described 
SFV sequences (reference strains) using ‘FASTA’. The reference strains used in this 
project are listed in Table 2.5. The sequences generated by Solexa (Illumina) 
sequencing were called ARKL10 (SFV L10) or ARKA774 (SFV A7(74)). 
 
Table 2.5: Reference strains of SFV used in this project 
Accession number/code name Strain of SFV Source 
AY112987; L10-IRE L10 Logue et al, submitted to 
NCBI in 2002, unpublished 
A774-FIN A7(74) Supplied by Dr. A. Hinkkanen 
Turku Immunology Centre, 
Finland. Strain was used in 
Tuittila et al (2000) and 
Tuittila & Hinkkanen (2003). 
SFV4-EST SFV4 Provided by Prof. A. Merits, 
Institute of Technology, 
University of Tartu, Estonia. 
 
Comparative sequence analysis 
Comparative sequence analysis was carried out using Jalview 2.7 (Waterhouse et al., 
2009). Evolutionary divergence between sequences at the nucleotide and the amino 
acid level was determined using MEGA 5 (www.megasoftware.net/megalinux.php). 
 
2.14 Protein structure prediction 
Three dimensional (3D) protein structures were predicted using Phyre2 
(www.rcsb.org). Phyre2 predicts the secondary structure of an amino acid sequence 
and generates a 3D model by using homologous crystallised proteins in the online 
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Protein Data Base as a template (Bennett-Lovsey et al., 2008). The 3D models were 
formatted using USFC Chimera (www.cgl.ucsf.edu/chimera/). 
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3.1 Introduction 
Macroautophagy (autophagy) describes the process in which intracellular materials 
are sequestered into double-membrane vesicles and targeted to lysosomes for 
degradation. Several studies have implicated autophagy in the innate and adaptive 
immune responses against diverse intracellular pathogens (Gutierrez et al., 
2004;Nakagawa et al., 2004;Birmingham et al., 2006), (Andrade et al., 2006;Zhao et 
al., 2008). During virus infection, autophagy is reported to (i) increase virus 
replication (Jackson et al., 2005), (ii) decrease virus replication (Liu et al., 2005) or 
(iii) have no affect on virus replication (Zhao et al., 2007b). The role of autophagy 
during virus infection appears to depend on cell line and virus studied. For 
alphaviruses, the effect of autophagy on virus replication varies between SINV, 
CHIKV and SFV. Autophagy functions against SINV infection in vivo and in vitro 
(Liang et al., 1998). In contrast, autophagy enhances CHIKV replication in HEK293 
cells (Krejbich-Trotot et al., 2011). Until recently, the potential role of autophagy in 
SFV infection was unknown. However, during the writing of this thesis, a paper was 
published which demonstrated that SFV4 infection induces the accumulation of 
autophagosomes in human osteosarcoma cells (HOS) and MEFs and that this has no 
affect on SFV replication (Eng et al., 2012). The objectives and data presented in this 
chapter were generated before the Eng et al (2012) paper was published. 
 
3.2.1 Objectives 
1. Establish an assay to measure the induction of autophagy in cell culture. 
2. Determine if SFV activates autophagy and if this differs between strains of 
SFV. 
3. Determine if the pharmacological induction or inhibition of autophagy affects 
SFV replication in cells. 
4. Determine if SFV proteins colocalise with the autophagy machinery. 
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3.2 Results 
3.2.1 Establishment of the autophagy assay to determine the 
accumulation of autophagosomes in the cell cytoplasm. 
In the autophagy assay a plasmid expressing GFP-LC3 is transfected into cells, 
which enables visualisation of the accumulation of autophagosomes, as described by 
Jackson et al. (2005). To investigate whether SFV4 infection induces autophagosome 
accumulation in cell culture, the autophagy assay was carried out in Huh7 cells 
infected with SFV4. The amount of GFP-LC3 plasmid transfected into Huh7 cells 
was optimised by transfecting cells with 0.5, 2, 4 or 8 µg of GFP-LC3 plasmid and 
determining the percentage of the cell culture expressing GFP at 24 h post 
transfection using fluorescence microscopy (2.10.1). Successfully transfected cells 
expressed GFP and, hereafter, are referred to as transfected cells. A mock-transfected 
control was included and no fluorescence was detected in this culture (data not 
shown). The experiment was repeated three times and a representative graph is 
shown in Fig. 3.1. Transfection using 0.5 – 4 µg of GFP-LC3 plasmid produced 
fluorescence in ≤25 % of the cell culture (Fig. 3.1). Approximately 13 % more Huh7 
cells were transfected using 8 µg of GFP-LC3 plasmid than with other plasmid 
amounts. However, the cells over expressed GFP which could affect the autophagy 
studies. Therefore, 0.5 µg of GFP-LC3 plasmid was chosen for further studies.  
 
Figure 3.1: Percentage of Huh7 cells expressing GFP following 
transfection with increasing amounts of GFP-LC3 plasmid. 
Huh7 cells were transfected with increasing amounts of GFP-LC3 plasmid. After 24 
h, the percentage of cells expressing GFP out of the total cells in a field was 
calculated. Bars are the mean of 15 microscope fields; error bars are standard 
deviations of the mean. 
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To clarify that the GFP-LC3 plasmid could be used to measure 
autophagosome accumulation, Huh7 cells were transfected with the GFP-LC3 
plasmid for 24 h and treated with rapamycin for 3 h. Then the percentage of 
transfected cells in the culture with ≥2 puncta, as a measure of autophagy, was 
determined (2.10.1). Rapamycin induces autophagy by inhibiting mTOR. Under 
normal conditions, mTOR negatively regulates autophagosome formation. Untreated 
transfected cells were included as a control. To optimise the concentration of 
rapamycin, Huh7 cells were treated with 2 µM or 4 µM of rapamcyin. Only cells 
expressing GFP were included in the calculations. Cells treated with rapamycin were 
markedly different from cells in the untreated control (Fig. 3.2.i). Rapamycin 
treatment induced the redistribution of GFP-LC3 and, therefore, autophagy in Huh7 
cells (Fig. 3.2). Significantly more Huh7 cells were determined to be undergoing 
autophagy in rapamycin treated cultures compared to the untreated control (p <0.05 
using the Mann-Whitney test) (Fig. 3.2.ii). Similar levels of autophagy were 
observed following treatment with either 2 µM or 4 µM of rapamycin and, therefore, 
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Figure 3.2: Autophagy in Huh7 cells transfected with the GFP-LC3 
plasmid and treated with rapamycin. 
(i) Huh7 cells were transfected with GFP-LC3 plasmid for 24 h and untreated or 
treated with 2 µM of rapamcyin for 3 h. Transfected cells with ≥2 GFP puncta were 
considered to have puncate staining. (ii) Huh7 cells were transfected with GFP-LC3 
plasmid for 24 h, mock-treated (green) or treated with 2 µM or 4 µM of rapamycin 
for 3 h (black) and the percentage of transfected cells undergoing autophagy was 
calculated out of the total cells in a field. Transfected cells with ≥2 GFP puncta were 
considered to have punctate staining. Bars are the mean of 15 microscope fields; 
error bars are standard deviations of the mean. * significant (p <0.05 by the Mann-
Whitney test). 
 
 Counting the number of puncta per cell as a measure of autophagy has 
been previously described in alphavirus studies (Krejbich-Trotot et al., 2011; Eng et 
al., 2012) and was tested in this study. However, the three-dimensional nature of the 
cell made accurate counting of puncta difficult and the technique was deemed 
unreliable.   
 It was therefore decided to establish additional techniques to complement 
the LC3 assay. A Western blot to detect the two forms of LC3 could not be 
established. Different methods of protein extraction, increasing antibody incubation 
times and different developing methods were explored. Several studies use Western 
blot to determine autophagy induction; possibly user inexperience explains the 
unsuccessful establishment of the Western blot. An attempt was also made to 
immunostain Huh7 cells for LC3 or Lamp1. Different methods to permeabilise cell 
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membranes were explored, various commercial providers of antibodies were tried, 
different antibody concentrations and incubation times were used, but cultures 
treated with rapamycin could not be differentiated from the untreated control (results 
not shown). When these autophagy studies were started, 3 years ago, the reagents 
available, including antibodies, were limited and probably not fully optimised. Today 
the autophagy field has expanded and multiple commercial antibodies and reagents 
are available. Returning to this work and establishing these techniques would 
enhance future studies. 
 
3.2.2 Does Semliki Forest virus infection induce 
autophagosome accumulation in Huh7 cells? 
The autophagy assay was used to investigate whether SFV infection induces 
autophagosome accumulation in Huh7 cells (2.10.1). Transfected cells were either 
mock-infected or infected with SFV4 at MOI 5 for 24 h or treated with rapamycin for 
3 h and then the percentage of cells with ≥2 puncta was calculated (2.10.2). In Huh7 
cells, SFV4 infection and rapamycin treatment both caused the accumulation of 
autophagosomes in approximately 50 % more of the monolayer than the mock-
infected culture (Fig. 3.3.ii). SFV4 induced autophagosome formation in more cells 
than rapamycin treatment. In conclusion, by 24 h post-infection SFV4 caused the 
accumulation of autophagosomes in Huh7 cells.  
 
Figure 3.3: Huh7 cells transfected with the GFP-LC3 plasmid and 
treated with rapamycin. 
Huh7 cells were transfected with GFP-LC3 plasmid for 24 h and then mock-treated 
and mock-infected (green), infected with SFV4 at MOI 5 for 24 h (blue) or treated 
with 2 µM of rapamycin for 3 h (black). Transfected cells with ≥2 GFP puncta were 
considered to be undergoing autophagy. The percentage of transfected cells 
undergoing autophagy was calculated out of the total cells in a field. Bars are the 
mean of 15 microscope fields; error bars are standard deviations of the mean. * 
significant (p <0.05 by the Mann-Whitney test). 
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To use GFP-LC3 expression to measure SFV induction of autophagy, all cells 
expressing GFP-LC3 must also contain virus. At a high MOI of 5, all cells in the 
culture should be infected with virus. An experiment was carried out to ensure that 
Huh7 cells positive for autophagy were also infected with SFV4. The autophagy 
assay was carried out on Huh7 cells infected with SFV4 at MOI 5 for 24 h and then 
mock-immunostained or immunostained for nsP3 or structural proteins. After 
immunostaining, only Huh7 containing ≥2 puncta and also stained positive for SFV 
nsP3 or the structural proteins were analysed for autophagy. An example of these 
cells is shown in Fig. 3.4.i. No red fluorescence was detected in the mock-
immunostained control (Fig. 3.4.i). Mock-infected cells were included as a control 
and only GFP was detected (data not shown). The experiment was repeated three 
times and representative graph is shown in Fig. 3.4.ii. A similar percentage of cells 
undergoing autophagy was observed in mock-immunostained Huh7 cells and the 
Huh7 cells positive for nsP3 or the SFV structural proteins. Therefore, Huh7 cells 
undergoing autophagy were also infected with SFV4. In further autophagy studies, 
Huh7 cells positive for autophagy in infected cultures were assumed to be infected 
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Figure 3.4: Autophagy in Huh7 cells transfected with the GFP-LC3 
plasmid and immunostained for nsP3 or structural proteins. 
The autophagy assay was carried out on Huh7 cells transfected with GFP-LC3 
plasmid for 24 h, infected with SFV4 at MOI 5 for 24 h and then mock 
immunostained (mock) or immunostained for nsP3 or structural proteins (structural). 
(i) Merged images. GFP-LC3 is green. NsP3 or structural proteins are red. Arrows 
indicate cells expressing GFP-LC3 and infected with SFV4. (ii) Cells with ≥2 GFP 
puncta were considered to have punctate staining. The percentage of transfected cells 
undergoing autophagy was calculated out of the total cells in a field. Bars are the 
mean of 15 microscope fields; error bars are standard deviations of the mean. 
 
Accumulation of autophagosomes during SFV4 infection could be due to (i) 
SFV4 infection inducing autophagy, (ii) SFV4 infection inhibiting autophagy 
downstream of the autophagosomes, preventing autolysosome formation and 
autophagy flux resulting in the accumulation of autophagosomes or (iii) SFV4 
infection inducing autophagy and also inhibing autophagosome degradation. To 
investigate the temporal accumulation of autophagosomes in SFV4 infected cultures, 
the autophagy assay was carried out on transfected Huh7 cells infected with SFV4 at 
MOI 5 and analysed for induction of autophagy at 3, 6 and 24 h post-infection 
(2.10.1). Mock-infected Huh7 cells and Huh7 cells treated with rapamycin were 
included as a controls. The experiment was repeated twice and a representative graph 
is shown in Fig. 3.5. SFV4 infection induced the accumulation of autophagosomes in 
significantly more cells than the negative control by 3 h post-infection (p <0.05 by 
the Mann Whitney test).  
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Figure 3.5: Time course of the induction of autophagy in Huh7 cells 
transfected with GFP-LC3 plasmid and then infected with SFV4. 
Huh7 cells were transfected with GFP-LC3 plasmid and then mock-infected (green), 
or infected with SFV4 at MOI 5 (blue) and analysed for autophagy at 3, 6 and 24 h 
post-infection. Huh7 cells were treated with 2 µM of rapamycin for 3 h (black). 
Transfected cells with ≥2 GFP puncta were considered to contain punctate staining. 
The percentage of transfected cells with punctate staining was calculated out of the 
total cells in a field. Bars are the mean of 15 microscope fields; error bars are 
standard deviations of the mean. * significant (p < 0.05 by the Mann-Whitney test). 
 
To further investigate this rapid accumulation of autophagosomes, the 
autophagy assay was carried out on transfected Huh7 cells infected with SFV4 at 
MOI 5 and at analysed for the induction of autophagy at hourly intervals. Mock-
infected Huh7 cells and Huh7 cells treated with rapamycin were included as controls. 
The experiment was repeated twice and a representative graph is shown in Fig. 3.6. 
At 1 h post-infection, SFV4 infected cultures had significantly more cells with ≥2 
puncta than the mock-infected control (p <0.05 by the Mann-Whitney test). This 
difference between infected and mock-infected cells was more defined by 3 h post-
infection. The percentage of SFV4 infected cells with ≥2 puncta increased over time 
until 5 - 6 h post-infection when the levels began to plateau. The rapid accumulation 
of autophagosomes in infected cultures suggests that SFV4 is inducing autophagy, 
since it is unlikely that SFV4 structural proteins could inhibit autophagosome 
degradation by 1 hour post-infection. Eng et al (2012) demonstrated that SFV4 
inhibits autophagosome degradation. SFV4 could both induce autophagy and inhibit 
autophagosome degradation. 
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Figure 3.6: Time course of autophagosome accumulation in Huh7 cells 
transfected with GFP-LC3 plasmid and then infected with SFV4. 
Huh7 cells were transfected with GFP-LC3 plasmid and then mock-treated (green) or 
infected with SFV4 at MOI 5 (blue) and analysed for autophagy at hourly intervals. 
Huh7 cells were treated with 2 µM of rapamycin for 3 h (black). Transfected cells 
with ≥2 GFP puncta were considered to contain punctate staining. The percentage of 
transfected cells with punctate staining was calculated out of the total cells in a field. 
Bars are the mean of 15 microscope fields; error bars are standard deviations of the 
mean. * significant (p <0.05 by the Mann-Whitney test). 
 
 To investigate whether other strains of SFV cause autophagosome 
accumulation, the autophagy assay was carried out on transfected Huh7 cells infected 
with SFV4, SFV L10 or SFV A7(74) at MOI 5 for 24 h and analysed for ≥2 puncta 
per cell (2.2.8, 2.10.1). Mock-infected cells and rapamycin treated cells were 
included as controls. The experiment was repeated three times and a representative 
graph is shown in Fig. 3.7. All three strains of SFV caused the accumulation of 
autophagosomes in significantly more cells by 24 h post-infection than the mock-
infected control. All three strains of SFV induced ≥2 puncta in a similar percentage 
of the monolayer by 24 h post-infection. The three strains of SFV induced 
autophagosome accumulation in more cells than the rapamycin control.  
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Figure 3.7: Comparison of the induction of autophagy in Huh7 cells 
transfected with GFP-LC3 plasmid and then infected with SFV4, SFV 
L10 or SFV A7(74). 
Huh7 cells were transfected with GFP-LC3 plasmid and then mock-infected (green; 
untreated) or infected with SFV4 (blue), SFV L10 (red; L10) or SFV A7(74) (dark 
green; A7(74)) at MOI 5 for 24 h and analysed. Huh7 cells were treated with 2 µM 
of rapamycin for 3 h (black; Rap). Transfected cells with ≥2 GFP puncta were 
considered to be undergoing autophagy. The percentage of transfected cells 
undergoing autophagy was calculated out of the total cells in a field. Bars are the 
mean of 15 microscope fields; error bars are standard deviations of the mean. * 
significant (p <0.05 by the Mann-Whitney test). 
 
3.2.3 Does the pharmacological induction or inhibition of 
autophagy affect Semliki Forest virus replication? 
SFV4 induced autophagy in Huh7 cells by 1 h post-infection (Fig. 3.6). As discussed 
in the introduction, autophagy can enhance, suppress or have no effect on virus 
replication. Studies were carried out to investigate the affect of autophagy on SFV 
replication. As a first study it was decided to investigate the effect of rapamycin 
treatment on subsequent SFV4 infection. Rapamycin targets mTOR resulting in the 
induction of autophagy, although that is not rapamycin’s only affect on the cell. 
Huh7 cells were treated with 2 µM of rapamycin for 3 h, infected with 
SFV4(3H)RLuc at MOI 0.1, 1 and 5 and RLuc levels were measured at 2, 3, 4, 5 and 
6 h post-infection (2.8.2). Mock-infected cells were included as a control at each 
time point and the RLuc values were subtracted from the infected cell values. Mock-
treated infected cells were included as a control at each time point. The experiment 
was repeated three times and representative graphs are shown in Fig. 3.8. At both 
MOI 1 and MOI 5, similar RLuc levels were detected in infected Huh7 cells with or 
without rapamycin treatment (Fig. 3.8.ii and iii). However, at a low MOI (0.01) RLuc 
levels were significantly lower following rapamycin treatment at both 5 and 6 h post-
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infection. These differences are clearer on a linear scale (Fig. 3.8.i). Since spread in 
the culture is not an issue at high MOI, this affect at low MOI could indicate that 
rapamycin pre-treatment is delaying virus release or reducing numbers of infectious 
virus released. At 5 – 6 h post-infection the second round of virus infection is 
expected. Overall, the data shows that rapamycin pre-treatment had no detectable 
affect on virus replication at high (1 or 5) MOI, but delayed virus replication at 5 – 6 
h post-infection at low (0.01) MOI. 
 
 
Figure 3.8: The effect of rapamycin pre-treatment on SFV4(3H)RLuc 
replication in Huh7 cells. 
 (i) Huh7 cells were treated with 2 µM of rapamycin (black) or mock-treated (blue), 
infected with SFV4(3H)RLuc at MOI 0.01 and RLuc levels were measured at hourly 
intervals from 2 to 6 h post-infection (right). RLuc levels at 5 and 6 h post-infection 
were plotted on a linear scale (left). Each point or bar represents the mean of three 
wells; error bars are standard deviations of the mean. The experiment was repeated 
using MOI 1 (ii) and MOI 5 (iii). * significant (p <0.05 by the Mann-Whitney test). 
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3MA is a pharmacological inhibitor of the autophagy pathway and its affect 
on SFV4 replication was investigated using SFV4(3H)RLuc virus. Firstly, to 
establish whether 3MA treatment inhibits autophagy in Huh7 cells, the autophagy 
assay was carried out on transfected Huh7 cells, which were mock-treated, treated 
with 10 mM 3MA and then 2 µM rapamycin or treated with 2 µM rapamycin. The 
experiment was repeated three times and a representative graph is shown in Fig. 3.9. 
Rapamycin induced significantly more autophagy in Huh7 cells compared to the 
mock-treated control (p <0.05 by the Mann Whitney test). However, only 
background levels of autophagy were detected in Huh7 cells treated with 3MA and 
then with rapamycin. These results show that 10 mM 3MA inhibited autophagy in 
Huh7 cells and this concentration of 3MA was used to investigate its effect on SFV4 
replication. Several studies have demonstrated that 3MA inhibits autophagy induced 
by various viruses, including the alphavirus CHIKV (Krejbich-Trotot et al., 2011). It 
is likely that 3MA inhibits autophagy induced by SFV infection, as with CHIKV. 
However, this study would have been enhanced by including Huh7 cells treated with 
3MA for 3 h and then infected with SFV4 to ensure that the 3MA also inhibits 
autophagy induced by SFV4.  
 
Figure 3.9: 3MA treatment inhibits autophagy in Huh7 cells. 
Huh7 cells transfected with GFP-LC3 plasmid were mock-treated (green; untreated), 
treated with 10 mM of 3MA for 3 h and then challenged with 2 µM of rapamycin for 
3 h (red; 3MA + Rap) or treated with 2 µM of rapamycin for 3 h (blue; Rap) and 
analysed for autophagy. Transfected cells with ≥2 GFP puncta were considered to be 
undergoing autophagy. The percentage of transfected cells undergoing autophagy 
was calculated out of the total cells in a field. Bars are the mean of 15 microscope 
fields; error bars are standard deviations of the mean. * significant (p <0.05 by the 
Mann-Whitney test). 
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Huh7 cells were treated with 10 mM 3MA for 3 h, infected with 
SFV4(3H)RLuc at MOI 0.1 or 5 and RLuc levels measured at 2, 3, 4, 5 and 6 h post-
infection (2.8.2). Mock-infected cells and mock-treated cells infected with 
SFV4(3H)RLuc were included as controls at each time point. MOI 1 was not 
included in these experiments because similar results were observed after infection 
with MOI 1 and MOI 5 in Fig. 3.8. At MOI 5, similar RLuc levels were detected in 
infected Huh7 cells both with and without 3MA treatment at all time points (Fig. 
3.10.ii). At MOI 0.01, RLuc levels were significantly higher following 3MA 
treatment at 4, 5 and 6 h post-infection (p <0.05 using the Mann Whitney test). The 5 
and 6 h results are clearer on a linear scale (Fig. 3.10.i). Thus 3MA inhibition of 
autophagy had no detectable effect on SFV4(3H)RLuc replication at MOI 5. In 
contrast, at a low MOI (0.01), 3MA treatment produced a significant increase in 
SFV4(3H)RLuc replication. This result is consistent with the inhibition of replication 
following rapamycin pre-treatment (Fig. 3.8). Together, these results suggest that 
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Figure 3.10: The affect of 3MA pre-treatment on SFV4(3H)RLuc 
replication in Huh7 cells. 
(i) Huh7 cells were treated with 10 mM of 3MA (red) or mock-treated (blue), 
infected with SFV4(3H)RLuc at MOI 0.01 and RLuc levels were measured at hourly 
intervals between 2 to 6 h post-infection (right). RLuc levels at 5 and 6 h post-
infection were plotted on a linear scale (left). Each point or bar represents the mean 
of three wells; error bars are standard deviations of the mean. (ii) The experiment 
was repeated using MOI 5. * significant (p <0.05 by the Mann-Whitney test). 
 
3.2.4 Does GFP-LC3 colocalise with SFV capsid, SFV nsP3 or 
dsRNA? 
Transfected Huh7 cells were infected with SFV4 at MOI 5 and immunostained for 
capsid, nsP3 or dsRNA at 6 and 24 h post-infection (2.3.1). dsRNA is a replication 
intermediate produced by viruses during infection. Cells were analysed for 
colocalisation events using the Zeiss-LSMpascal microscope. Uninfected Huh7 cells 
were included as a negative control and only GFP was detected (data not shown). At 
6 h post-infection, GFP-LC3 colocalised with nsP3, capsid or dsRNA in ≤3 % of 100 
cells (Fig. 3.11.i). At 24 h post-infection, the number of colocalisation events 
between GFP-LC3 and nsP3, capsid or dsRNA increased, but were still extremely 
rare at ≤5 % of 100 cells (Fig. 3.11.ii and Fig. 3.12). Significantly more nsP3 and 
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dsRNA colocalised with GFP-LC3 than with capsid (Fig. 3.11.ii). Even in cells 
where GFP colocalisation had been detected, the majority of the GFP puncta did not 
colocalise with nsP3, capsid or dsRNA. The results presented here strongly suggest 
that LC3 and, presumably, the autophagosomes rarely interact with nsP3, capsid or 
dsRNA.  
 
Figure 3.11: GFP-LC3 rarely co-localises with capsid, nsP3 or dsRNA in 
Huh7 cells infected with SFV4. 
Huh7 were transfected with GFP-LC3 plasmid, infected with SFV4 at MOI 5 for (i) 
6 h or (ii) 24 h and immunostained for capsid, nsP3 or dsRNA and 100 cells were 
analysed for colocalisation events. Each bar represents the mean of three 
experiments; error bars are standard deviations of the mean. * significant (p <0.05 by 
the Mann-Whitney test).  
 
 




Figure 3.12: Confocal microscopy to determine if GFP-LC3 co-localises 
with nsP3, capsid or dsRNA in Huh7 cells at 24 h post-infection. 
Huh7 cells were transfected with GFP-LC3 plasmid, infected with SFV4 (MOI 5) for 
24 h and immunostained for capsid (A, B and C), nsP3 (D and E) or dsRNA (F and 
G). Each image is one section. Scale bars represent 2 µm. The area within the white 
boxes was magnified. Arrows indicate possible colocalisation events; white hatched 
boxes enclose a magnified colocalisation event. 
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3.2.5 Summary of findings 
• SFV4, SFV L10 and SFV A7(74) infection all induced autophagosome 
accumulation in Huh7 cells by 1 h post-infection. 
• At high MOI, pharmacological induction or inhibition of autophagy did not 
affect SFV4(3H)RLuc replication. 
• At low MOI, pharmacological induction of autophagy reduced 
SFV4(3H)RLuc replication, while pharmacological inhibition increased 
SFV4(3H)RLuc replication in Huh7 cells. 
• GFP-LC3 rarely colocalised with capsid, nsP3 or dsRNA in Huh7 cells at 6 h 
and 24 h post-infection.  
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3.3 Discussion 
In the results presented in this chapter, SFV4, SFV L10 and SFV A7(74) infection 
induced the accumulation of autophagosomes in Huh7 cells as early as 1 hour post-
infection (Figs 3.6 and 3.7). Accumulation of autophagomes in the cytoplasm of 
infected cells could be due to (i) SFV infection inducing the formation of 
autophagosomes, (ii) SFV infection inhibiting the formation and degradation of 
autolysosomes, which would cause the accumulation of autophagosomes in the 
cytoplasm or (iii) both induction and inhibition of autophagy. In a paper published 
during the writing of this thesis, Eng et al (2012) reported that SFV4 infection results 
in the accumulation of autophagosomes at 4 – 8 h post-infection and demonstrated 
that SFV4 infection inhibits autophagosome degradation in HOS and MEFs. Based 
on the relatively late detection of autophagosomes, the authors conclude that SFV4 
infection inhibits as opposed to induces autophagy. In their study, the authors used a 
combination of techniques to demonstrate autophagy, including (i) determining the 
number of cells with GFP-LC3 puncta as a measure of autophagosomes, as in this 
study, (ii) FACS to measure GFP-LC3 accumulation in cells and (iii) Western blot 
for LC3-II. In Eng et al (2012) GFP-LC3 puncta, autophagosome accumulation was 
detected by 4 h post-infection; earlier time-points were not analysed. In contrast, by 
FACS analysis and in the Western blot, autophagy appeared to occur between 4 and 
8 h post-infection. Possibly, counting GFP-LC3 is more sensitive than FACS and 
Western blot and, therefore, autophagosome accumulation could be occurring earlier 
than 4 h post-infection, as presented in this chapter.  
Rapid accumulation of autophagosomes during SFV infection presented in 
this chapter suggests that SFV activates autophagy. One possible candidate for 
autophagy induction is dsRNA binding to PRR such as the TLR, NLR and RLR. 
Studies in bacteria demonstrate that activation of TLR and NLR induces autophagy 
(Yuan et al., 2009;Travassos et al., 2010). The RLR family can also induce 
autophagy after binding dsRNA (Tormo et al., 2009). Autophagy can mediate RLR 
activity through the autophagy conjugate Atg5-Atg12 binding RIG-I, mda-5 and IPS-
1 (Jounai et al., 2007). SFV4 enters cells and replicates in the cell cytoplasm on 
modified endosomes, lysosomes or the plasma membrane. Therefore, the most likely 
PRRs for inducing autophagy following SFV4 infection are the RLR. The role of 
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RLRs during SFV infection has not been investigated, but mda-5 was activated 
during SINV infection of MEFs (Burke et al., 2009). Therefore, it is possible that the 
RLR, in particular mda-5, rapidly induces autophagy following detection of SFV4 
infection. However, Eng et al (2012) reported that structural protein production is 
essential for the induction of autophagy as autophagosome accumulation did not 
occur in VRP infected cells. This could act through the UPR, which is known to be 
activated in SFV infection (Barry et al., 2010). 
One objective of this chapter was to determine if autophagy had a proviral, 
antiviral or no affect on SFV replication. Studies have demonstrated autophagy to be 
an antiviral mechanism against SINV infection both in cell culture and in mice 
(Liang et al., 1998, Orvedahl et al., 2010). During SINV infection, capsid is reported 
to colocalise with the autophagosome marker GFP-LC3 in mouse neurones, MEFs 
and, on occasion, in HeLa cells. Autophagy is essential for the clearance of capsid 
from mouse neurones and capsid immunoprecipitated with the autophagy protein p62 
in HeLa cells (Orvedahl et al., 2010). The authors suggest that p62 selectively targets 
capsid to the autophagosomes for degradation to clear virus from infected cells 
(Orvedahl et al., 2010). However, autophagy had no affect on the replication of 
SINV in MEFs (Orvedahl et al., 2010).  
In contrast to SINV, pharmacological inhibition or siRNA inhibition of 
autophagy decreased CHIKV replication in HEK293 cells (Krejbich-Trotot et al., 
2011). Conversely, pharmacological induction of autophagy enhanced CHIKV 
replication. Taken together, these results suggest that autophagy is proviral in the 
case of CHIKV infection (Krejbich-Trotot et al., 2011). Autophagy also enhances 
virus replication in DENV (Lee et al., 2008;Li et al., 2012b), JEV (Li et al., 2012a), 
PV (Jackson et al., 2005), coxsackievirus B3 virus (Wong et al., 2008), FMDV 
(O'Donnell et al., 2011), SARS-CoV (Prentice et al., 2004) and HCV (Dreux & 
Chisari, 2009). Eng et al (2012) reported that autophagy had no affect on SFV4 
replication in HOS and MEFs and that the autophagy machinery rarely colocalised 
with either virus replicase or structural proteins. Similarly, in human rhinovirus and 
coronavirus infections, the absence of gene ATG5 had no affect on virus replication 
(Brabec-Zaruba et al., 2007;Zhao et al., 2007b).  
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In the studies presented here, pharmacological induction or inhibition of 
autophagy did not affect SFV4(3H)RLuc replication at a high MOI (Fig. 3.8 and 
3.10). In addition, the autophagosome marker GFP-LC3 rarely colocalised with 
capsid, nsP3 or dsRNA at either 6 h or 24 h post-infection (Fig. 3.11 and 3.12). 
However, at low MOI of 0.01, pharmacological induction of autophagy reduced 
SFV4(3H)RLuc replication in Huh7 cells at 5 and 6 h post-infection, while the 
pharmacological inhibition of autophagy increased replication at 4, 5 and 6 h post-
infection (Fig. 3.8 and 3.10). The data at a high MOI indicate that autophagy is not 
required for SFV replication or in degrading virus proteins. Since spread in the 
culture is not an issue at high MOI, the effect at low MOI could indicate that 
rapamycin pre-treatment is delaying virus release or reducing numbers of infectious 
virus released, while 3MA enhances this. Indeed, 5 – 6 h post-infection is consistent 
with the time at which the second round of virus infection is expected. Eng et al 
(2012) only investigated autophagy at MOI 1. Taken together, the studies published 
by Eng et al (2012) confirm the data presented in this chapter.  
Possible explanations for the differences between the affect of autophagy on 
CHIKV, SFV and SINV infection include (i) the viruses interact with the autophagy 
machinery differently and/or (ii) the affect of autophagy on virus replication varies 
between cell lines or between species. The observation that autophagy enhances 
CHIKV replication, while having no affect on SFV4 replication could indicate that 
CHIKV cannot inhibit autophagosome degradation in contrast to SFV4. It would be 
interesting to determine if autophagy processes downstream of autophagosome 
formation occur in CHIKV infected cells.  
  
3.3.1 Final summary 
The role of autophagy during SFV infection until recently had not been investigated. 
Most positive ssRNA viruses studied to date induce autophagy. Autophagy, in 
general, enhances virus replication, including during CHIKV infection of HEK293 
cells. In this chapter, SFV4, SFV L10 and SFV A7(74) induced autophagy in Huh7 
cells by 1 hour post-infection. Autophagy had no effect on SFV4 replication at a high 
MOI of 5. However, at a low MOI of 0.01 the autophagy reduced SFV titres. NsP3, 
capsid and dsRNA rarely colocalised with the autophagosome marker LC3. 
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Together, the data suggest that (i) SFV infection causes the accumulation of 
autophagosomes in vitro, (ii) autophagy has no affect on SFV replication at a high 
MOI and (iii) autophagy reduces SFV titres at a low MOI, presumably by restricting 
virus spread. Studies recently published by Eng et al (2012) largely confirm the data 
presented here. Investigation into the interaction between SFV and autophagy was 
not continued in this thesis.  
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4.1 Introduction 
There are several strains of SFV which can be divided into two groups based on their 
virulence in adult mice (Bradish et al., 1971). The most commonly studied strains of 
SFV include the virulent SFV L10 and the avirulent SFV A7(74) and SFV4. The 
factors that determine the virulence of the different strains remain unclear. One 
possibility is differential interaction with the type-I IFN response. Strains of SFV 
induce the production of IFN both in vitro and in vivo (Bradish et al., 1975), 
although direct measurement of IFN induction in cell culture has only been 
investigated for SFV4 (Breakwell et al., 2007). Several studies have demonstrated 
that strains of SFV are sensitive to IFN (Finter, 1966). The effect of IFN on SFV 
infection depends on the virus strain, dose of IFN and the time of administration 
(Smillie et al., 1973;Bradish & Titmuss, 1981;Deuber & Pavlovic, 2007). More 
recently, one study reported that strains of SFV vary in their sensitivity to IFN pre-
treatment and that this may determine virulence in cell culture (Deuber & Pavlovic, 
2007). It is not known if the well-characterised strains of SFV differ in their 
interaction with IFN and if this determines virulence.  
In humans, SFV infection only causes a mild or subclinical disease (Mathiot 
et al., 1990). In contrast, CHIKV, an alphavirus closely related to SFV, is currently 
causing debilitating disease in millions of humans worldwide (Enserink, 2007). 
However, CHIKV is avirulent in mice unless the mice are deficient in the type-I IFN 
system (Couderc et al., 2008). One explanation for the difference between SFV and 
CHIKV is that the viruses differ in their sensitivity to human and mouse IFN. It can 
be hypothesised that CHIKV is more sensitive to mouse IFN than to human IFN and 
SFV is more sensitive to human IFN than to mouse IFN. 
It is clear that the type-I IFN response is essential in controlling SFV 
infection in mice. It remains to be determined if, (i) strains of SFV interact 
differently with the type-I IFN system; (ii) sensitivity to type-I IFN is a determinant 
of virulence; (iii) SFV is more sensitive to human type-I IFN than mouse type-I IFN; 
(iv) SFV evades and/or inhibits the mouse type-I IFN response better than the human 
type-I IFN response; (v) SFV and CHIKV differ in their induction and/or sensitivity 
to human and mouse type-I IFN. 
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4.1.1 Objectives 
1. Determine if virulent (SFV L10) and avirulent (SFV A7(74) and SFV4) 
strains replicate efficiently in IFN competent human cells and how this 
compares to replication in IFN competent mouse cells. 
2. Determine if IFN affects SFV replication in human and mouse cells. 
3. Determine if virulent (SFV L10) and avirulent (SFV A7(74) and SFV4) 
strains induce different amounts of functional IFN and if this varies between 
mouse and human cells. 
4. Determine if virulent (SFV L10) and avirulent (SFV A7(74) and SFV4) 
strains differ in their sensitivity to IFN in human and mouse cells.  
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4.2.1 Comparison of SFV replication in human and mouse 
cells 
To investigate SFV replication in IFN competent human cells, a standard plaque 
assay was carried out in MRC5, A549 and 2fTGH cells infected with virulent SFV 
L10 or avirulent SFV A7(74) or SFV4 (2.2.9). All three viruses infected MRC5, 
A549 and 2fTGH cells, as seen by changes in the monolayer (Fig. 4.1.i). In MRC5 
and A549 cells, all three strains formed plaques, which consisted of a mixture of live 
and dead cells; these were termed “cloudy plaques” (Fig. 4.1.i). These plaques were 
difficult to detect with the naked eye, but were clearly observed under the 
microscope (Fig. 4.1.ii). The magnified plaques in Fig. 4.1.ii are representative of 
plaques produced by SFV L10 and SFV4 infection in MRC5, A549 and 2fTGH cells. 
Interestingly, in the A549 cells, SFV A7(74) produced larger plaques than either 
SFV L10 or SFV4. In contrast to the cloudy plaques in MRC5 and A549 cells, in 
2fTGH cultures all three viruses produced an unusual response, an agglomeration of 
cells (Fig. 4.1).  
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Figure 4.1: Plaque assays of SFV A7(74), L10 and SFV4 in human cell 
lines. 
(i) Plaque assays were carried out in human MRC5, A549 and 2fTGH cell lines 
infected with SFV A7(74), SFV L10 or SFV4. (ii) Individual plaques from MRC5 
(A), A549 (B) or 2fTGH (C) cells infected with SFV A7(74). Bars represent 500 µm. 
Arrowheads identify one plaque.  
 
To investigate 2fTGH infection in greater detail, a standard plaque assay was 
carried out on 2fTGH cells infected with one of the three strains, SFV4. To observe 
the course of infection, cells were immunostained for nsP3 (2.2.9). Mock-infected 
cells were included as a negative control. No nsP3 was detected in the negative 
control (Fig. 4.2.C). NsP3 was clearly detected in the distinct cell agglomeration 
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areas in the infected 2fTGH cell monolayer (Fig. 4.2.A). Under higher magnification, 
these agglomerations could be seen to be a mixture of infected and uninfected cells 
(Fig. 4.2.B). Extensive cell death was not detected within these agglomerations (Fig. 
4.2.B). In conclusion, SFV4 does infect 2fTGH cells, but does not produce plaques 
suggesting that virus replication and/or spread is restricted in these cells and that 
these cells do not readily undergo cell death upon infection. Most studies to date 
indicate that infection of mammalian cells with various strains of SFV, including 
SFV L10, A7(74) and SFV4, induce apoptosis (Glasgow et al., 1997;Scallan et al., 
1997;Barry et al., 2010). 
 
Figure 4.2: SFV4 infection of 2fTGH cells. 
Plaque assay in 2fTGH cells infected with SFV4 (A and B) or mock-infected (C). 
Cells were immunostained for nsP3 (brown cells). The black arrow identifies a group 
of infected cells. The yellow arrow identifies an infected cell. Bars represent 100 µm 
(A) or 10 µm (B and C). 
 
To compare SFV replication in human and mouse cells, plaque assays were 
also carried out in IFN competent mouse L929 cells with the same three strains of 
SFV (2.2.9). In L929 cells, all three virus strains produced distinct clear plaques (Fig. 
4.3), which were markedly different from those seen with human cells (Figs. 4.1 and 
4.3). In L929 cells, plaques consisted of dead cells rather than the mixture of live and 
dead cells as seen with two of the human cell lines MRC5 and A549.  
 
Figure 4.3: SFV A7(74), L10 and SFV4 produce clear plaques in L929 
cells. 
Plaque assays in L929 cells infected with SFV A7(74) (A), L10 (B) or SFV4 (C). 
The yellow arrow identifies a single plaque. 
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To investigate whether the unusual plaques seen with human 2fTGH, MRC5 
and A549 cells were due to the IFN response, plaque assays were carried out in 
human U4C cells. U4C cells, a derivative of 2fTGH, are deficient in JAK1 and 
cannot respond to IFN (Muller et al., 1993). Infection with all three virus strains 
produced clear plaques in U4C cells, unlike in 2fTGH, MRC5 or A549 cells (Figs. 
4.1 and 4.4). The clear plaques produced by SFV A7(74), L10 and SFV4 on U4C 
cells were similar to those observed on mouse L929 cells (Figs. 4.3 and 4.4). 
 
 
Figure 4.4: SFV A7(74), L10 and SFV4 produce clear plaques in U4C 
cells. 
Plaque assays in U4C cells infected with SFV A7(74) (A), L10 (B) or SFV4 (C). The 
yellow arrow identifies a single plaque. 
 
 The plaques in U4C cells were further analysed by immunostaining for nsP3. 
Mock-infected cultures were included as a control and no virus was detected (Fig. 
4.5.C). Areas of dead cells were clearly identified in the infected U4C monolayer 
(Fig. 4.5.A). This was completely different to the infected parental 2fTGH cell 
monolayer (Fig. 4.2.A). NsP3 positive cells were located at the edge of the plaques, 
consistent with the spread of virus outwards from the initial site of infection. Under 
higher magnification, unlike with 2fTGH cells, infected U4C cells were clearly 
undergoing apoptosis (Fig. 4.5.B). 
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Figure 4.5: SFV4 infection of U4C cells. 
Plaque assays on U4C cells infected with SFV4 (A and B) or mock-infected (C). 
Cells were immunostained for nsP3 (brown cells). The black arrow identifies a 
plaque. The white arrow identifies apoptotic bodies. ac labels an apoptotic cell. Bars 
represent 100 µm (A) or 10 µm (B and C). 
 
4.2.2 Does IFN affect SFV replication in human and mouse 
cells? 
An IFN sensitivity assay (2.5) was established to determine if (i) IFN limits SFV4 
infection in human cells and (ii) how this compares to the effect of IFN in mouse 
cells. IFN competent human 2fTGH and mouse L929 cells were treated with 0 
(mock-treated control), 1, 10, 100 or 1000 U/ml of IFN-α for 16 h, then infected with 
SFV4(3H)RLuc at MOI 5 for 24 h and analysed for RLuc levels (2.8.2). The IFN-α 
used was species matched; 2fTGH cells were treated with human IFN-α and L929 
cells with mouse IFN-α. The experiment was repeated three times and representative 
graphs are shown in Fig. 4.6.  
 In both cell lines, IFN-α pre-treatment reduced RLuc levels compared to the 
mock-treated control (Fig. 4.6). The level of RLuc production decreased with 
increasing concentrations of IFN-α until it plateaued at 100 U/ml of IFN-α. Even at 
high concentrations of IFN-α, SFV4(3H)RLuc replication was not completely 
abolished; RLuc remained detectable in both human and mouse cultures treated with 
even 1000 U/ml IFN-α; 100 U/ ml of IFN-α reduced RLuc levels by >99 %. These 
results indicate that SFV is highly, but not completely, sensitive to IFN-α pre-
treatment. Based on these results, 10 U/ml of IFN-α was used in all following IFN 
sensitivity assays. 
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Figure 4.6: Sensitivity of SFV4(3H)RLuc to IFN treatment in 2fTGH and 
L929 cells. 
(i) 2fTGH or (ii) L929 cells were treated with species matched IFN-α for 16 h and 
then infected with SFV4(3H)RLuc at MOI 5. 24 h post-infection, cultures were 
assayed for RLuc levels. Each bar is the mean of triplicate experiments, error bars are 
standard deviations of the mean. 
 
In both human and mouse cells, prior treatment of cells with 10 U/ml of IFN-
α reduced RLuc levels by >90 %, but did not abolish SFV replication (Fig. 4.6). 
Possible explanations for this residual virus activity include (i) SFV replicates in 
most IFN treated cells at low levels, (ii) some cells, perhaps related to the cell cycle, 
are not rendered into the antiviral state by IFN pre-treatment and SFV replicates in 
these or (iii) in some cells, again perhaps related to cell cycle, SFV is able to 
disassemble the antiviral state and replicate to high levels. A series of experiments 
were carried out on 2fTGH and L929 cells to investigate these possibilities.  
The mutant virus SFV4(3F)-ZsGreen was used in these experiments, which 
expresses ZsGreen as a protein fused to nsP3 during replication. This enables the 
location of nsP3 to be visualised by fluorescence microscopy. First, an experiment 
was carried out to investigate whether ZsGreen detection during SFV4(3F)-ZsGreen 
is a sensitive method to detect virus replication. 2fTGH and L929 cells were infected 
with SFV4(3F)-ZsGreen at MOI 5 for 24 h and then immunostained for dsRNA 
(2.3.1). Mock-infected negative controls were included. Fluorescence was not 
detected in the negative control (data not shown). In both 2fTGH and L929 cells, all 
cells that expressed ZsGreen also stained positive for dsRNA (Fig. 4.7). Similarly, all 
cells that stained positive for dsRNA expressed ZsGreen. This result indicates that 
ZsGreen expression is an appropriate tool to detect virus replication. 




Figure 4.7: All 2fTGH or L929 cells expressing ZsGreen also stained 
positive for dsRNA 
2fTGH and L929 cells were infected with SFV4(3F)-ZsGreen at MOI 5 for 24 h and 
analysed for ZsGreen fused to virus nsP3 (A), red-stained dsRNA (B), blue-stained 
nuclei (C) and merged image (D).  
 
Next, the IFN sensitivity assay was carried out on L929 cells infected with 
SFV4(3F)-ZsGreen or SFV4(3H)RLuc at MOI 30 and analysed by microscopy for 
ZsGreen expression, cell viability or RLuc production at various hours post-infection 
(Fig. 4.8). In L929 cells, IFN pre-treatment reduced the percentage of the cell 
monolayer expressing ZsGreen compared to the mock-treated infected control (Figs 
4.8.i). At 8 h post-infection, ZsGreen was detected in approximately 5 % of L929 
cells pre-treated with IFN. This had not increased by 48 h post-infection (Fig. 4.8.i). 
In contrast, by 24 h post-infection ZsGreen was detected in approximately 97 % of 
the L929 cell monolayer in the control (no IFN).  
The Wst-1 assay measures mitochondrial dehydrogenase activity. As cells 
die, mitochondria stop functioning and mitochondrial dehydrogenases lose their 
activity. Therefore, the Wst-1 assay is a measure of cell viability. A Wst-1 viability 
assay was carried out on L929 cells pre-treated with IFN and infected with 
SFV4(3F)-ZsGreen virus at MOI 30 for 0, 8, 12 or 24 h post-infection (2.7). Cultures 
mock-treated with IFN and infected with SFV4(3F)-ZsGreen and cultures mock-
treated with IFN and mock-infected were included controls. Cultures pre-treated with 
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IFN and infected with SFV4(3F)-ZsGreen increased in viability from 8 h post-
infection and had a similar viability to the mock-infected culture (Fig. 4.8.ii). 
The IFN sensitivity assay was carried out in L929 cells infected with 
SFV4(3H)RLuc at MOI 30 and assayed for RLuc levels at 2, 4, 6, 8, 10, 12 and 24 h 
post-infection (2.5). A culture mock-treated and mock-infected was included as a 
control. In L929 cultures, RLuc levels in IFN pre-treated cells were consistently 
lower at all time points than in the mock-treated cells (Fig. 4.8.iii). RLuc was 
detectable at 2 h post-infection in the mock-treated cells, but was only detectable at 4 
h post-infection in IFN pre-treated cells (Fig. 4.8.iii). At 24 h p.i., no RLuc was 
detected in the culture treated with IFN and then infected with SFV4(3H)RLuc, 
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Figure 4.8: Affects of IFN pre-treatment on SFV4(3F)-ZsGreen and 
SFV4(3H)RLuc replication in L929 cells. 
(i) L929 cells were treated with mouse IFN-α (black) or mock-treated (blue) for 16 h 
and then infected with SFV4(3F)-ZsGreen at MOI 30. At 8, 24 and 48 h post-
infection the mean percentage of the cell monolayer expressing ZsGreen in 15 fields 
was enumerated using fluorescence microscopy. (ii) The experiment was repeated 
and the Wst-1 cell viability assay was carried out at 0, 8, 24 and 48 h post-infection. 
Mock-infected cells were included (red). Dotted line represents the background. (iii) 
L929 cells were treated with mouse IFN-α (black) or mock-treated (blue) for 16 h 
and then infected with SFV4(3H)RLuc at MOI 30 and assayed for RLuc levels at 2 h 
intervals for 24 h. Luciferase units are given relative to those in a culture mock-
treated and mock-infected. Each bar or point are the mean of triplicate experiments, 
error bars are standard deviations of the mean. 
 
Fig. 4.8.i indicates that SFV only replicated to detectable levels in a small 
subset of cells; while in Fig. 4.8.iii RLuc levels were consistently lower in IFN pre-
treated and infected cultures compared to untreated and infected cultures. These 
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results are consistent with the suggestions described earlier that SFV replicates in 
IFN pre-treated cells at low levels and at high levels in a few cells either because 
these cells are somehow different (cell cycle) and are not in an antiviral state or 
because the virus disassembles the antiviral state.  
In Fig. 4.8.iii, there was a delay of 2 h in RLuc detection compared to the 
untreated and mock-infected control. This delay may reflect the time taken for SFV 
to establish a low level of replication in the small subset of cells not in the antiviral 
state or, more likely, to successfully dismantle the antiviral state in a few cells. RLuc 
was eliminated from IFN pre-treated cultures by 24 h post-infection, unlike in the 
untreated and mock-infected control (Fig. 4.8.iii). Most likely this is due to the 
antiviral state preventing SFV spread and the induction of apoptosis eliminating 
infected cells. As <5 % of the L929 cell monolayer was detectably infected with SFV 
in IFN pre-treated cultures, a low level of apoptosis would be masked in these 
cultures and not visible by Wst-1 assay. Consistent with this explanation, in Fig. 
4.8.ii L929 cultures pre-treated with IFN and infected increase in viability, while the 
mock-treated infected control decreases in viability. 
Taken together, the data indicate that (i) SFV4 replication is reduced by pre- 
treatment of L929 cells with IFN-α; the percentage of cells expressing ZsGreen and 
the amount of RLuc produced were >90 % and >99 % lower respectively than 
untreated cultures, and (ii) IFN pre-treatment protected L929 cultures from death 
induced by SFV4(3F)-ZsGreen infection.  
The experiments were repeated in human 2fTGH cells. The IFN sensitivity 
assay was carried on human 2fTGH cultures infected with SFV4(3F)-ZsGreen or 
SFV4(3H)RLuc again at MOI 30 and analysed for ZsGreen expression, cell viability 
or RLuc production at various hours post-infection (Fig. 4.9). In 2fTGH cells, IFN 
pre-treatment reduced the percentage of cells expressing ZsGreen compared to the 
mock-treated control, as observed in the L929 cell cultures (Figs 4.9.i). At 8 h post-
infection, ZsGreen was detected in approximately 5 % of the 2fTGH cell monolayer 
pre-treated with IFN. This had not increased even by 48 h post-infection. In contrast, 
by 24 h post-infection ZsGreen was detected in approximately 97 % of the 2fTGH 
cells in the mock-treated control.  
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A Wst-1 viability assay was carried out on 2fTGH cultures treated with IFN 
and infected with SFV4(3F)-ZsGreen virus at MOI 30 at 0, 8, 12 and 24 h post-
infection (2.7). Cultures mock-treated with IFN and infected with SFV4(3F)-
ZsGreen and cells mock-treated with IFN and mock-infected were included as 
controls. The viability of 2fTGH cultures pre-treated with IFN and then infected with 
virus was completely different from that of L929 cultures (Figs 4.8.ii and 4.9.ii). In 
2fTGH cells, the viability decreased from 8 h post-infection following IFN treatment, 
which was similar to the untreated infected culture, not the control uninfected culture 
(Fig. 4.8.ii).  
The IFN sensitivity assay was also carried out in 2fTGH cells infected with 
SFV4(3H)RLuc and RLuc levels were measured at 2, 4, 6, 8, 10, 12 and 24 h post-
infection (2.5). A culture mock-treated and mock-infected was included as a control. 
In 2fTGH cells, RLuc levels in IFN pre-treated cells were consistently lower at all 
time points than in the mock-treated and infected cell cultures (Fig. 4.9.iii). RLuc was 
first detected at 2 h post-infection in both treated and mock-treated cells. This is 
different to the result observed in L929 cells where there was a 2 h delay in first virus 
detection in IFN pre-treated cells (Figs 4.8.iii and 4.9.iii). Again in contrast to L929 
cells, virus replication remained detectable in the IFN pre-treated culture at 24 h 
post-infection. 
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Figure 4.9: Affects of IFN pre-treatment on SFV4(3F)-ZsGreen and 
SFV4(3H)RLuc replication in 2fTGH cells. 
(i) 2fTGH cells were treated with mouse IFN-α (black) or untreated (blue) for 16 h 
and then infected with SFV4(3F)-ZsGreen at MOI 30. At 8, 24 and 48 h post-
infection the mean percentage of the cell monolayer expressing ZsGreen in 15 fields 
was enumerated using fluorescence microscopy. (ii) The experiment was repeated 
and the Wst-1 cell viability assay was carried out at 0, 8, 24 and 48 h post-infection. 
Mock-infected cells were included (red). Dotted line represents the background. (iii) 
2fTGH cells were treated with mouse IFN-α (black) or mock-treated (blue) for 16 h 
and then infected with SFV4(3H)RLuc at MOI 30 and assayed for RLuc levels at 2 h 
intervals for 24 h. Luciferase units are given relative to those in a culture mock-
treated and mock-infected. Each bar or point are the mean of triplicate experiments, 
error bars are standard deviations of the mean. 
 
Taken together, this data indicates that SFV replication is strongly reduced by 
IFN pre-treatment in both human 2fTGH and mouse L929 cells. However, unlike in 
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L929 cultures, IFN pre-treatment did not appear to protect the viability of the 2fTGH 
culture during infection, even though >95 % of the cells in the monolayer were either 
uninfected or did not have a high enough level of infection for detection. Possible 
explanations for the loss in 2fTGH culture viability following IFN pre-treatment and 
SFV infection include, (i) IFN treatment is toxic to 2fTGH cells at this concentration, 
(ii) the majority of the monolayer was infected with virus, but at low levels which 
could not be detected by ZsGreen expression and the presence of virus alone or virus 
and pre-sensitisation by IFN triggered cell death or (iii) the small proportion of 
2fTGH cells with a high level of virus replication are secreting a protein (e.g. TNF-
α) which induces cell death in neighbouring cells. There is a discrepancy between 
the viability results and the plaque assay results for 2fTGH cultures (Figs. 4.1 and 
4.9).  
To investigate if IFN alone is toxic to 2fTGH cells, as has been previously 
reported (Choi et al., 2003), a Wst-1 assay was carried on 2fTGH cultures treated 
with IFN for 8, 24 and 48 h. Untreated and mock-infected cultures and untreated 
cultures infected with SFV4(3F)-ZsGreen at MOI 30 were included as controls. 
Following IFN treatment, viability of the 2fTGH cultures increased from 8 h post-
infection onwards in parallel to the untreated and mock-infected control (Fig. 4.10). 
In contrast, the viability of the 2fTGH cultures in the virus infected control decreased 
over 48 h. In conclusion, IFN alone did not reduce the viability of the culture in this 
experiment. 
 
Figure 4.10: IFN does not induce apoptosis in 2fTGH cells. 
A Wst-1 assay was carried out on 2fTGH cells treated with 10 U/ml of IFN-α 
(black), untreated and infected with SFV4(3F)-ZsGreen at MOI 30 (blue) or mock-
treated and mock-infected (red) at 8, 24 and 48 h post-infection. Dotted line 
represents the background. Each point is the mean of triplicate samples, error bars 
are standard deviations of the mean. 
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 Taken together, these results clearly demonstrate that IFN pre-treatment 
reduces SFV replication in human 2fTGH and mouse L929 cells. However, the 
viability of cultures following IFN pre-treatment and SFV infection varies between 
human 2fTGH and mouse L929 cells.  
 
4.2.3 Establishment of the IFN bioassay 
An IFN bioassay was established to measure functional IFN levels. During infection 
of MEFs SFV4 induces cellular translation shutoff at 2 to 3 h post-infection 
(Breakwell, 2007). This may affect levels of IFN produced during infection. 
Functional IFN levels were investigated to measure the IFN response during SFV 
infection. The bioassay used was based on that previously described by Millers and 
Anders (2003). In this assay, infectious virus in test samples is neutralised by acid 
treatment. However, acid treatment is a time consuming process requiring incubation 
of the supernatant at pH 2 for four days. An alternative method uses UV light to 
inactivate the virus (Dr. Marian Killip, University of St. Andrews, personal 
communication). A method to inactivate virus with UV light was established. 
Efficiency of UV light inactivation depends on the distance of the sample from the 
UV light source, the surface area, the volume of the sample and the length of 
exposure. These parameters were examined when the bioassay was established.  
IFN bioassay samples were prepared by infecting mouse L929 or human 
2fTGH cells with SFV4(3F)-ZsGreen virus at MOI 5 for 24 h (2.4). To optimise the 
neutralisation of the virus in the sample by UV light, samples were aliquoted in 500 
µl volumes into 25 ml universals, eppendorfs, 24-well plates or 6-well plates, 
exposed to UV light for increasing durations of time, added to BHK-21 cells and 
compared for virus presence by enumerating green cells by fluorescence microscopy 
. Mock-infected cultures and infected cultures not exposed to UV light were included 
as controls. The experiment was repeated three times. A representative result is 
shown in Fig. 4.11. No virus was detected in the mock-infected control.  
Exposure to UV light did not destroy virus infectivity in either 25 ml 
universals or eppendorfs. Exposure to UV light greatly reduced virus infectivity in 
24-well and 6-well plates. Efficacy increased with exposure time. Even after an 
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exposure time of 120 minutes, on transfer of samples onto a BHK-21 cell monolayer 
fluorescent virus was detected in the monolayer. This result indicates that at least the 
replicase section of the genome remained intact for replication. To determine if the 
virus present in the samples from the 24-well plate could produce a viable infection, 
a standard plaque assay was carried out on BHK-21 cells treated with the 24-well 
plate samples after 5, 15, 30 and 60 minutes exposure (2.2.9). No plaques were 
observed at any time-point (data not shown). Based on these results, the most 
efficient technique for neutralising virus by UV light was determined to be placing 
the samples in 24-well plates and exposing them to UV light for ≥30 minutes. 
 
 
Figure 4.11: UV light inactivation of SFV4(3F)-ZsGreen under different 
conditions. 
(i) 2fTGH or (ii) L929 cells were infected with SFV4(3F)-ZsGreen at MOI 5 for 24 
h. The supernatant was divided into 500 µl volumes and added to a 6-well plate 
(blue), 24-well plate (black), a 25 ml universal (green) or an eppendorf (red) and 
exposed to UV light in a Stratalinker 1800 for 5, 15, 30 and 60 minutes. Pink, 
infected supernatant without exposure to UV light. Orange, mock-infected 
supernatants. The supernatant was then added to BHK-21 cells for 48 h and analysed 
for ZsGreen positive cells. The decrease in infection was calculated by measuring 
ZsGreen positive cells in 15 fields and dividing the mean number of cells expressing 
ZsGreen in mock-treated cultures. Each point represents one experiment. The graph 
is representative of three experiments.  
 
The efficiency of UV light and acid to neutralise virus was compared by 
infecting L929 or 2fTGH cells with SFV4(3H)-ZsGreen at MOI 5 for 24 h, exposing 
the supernatant samples to UV light or acid and then adding samples to BHK-21 
cells and analysing the level of infection by fluorescence microscopy. Similar 
infection levels of BHK-21 cells were observed when cells were exposed to 
supernatant from L929 or 2fTGH cells inactivated using acid or inactivated by UV 
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(Fig. 4.12). Therefore, UV light inactivation, which was faster, was selected for 
future use. 
 
Figure 4.12: Comparison of virus neutralisation using UV light 
inactivation or acid treatment. 
(i) 2fTGH or (ii) L929 cells were infected with SFV4(3F)-ZsGreen at MOI 5 for 24 
h, the supernatant was collected, exposed to UV light (30 minutes, Stratalinker 1800) 
(black) or acid treatment (pH 2, 4 days) (blue) then added to BHK-21 cell 
monolayers and analysed for ZsGreen expression. The decrease in infection was 
calculated by measuring the number of ZsGreen positive cells in 15 fields and 
dividing by the mean number of ZsGreen positive cells in the mock-treated 
supernatant. Each bar represents the mean of three experiments, error bars are 
standard deviations of the mean. 
 
To establish the IFN bioassay, samples were prepared from L929 or 2fTGH 
cells infected with SFV4 or SFV4nsP2RDR at MOI 5 for 24 h and neutalised by UV 
exposure. SFV4nsP2RDR is a mutant strain of SFV4 with a point mutation in the 
nuclear localisation signal RRR within nsP2 (Rikkonen et al., 1992). It has been 
reported that SFV4nsP2RDR induces significantly more functional IFN than SFV4 
(Breakwell et al., 2007). Therefore, it was considered that SFV4 and SFV4nsP2RDR 
would provide the dynamic range of IFN induction needed in the IFN bioassay. The 
IFN bioassay determines the endpoint of the experiment at which ≥50 % of the cell 
monolayer is protected by IFN from a challenge virus infection. L929 and A549-
NPro cells were used in the bioassay to measure mouse and human IFN respectively; 
both cell lines respond to IFN. A549-NPro cells cannot produce IFN.  
SFV A7(74) was used to challenge L929 cells and EMCV to challenge A549-
NPro cells. SFV A7(74) was not used on human cells, due to the hypothesis that SFV 
is more sensitive to human IFN than to mouse IFN. To determine the amount of 
challenge virus to use, L929 and A549-NPro cells were pre-treated with samples 
likely to contain IFN and then infected with different MOIs of challenge virus for 48 
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h. Monolayers were fixed, stained with toludine blue and analysed for the end-point 
dilution at which ≥50 % of the cell monolayer is protected. Even at MOI 0.1 of 
challenge virus, both the L929 and the 2fTGH cell monolayers were completely 
destroyed if the monolayers were pre-treated with inactivated supernatant from SFV4 
infected cells (Fig. 4.13). In contrast, in L929 or 2fTGH cells exposed to supernatant 
from SFV4nsP2RDR infection, the endpoint dilution increased with decreasing MOI 
of the challenge virus. The greatest endpoint dilution was at MOI 0.1 (Fig. 4.13). 
Based on these results, MOI 0.1 was selected for both the SFV A7(74) and the 
EMCV challenge.  
 
Figure 4.13: IFN bioassay endpoint following challenge with SFV A7(74) 
at different MOI. 
(i) 2fTGH and (ii) L929 cells were overlayed with UV inactivated supernatant from 
SFV4 (blue) or SFV4nsP2RDR (pink) infection for 24 h. A 2-fold serial dilution was 
carried out on the supernatant. 2fTGH and L929 cells then challenged was added at 
MOI 0.1, 1 or 10 and incubated for 48 h. Cells were fixed, stained and analysed for 
the endpoint. The endpoint is the dilution at which ≥50 % of the cells are protected 
from challenge virus induced CPE. Each bar is the mean of triplicate results. Values 
are the reciprocal dilution endpoint. The graph is a representation of three 
experiments. 
 
A mouse or human International IFN standard was included in all IFN bioassays. 
The limit of detection for each bioassay was the end-point at which ≥50 % of the 
monolayer pre-treated with the International IFN standard was protected. The 
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4.2.4 Comparison of IFN production by human and mouse 
fibroblasts infected with SFV4, SFV L10 or SFV A7(74)  
The IFN bioassay was used to compare IFN production by human and mouse 
fibroblasts infected with SFV4, SFV L10 or SFV A7(74). A similar and high level of 
infected cells is preferable for comparison of IFN induction. Therefore, the 
percentage of cell infected was analysed for 2fTGH and L929 cells infected with 
each of three strains of SFV at MOI 5 by immunostaining for nsP3 at 24 h post-
infection (2.3.1). Mock-infected cultures were included as controls. Low levels of 
non-specific staining were observed in the controls (Figs 4.14.D and H). By 24 h 
post-infection, all three strains infected approximately 97 % of both cell monolayers 
(Fig. 4.14).  
 
 
Figure 4.14: Strains of SFV infected most 2fTGH cells and L929 cells by 
24 h post-infection. 
2fTGH or L929 cells were infected with SFV4 (A & E), SFV L10 (B & F), SFV 
A7(74) (C & G) (MOI 5) for 24 h or mock-infected (D & H, mock) and 
immunostained for nsP3. NsP3 is stained red and the nuclei are stained blue.  
 
An IFN bioassay was carried out on UV light inactivated supernatants from 
2fTGH and L929 cells infected with SFV L10, SFV A7(74) or SFV4 at MOI 5 for 24 
h. In parallel, virus levels in the supernatant were determined by plaque assay (2.2.9). 
SeV was included to demonstrate the amount of IFN that the cells were capable of 
producing during a virus infection. SeV (Paramyxoviridae) is a negative-strand RNA 
virus, which is reported to induce high levels of IFN. SeV does not form plaques and, 
therefore, was not included in the plaque assays. Mock-infected cultures were 
included as controls. No infectious virus was detected in mock-infected cultures 
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(data not shown). The experiment was carried out three times and the results were 
combined.  
The titres of infectious virus were similar between SFV L10 and SFV4 in 
both cell lines (Fig. 4.15.i and ii). SFV A7(74) produced higher titres of infectious 
virus than SFV4 and SFV L10. This was significant in the L929 cells (p <0.05 by the 
Mann-Whitney test); SFV A7(74) titres in L929 cells were 0.5 log higher than those 
for SFV4. In both cell lines, all three strains induced relatively little IFN in 
comparison to that induced by SeV (Fig. 4.15.iii and iv). Similar levels of IFN were 
induced by SFV L10, A7(74) and SFV4 in human 2fTGH cells (Fig. 4.15.ii). In 
contrast, SFV4 induced significantly more IFN than SFV L10 or SFV A7(74) in 
mouse L929 cells. SFV L10 also induced significantly more IFN than SFV A7(74) in 
the L929 cells (Fig. 4.15.iv). In L929 cells, infectious virus titres and IFN induction 
levels were inverse, with SFV A7(74) producing the highest virus tire and inducing 
the lowest level of IFN. 
 
 
Figure 4.15: Functional IFN induced by SeV , SFV4, SFV L10 or SFV 
A7(74) infected fibroblasts. 
(i) and (iii) 2fTGH or (ii) and (iv) L929 cells were infected with SeV, SFV4, SFV 
L10 or SFV A7(74) at MOI 5 for 24 h and assayed for infectious virus (i and ii) or 
functional IFN (iii and iv). Each point represents one experiment. Each bar is the 
mean of triplicate experiments, error bars are standard deviations of the mean. * = 
significant difference (p < 0.05 Mann-Whitney test). 
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To determine whether similar results would be observed in different cell 
lines, the experiment was repeated using human Hs 633T cells and mouse NIH 3T3 
cells. No infectious virus was detected in mock-infected cells (data not shown). 
Similar titres of infectious virus were produced by SFV L10 and SFV4 in both cell 
lines (Fig. 4.16.i and ii). In both cell lines, significantly higher titres of infectious 
SFV A7(74) (0.5 log) were detected compared to SFV4. In Hs 633T cells, SFV 
A7(74) titres were also higher than SFV L10. In contrast, SFV A7(74) and L10 
replicated to similar titres in NIH 3T3 cells. Again, all three strains induced 
considerably lower levels of IFN than SeV in both cell lines (Fig. 4.16.iii and iv). In 
NIH 3T3 cells, as in L929 cells, SFV4 induced significantly more IFN than SFV L10 
(p <0.05 by the Mann-Whitney test). 
Taken together with the data presented in Fig. 4.15, it can be concluded that 
all three strains of SFV tested induced relatively little IFN in human or mouse 
fibroblasts in comparison to SeV infection. In human fibroblasts, IFN levels were not 
significantly different between the virus strains, even though SFV A7(74) replicated 
to higher titres. In mouse L929 cells, virus production (SFV A7(74) > SFV L10 > 
SFV4) was inversely related to IFN levels (SFV4 > SFV L10 > SFV A7(74)), as 
might be expected. However, in mouse NIH 3T3 cells, this correlation between virus 
titres and IFN levels was not observed. In both L929 and NIH 3T3 cells, SFV4 
induced significantly more IFN than SFV L10. 
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Figure 4.16: Functional IFN induced by SeV, SFV4, SFV L10 or SFV 
A7(74) infected fibroblasts. 
(i) and (iii) Hs 633T cells or (ii) and (iv) NIH 3T3 cells were infected with SeV, 
SFV4, SFV L10 or SFV A7(74) at MOI 5 for 24 h and then assayed for infectious 
virus (i and ii) or functional IFN (iii and iv). Each point represents one experiment. 
Each bar is the mean of triplicate experiments, error bars are standard deviations of 
the mean. Error bars in (v) are too small to see. * = significant difference (p 0.05 
Mann-Whitney test). 
 
4.2.5 Comparison of the sensitivity of SFV L10, A7(74) and 
SFV4 to human and mouse IFN in fibroblasts  
One study reports that SFV strains differ in their sensitivity to the effects of IFN pre-
treatment (Deuber & Pavlovic, 2007). To determine if the well characterised SFV 
L10, A7(74) and SFV4 strains also differ in sensitivity to the affects of IFN, an IFN 
sensitivity assay was carried out on 2fTGH, Hs 633T, L929 and NIH 3T3 cells 
infected with the three strains of SFV at MOI 5 for 24 h. Virus titres in the 
supernatant were measured by plaque assay. The experiment was carried out three 
times and the results were combined. No infectious virus was detected in mock-
infected cells (data not shown). Treatment of mouse or human cells with IFN prior to 
infection reduced the titres of all three viruses by ≥ 75 % (Fig. 4.17). Taken together, 
it can be concluded that that these three strains of SFV are highly and equally 
sensitive to IFN pre-treatment and that this sensitivity does not vary between human 
and mouse cells. 
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Figure 4.17: SFV4, SFV L10 and SFV A7(74) are equally susceptible to 
IFN pre-treatment in human and mouse fibroblasts. 
(i) 2fTGH cells, (ii) Hs 633T cells, (iii) L929 cells and (iv) NIH 3T3 cells were 
treated with 10 U/ml of IFN-α or mock-treated for 16 h and then infected with SFV4, 
SFV L10 or SFV A7(74) at MOI 5. At 24 h post-infection samples were assayed for 
infectious virus by plaque assay and expressed as a percentage of the mock-treated 
control. Each bar is the mean of triplicate experiments, error bars are standard 
deviations of the mean.  
 
4.2.6 Summary of findings 
• Plaque phenotype varied between human and mouse cells infected with SFV 
L10, SFV A7(74) and SFV4. 
• Plaque phenotype varied between human cells with an intact IFN system and 
cells with a defective IFN system infected with SFV L10, SFV A7(74) and 
SFV4. 
• Treatment of cultures with IFN prior to infection with SFV4(3H)RLuc, 
SFV4(3F)-ZsGreen, SFV L10, SFV A7(74) or SFV4 greatly reduced virus 
replication.  
• SFV L10, SFV A7(74) and SFV4 were equally sensitive to the effects of IFN 
pre-treatment in both human and mouse cells. 
• The viability of cell cultures following IFN treatment and infection was 
completely different in human cell cultures compared to mouse cell cultures: 
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human cultures decreased in viability, whereas mouse cultures increased in 
viability. 
• SFV L10, SFV A7(74) and SFV4 infection induced low levels of IFN relative 
to SeV, in both human and mouse cells. 
• In human cells, similar levels of IFN were induced by SFV L10, SFV A7(74) 
and SFV4 infection. 
• In mouse fibroblasts, infection with SFV4 induced more IFN than infection 
with SFV L10. The results for SFV A7(74) infection were variable. 
4.2.7 Conclusions 
The results presented in this chapter indicate that SFV plaque phenotype depends on 
(i) cell species, whether the cells are human or mouse, and (ii), at least in the case of 
human cells, the presence of an intact IFN system. All three strains of SFV studied 
were equally sensitive to IFN pre-treatment in mouse and human fibroblasts, 
although virus replication was not completely abolished. All three strains of SFV 
induced only small amounts of IFN compared to SeV infection in both mouse and 
human fibroblasts. In human fibroblasts, the three strains of SFV induced similar 
amounts of IFN. In mouse fibroblasts, SFV4 induced significantly more IFN than 
SFV L10. Culture viability varied between human and mouse fibroblasts following 
IFN pre-treatment and infection. 
 
Chapter 4  Results 
 134 
4.3 Discussion 
This chapter examined (i) the interaction of SFV with IFN in human cells compared 
to mouse cells and (ii) the interaction of different strains of SFV with the IFN 
system. These will be discussed in turn. 
 
4.3.1 The interaction of SFV with IFN in human cells 
compared to mouse cells  
RNA viruses have been responsible for many recent outbreaks and epidemics in 
humans and other animals; influenza virus, SARS-CoV, CHIKV, DENV and WNV 
are examples. The emergence or re-emergence of a virus requires successful 
infection of a host and in the case of vector-borne disease, a vector. Disease in a new 
host can be driven by a number of parameters including (i) change in distribution of 
virus, host or vector, (ii) more efficient virus entry into the host or host tissues or 
cells and/or (iii) evasion of host cellular innate or adaptive immune responses. In 
November 2002, SARS-CoV emerged in China and caused severe respiratory 
disease. Due to rapid international travel, SARS-CoV spread to Canada, Vietnam and 
Singapore and infected thousands of people. In the case of SARS, the mutation of 
two amino acids probably enabled it to transfer from Civet cats to humans, replicate 
efficiently and, presumably, transmit to other humans (Qu et al., 2005). Since 2005, 
CHIKV has re-emerged throughout Africa, Asia and the Indian Sub-continent. 
Clinical cases have also occurred in Italy, 2007 and France, 2010 (Rezza et al., 
2007;Grandadam et al., 2011). Between 2005 and 2006 CHIKV emerged in the 
Indian Ocean island of La Reunion and produced 265,000 clinical cases in a 
population of 770,000 (Enserink, 2007). The original vector of CHIKV was the 
Aedes aegypti mosquito. The mutation of a single amino acid in the glycoprotein E1 
enabled CHIKV to efficiently infect Aedes albopictus and extend its geographical 
range (Tsetsarkin et al., 2007). The question remains: why is CHIKV causing human 
epidemics while the closely related SFV is not? A proposed explanation for the 
difference between SFV and CHIKV is that SFV cannot evade or control the human 
IFN system. Conversely, CHIKV may not be able to evade or control the mouse IFN 
system since it appears to be difficult to infect mice unless they are deficient in IFN 
responses (Couderc et al., 2008).  
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 In this chapter, the interaction of SFV with the human type-I IFN system was 
investigated and compared to its interaction with the mouse system. In plaque assays 
on human cells, SFV infection only produced cloudy plaques or cellular 
agglomerations (Fig. 4.1). On inspection under the microscope, cell death was not 
obvious in infected 2fTGH cells. In contrast, clear plaques were observed in mouse 
L929 cells infected with all three strains of SFV (Fig. 4.3). When the IFN system 
was compromised in human cells, SFV infection produced clear plaques (Fig. 4.4). 
Immunostaining studies to investigate numbers of infected cells showed that areas of 
human cells were infected, but they did not appear to be dying (Fig. 4.2). The data 
suggests that the plaque phenotype produced by SFV infection depends on the 
whether the cells are human or mouse and, in the case of human cells, whether the 
IFN system is intact. 
 The interaction of SFV with type-I IFN was investigated further in human 
and mouse fibroblasts. In both human and mouse cells, pre-treatment with IFN 
reduced SFV replication, although even at high concentrations of IFN-α replication 
was not completely abolished (Figs 4.6, 4.7, 4.8 and 4.17). Possible explanations for 
this residual virus activity include (i) SFV replicates in most IFN treated cells at low 
levels, (ii) some cells, perhaps related to the cell cycle, are not rendered into the 
antiviral state by IFN pre-treatment and SFV replicates in these or (iii) in some cells, 
again perhaps related to cell cycle, SFV is able to disassemble the antiviral state and 
replicate to high levels. In Fig. 4.7.i SFV only replicated to detectable levels in a 
small subset of cells; while in Fig. 4.7.iii RLuc levels were consistently lower in IFN 
pre-treated and infected cultures compared to untreated and infected cultures. These 
results are consistent with the suggestions above that SFV replicates in IFN pre-
treated cells at low levels (i) and at high levels in a few cells either because these 
cells are somehow different (cell cycle) and are not in an antiviral state (ii) or 
because, most likely, the virus disassembles the antiviral state (iii). In Fig. 4.7.iii, 
there was a delay of 2 h in RLuc detection compared to the untreated and mock-
infected control. This delay may reflect the time taken for SFV to successfully 
dismantle the antiviral state in a few cells. 
The results in Figs 4.6, 4.7, 4.8 and 4.17 indicate that SFV is sensitive to the 
IFN-induced antiviral state in both human and mouse fibroblasts. However, the 
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viability of cultures pre-treated with IFN and then infected with SFV varied between 
human and mouse cultures. In mouse L929 cultures, viability increased following 
IFN pre-treatment and infection, as in the mock infected control. This result suggests 
that IFN pre-treatment protects L929 cultures from SFV induced cell death. In 
contrast, in 2fTGH cultures pre-treated with IFN and infected with SFV, the viability 
decreased over time, as in the untreated and infected control. Possible explanations 
for the loss in 2fTGH culture viability following IFN treatment and SFV infection 
include that (i) IFN treatment is toxic to 2fTGH cells at this concentration, (ii) the 
majority of the monolayer was infected with virus at low levels which could not be 
detected by ZsGreen expression, and IFN pre-treatment sensitised these cells to 
apoptosis following subsequent virus infection and/or (iii) infected 2fTGH cells 
secrete a protein which induces cell death in neighbouring cells. Fig. 4.9 indicated 
that 10 U/ml of IFN-α was not toxic to 2fTGH cell cultures. In support of (iii), 
Kumar et al (1997) reported that the ISG TNF-α can induce 2fTGH cell death TNF-
α induction of cell death in 2fTGH or, potentially, other cell lines could prove vital 
in eliminating SFV infection. Explanations (ii) and (iii) seem most likely and cannot 
be distinguished by the studies presented here. In conclusion, SFV is sensitive to the 
antiviral state in both human and mouse fibroblasts. 
Treatment of cultures with IFN prior to infection reduced SFV replication by 
≥75 % in both human and mouse cells (Fig. 4.17). Therefore increased sensitivity of 
SFV to human IFN does not appear to be responsible for the avirulence of SFV in 
humans. The levels of IFN induced during SFV infection were compared in human 
and mouse cells and here differences were observed (Fig. 4.15 and 4.16). In human 
cells, SFV L10, SFV A7(74) and SFV4 induced similar low levels of IFN. In contrast 
in mouse cells, SFV4 induced more IFN than SFV L10. However, all three strains 
induced extremely little IFN relative to SeV in both human and mouse cells. The 
SeV used was purchased and may contain defective particles that strongly induce the 
IFN response in cell culture. In contrast, all three strains of SFV were carefully 
propagated to limit the production of defective particles. It is likely that poor 
propagation of SFV would result in defective particles and IFN induction similar to 
in SeV infection. Potentially, strains of SFV have evolved to inhibit the IFN response 
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in both human and mouse cells. Given the sensitivity of SFV to IFN pre-treatment, it 
is unsurprising that SFV may have evolved mechanism(s) to inhibit IFN production.  
The data presented here suggests that SFV replicates differently in human and 
mouse cells. IFN is important in controlling SFV infection and, hence, its production 
is largely inhibited by SFV. However, based on these results, it is unlikely that IFN 
induction is responsible for the mild infection of SFV in humans. However, the 
results presented here do not exclude the possibility that IFN does determine the 
pathogenesis of CHIKV in mice. It would be interesting to directly compare CHIKV 
and SFV induction of IFN and sensitivity to the effects of IFN in both human and 
mouse cells. This was planned to be part of this study, but was not done due to the 
unavailability of a category 3 laboratory. 
 
4.3.2 The interaction of different strains of SFV with the IFN 
system 
The second focus of this chapter was the influence of IFN in determining the 
virulence of different strains of SFV. Several strains of SFV have been identified that 
differ in virulence in adult mice (Bradish et al., 1971). Well-characterised strains 
include the virulent SFV L10 and the avirulent SFV A7(74) and SFV4. The factor(s) 
that determine virulence remain unclear. One possible explanation is that the strains 
have different interactions with the IFN response, which affects IFN induction and/or 
IFN efficacy and this determines strain virulence. In this chapter, SFV L10, SFV 
A7(74) and SFV4 strains were compared for IFN induction and sensitivity to the 
effects of IFN in fibroblasts. Previous studies showed that SFV infection induces IFN 
production in mice and that IFN controls SFV spread in mice (Bradish et al., 
1975;Fragkoudis et al., 2007). One study reports that strains of SFV vary in their 
sensitivity to IFN pre-treatment in MEFs (Deuber & Pavlovic, 2007). In that study, 
MEFs were treated with 500 U/ml of IFN-α for 16 h and then infected with the 
virulent L10 or the previously unreported avirulent SFV V42. At 24 h post-infection, 
the supernatants were collected and compared for infectious virus titres by plaque 
assay. SFV V42 had a greater reduction in virus titre than SFV L10 and was 
suggested, therefore, to be more sensitive to the effects of IFN (Deuber & Pavlovic, 
2007). In the similar study carried out in this research project, SFV L10, SFV A7(74) 
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and SFV4 were equally sensitive to the effects of IFN pre-treatment (Fig. 4.17). This 
was observed in four different fibroblast cell lines, both human and mouse. This 
result is consistent with a small study by Bradish and Titmuss (1981) that 
demonstrated a similar reduction in the replication of SFV L10 and SFV A7(74) 
following IFN treatment of mice. Possible explanations for the difference found by 
Deuber and Pavlovic (2007) include (i) SFV replicates differently in primary cells 
(MEFs) compared to continuous cell lines (L929 cells and others), (ii) high 
concentrations of IFN are required to detect differences in the strains and/or (iii) V42 
is an unusual strain that behaves differently to the other strains of SFV. 
Induction of IFN by SFV L10, SFV A7(74) and SFV4 varied between human 
and mouse cells (Figs 4.15 and 4.16). In human fibroblasts, similar levels of IFN 
were induced by all three strains (Figs 4.15.iii and 4.16.iii). This suggests that there 
is no difference between the strains in inducing and/or inhibiting and/or evading the 
IFN response in human fibroblasts. In contrast, in two lines of mouse fibroblasts, 
SFV4 induced significantly more IFN than SFV L10 (Figs 4.15.iv and 4.16.iv) and in 
one cell line more than SFV A7(74). All three strains infected >90 % of the cell 
monolayer (Fig. 4.14). One possible explanation is that SFV4 is less efficient at 
inhibiting and/or evading the mouse IFN response than SFV L10 or SFV A7(74) and, 
therefore, greater levels of IFN are induced. This would also explain why SFV4 is 
less virulent after ip inoculation in the mouse than SFV L10. It would be interesting 
to compare the IFN levels in mice infected with SFV4 and SFV L10 to confirm this 
observation.  
 Interestingly, the levels of IFN induced by SFV infection were extremely low 
compared to SeV infection (Figs 4.15 and 4.16). This data supports a study showing 
that CHIKV, SINV, VEEV and EEEV induce low levels of IFN compared to SeV in 
MEFs (Burke et al., 2009). The ability of alphaviruses to inhibit the IFN response is 
surprising considering that SFV infection induces a detectable IFN response in mice 
(Bradish et al., 1975;Fragkoudis et al., 2007). One possible explanation for an 
observed IFN response in infected mice is that another cell line, such as the pDC, 
produces IFN and not the fibroblasts. pDCs are potent producers of IFN during virus 
infection in mice (Cella et al., 1999;Barchet et al., 2002;Dalod et al., 2002). It would 
be interesting to test this hypothesis in mice deficient in pDCs, as was done with 
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VEEV VRP (Tonkin et al., 2012). An alternative explanation is that during infection 
of mice SFV undergoes multiple rounds of replication and defective particles are 
produced. Defective particles can induce the IFN response, as suggested for SeV 
infection of cell cultures in the experiments presented here. This hypothesis would 
explain the levels of IFN detected in mice infected with SFV.  
Possible explanations for difference in IFN production by strains of SFV and 
SeV include (i) strains of SFV inhibit the IFN response more efficiently than SeV 
infection or (ii) SeV induces the IFN response more efficiently than SFV infection. 
Studies using SFV and SINV demonstrate that the nuclear transcription factors NF-
kB and IRF-3 translocate to the nucleus after infection (Breakwell et al., 2007;Burke 
et al., 2009). NF-kB and IRF-3 induce transcription of the IFN genes. Therefore, any 
IFN inhibition is likely to be downstream of the transcription of IFN. Recent studies 
demonstrate that CHIKV and SINV inhibit the phosphorylation of STAT1 (Fros et 
al., 2010;Simmons et al., 2010). STAT1 is required for IFN signalling in cells. SFV 
may also inhibit STAT1 phosphorylation. 
 
4.3.3 Final Summary 
CHIKV is currently epidemic throughout the tropics, while the closely related SFV is 
not. A proposed explanation for the difference between SFV and CHIKV is that SFV 
cannot evade or control the human IFN system, while CHIKV can. In the data 
presented here, SFV did not produce typical plaques on human cells and this was 
related to an intact IFN response. Strains of SFV induced extremely little IFN in both 
human and mouse cells compared to SeV infection. Furthermore, strains of SFV 
were extremely sensitive to the effects of IFN pre-treatment in both human and 
mouse cells. Therefore, IFN is important in controlling SFV infection, but IFN does 
not appear to be the determining factor in the avirulence of SFV in humans.  
 Studies in the literature have proposed that the virulence of strains of SFV is 
determined by the IFN response. However, in the data presented here three strains of 
SFV, which have a different virulence in adult mice, induced, in general, similar 
amounts of IFN. Furthermore, the three strains of SFV were equally sensitive to the 
effects of IFN pre-treatment. Therefore, the IFN response does not appear to 
determine SFV strain virulence. Interestingly, the three strains induced extremely 
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little IFN in fibroblasts relative to SeV infection. That SFV may antagonise the IFN 
response will be explored in the next chapter. 
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5.1 Introduction 
The results presented in the previous chapter showed that three strains of SFV 
induced only low levels of IFN, at least relative to SeV infection, in human and 
mouse fibroblasts (Figs 4.15 and 4.16). SFV encodes nine proteins: the replicase 
proteins nsPs 1-4 in the 5’ two thirds of the genome and the structural proteins 
(capsid protein, the envelope glycoproteins and 6K) in the 3’ third. NsP2 has been 
implicated in antagonising the IFN system (Fazakerley et al., 2002; Breakwell et al., 
2007), although the mechanism remains unclear. NsP3 has been demonstrated to be a 
virulence determinant (Tarbatt et al., 1997; Tuittila et al., 2000). The potential 
interaction of nsP3 with the IFN system has not been investigated. In this chapter, 
nsP2 and nsP3 (1.1.2) and their interaction with the IFN response will be investigated 
using the mutant viruses SFV4-RDR (Rikkonen et al., 1992) and SFV4nsP3∆50 
(Vihinen et al., 2001)). SFV4-RDR and SFV4nsP3∆50 are described in section 1.1.2 
and 1.1.3 and a schematic representation is shown in Fig 2.1. In addition, a 
mechanism by which SFV antagonises the IFN system will be proposed. 
 
5.1.2 Objectives 
1. Determine if SFV4-RDR or SFV4nsP3∆50 infections induce more IFN than 
SFV4 in mouse and human cells.  
2. Determine if SFV4-RDR or SFV4nsP3∆50 are more sensitive to the effect of 
IFN than SFV4 in mouse and human cells.  
3. Determine if strains of SFV inhibit the phosphorylation of STAT1 and, if so, 
does this differ between SFV4 and SFV4-RDR or SFV4nsP3∆50 infection in 
mouse and human cells. 
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5.2 Results 
5.2.1 Comparison of IFN production by fibroblasts infected 
with SFV4, SFV4-RDR or SFV4nsP3∆50 
To confirm that nsP2 is involved in inhibiting the IFN system and to investigate 
whether the C-terminal hyperphosphorylated region of nsP3 also affects the IFN 
system, two mutants were analysed: SFV4-RDR and SFV4nsP3∆50 (Table 2.2). 
Firstly, to ensure that SFV4-RDR and SFV4nsP3∆50 had the correct mutation, NIH 
3T3 cells were infected with SFV4, SFV4-RDR or SFV4nsP3∆50 at MOI 10 for 6 h, 
the RNA was extracted and converted into cDNA, the sequence encoding nsP2 or 
nsP3 were amplified by PCR and the product was sent to Dundee Sequencing 
Services for sequencing (2.13.1). The sequence of each virus was as expected. 
To study the effect of IFN induction, a high level of infection is preferable. 
To determine the level of infection, 2fTGH or L929 cells were infected with SFV4, 
SFV4-RDR or SFV4nsP3∆50 at MOI 5 for 24 h and immunostained for virus nsP1 
(2.3.1). In Fig. 4.14 cells infected with SFV were immunostained for nsP3. In the 
present experiment nsP1 was selected instead because the deletion in SFV4nsP3∆50 
could affect the binding affinity of the anti-nsP3 antibody. 2fTGH and L929 cells 
were used as representative human and mouse cell lines. Low levels of background 
fluorescence were observed in the negative control (Fig. 5.1). In SFV4 and SFV4-
RDR infection, nsP1 was detected in over 90 % of the cells in both cell lines (Fig. 
5.1). In contrast, in SFV4nsP3∆50 infection, nsP1 was only detected in 50 - 70 % of 
cells in either cell line (Fig. 5.1). Even at MOI 30, the percentage of cells infected 
with SFV4nsP3∆50 did not increase (data not shown). Given the nature of the 
deletion in SFV4nsP3∆50 it is unlikely that SFV4nsP3∆50 entered fewer cells than 
SFV4. It is more likely that this deletion in nsP3 affects the ability of the virus to 
replicate to detectable levels in some cells in the culture, perhaps related to cell 
cycle. 
 






Figure 5.1: Extent of infection of 2fTGH and L929 cells with SFV4, SFV4-
RDR or SFV4nsP3∆50 
 (i) 2fTGH cells were infected with SFV4 (A), SFV4-RDR (B), SFV4nsP3∆50 (C) at 
MOI 5 for 24 h or mock-infected (D) and immunostained for virus nsP1 (red). Nuclei 
are stained blue. Arrows identify nsP1-negative cells. (ii) 2fTGH cells positive for 
nsP1 were calculated as a percentage of the total number of cells. Bars are the mean 
of 15 microscope fields; error bars are standard deviations of the mean. (iii) The 
experiment was repeated in L929 cells. 
 
To investigate the effect of nsP2RDR and nsP3∆50 on IFN induction, human 
fibroblast cell lines 2fTGH and Hs 633T and mouse fibroblast cell lines L929 and 
NIH 3T3 were infected at MOI 5 with SFV4, SFV4-RDR or SFV4nsP3∆50 for 24 h. 
The supernatant was analysed for infectious virus (plaque assay) and the amount of 
IFN (IFN bioassay) (2.2.9, 2.4). SeV was included to demonstrate the amount of IFN 
that the cells were capable of producing during a virus infection. No infectious virus 
was detected in mock-infected cells (data not shown). The experiment was carried 
out three times and the results combined. In general, SFV4 produced higher titres of 
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infectious virus than SFV4-RDR or SFV4nsP3∆50 (Fig. 5.2). The difference 
between SFV4 and SFV4-RDR was significant in both human cell lines (p<0.05 by 
the Mann-Whitney test), but not in either mouse cell line. The difference between 
SFV4 and SFV4nsP3∆50 was significant in L929 cells and Hs 633T cells (p<0.05 by 
the Mann-Whitney) (Fig. 5.2.ii and 5.2.iii). As in chapter 4, NIH 3T3 cells showed 
the greatest variability between replicates and no significant differences between 
viruses (Fig. 5.2.iv). In Hs 633T cells, production of infectious virus with all three 
strains was reduced by >90 % compared to the other cell lines (Fig. 5.2.iii).  
 
 
Figure 5.2: Infectious virus titres in fibroblasts infected with SFV4, 
SFV4-RDR or SFV4nsP3∆50 
 (i) 2fTGH cells, (ii) L929 cells, (iii) Hs 633T cells or (iv) NIH 3T3 cells were 
infected with SFV4 (blue circle), SFV4-RDR (RDR, pink square) or SFV4nsP3∆50 
(Delta50, grey triangle) at MOI 5 for 24 h and infectious virus measured by plaque 
assay. Each symbol represents one experiment. The experiment was repeated three 
times and combined. * significant difference (p <0.05 by the Mann-Whitney test). 
 
 IFN induction during infection with SFV4 or SFV4-RDR at MOI 5 was 
compared (Fig. 5.3). SFV4-RDR induced significantly higher levels of IFN than 
SFV4 in all four cell lines (p <0.05 by the Mann-Whitney test). In two of the cell 
lines, SFV4-RDR induced similar levels of IFN to infection with SeV. This induction 
was not dependent on whether the cells were human or mouse. 
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Figure 5.3: IFN production by fibroblasts infected with SeV, SFV4 or 
SFV4-RDR 
 (i) 2fTGH cells, (ii) L929 cells, (iii) Hs 633T cells or (iv) NIH 3T3 cells were 
infected with SeV (SeV, Black), SFV4 (blue) or SFV4-RDR (RDR, pink) at MOI 5 
for 24 h and IFN levels were measured using the IFN bioassay. Striped columns are 
human cell lines (i & iii) and clear columns are mouse cell lines (ii & iv). Each 
column represents the mean of three experiments; bars are standard deviations of the 
mean. * significant difference (p <0.05 by the Mann-Whitney test). 
 
 Next, IFN induction during infection at MOI 5 with SFV4 or SFV4nsP3∆50 
was compared. Both SFV4 and SFV4nsP3∆50 induced much lower levels of IFN 
than SeV in all four cells lines (Fig. 5.4). In general, SFV4nsP3∆50 induced more 
IFN than SFV4. This was significant in mouse L929 and NIH 3T3 cells (p <0.05 by 
the Mann-Whitney test). In Hs 633T cells, SFV4 induced more IFN than 
SFV4nsP3∆50. This was in contrast to 2fTGH, L929 or NIH 3T3 cell cultures. One 
possible explanation is that SFV4nsP3∆50 only replicates in Hs 633T at low levels 
(Fig. 5.2), which in turn may only induce small amounts of IFN.  
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Figure 5.4: IFN production by fibroblasts infected with SFV4 or 
SFV4nsP3∆50 
(i) 2fTGH cells, (ii) L929 cells, (iii) Hs 633T cells or (iv) NIH 3T3 cells were 
infected with SeV (SeV), SFV4 (blue) or SFV4nsP3∆50 (Delta50, grey) at MOI 5 for 
24 h and IFN levels were measured using the IFN bioassay. Striped columns are 
human cell lines (i & iii) and clear columns are mouse cell lines (ii & iv). Each 
column represents the mean of three experiments; bars are standard deviations of the 
mean. * significant difference (p <0.05 by the Mann-Whitney test). 
 
To investigate whether SFV4, SFV4-RDR and SFV4nsP3∆50 infect Hs 633T 
cells less efficiently than 2fTGH cells; 2fTGH and Hs 633T cells were infected with 
SFV4, SFV4-RDR and SFV4nsP3∆50 at MOI 5 for 24 h and immunostained for 
nsP1. In Hs 633T cells, ≥50 % less of the cell monolayer stained positive for nsP1 
compared to in 2fTGH cells in SFV4, SFV4-RDR and SFV4nsP3∆50 infections 
(Fig. 5.5). In both 2fTGH and Hs 633T cells, nsP1 was detected in fewer cells in 
cultures infected with SFV4nsP3∆50 than SFV4. In Hs 633T cells, nsP1 was only 
detected in ≤10 % cells infected with SFV4nsP3∆50. The results in Fig. 5.5 support 
the data presented in Fig. 5.2. Taken together, the data in Figs 5.2 and 5.5 indicate 
that SFV4nsP3∆50 infects Hs 633T at low levels, which may explain why this virus 
induces less IFN than SFV in this cell line. If the values in Fig. 5.4 are normalised to 
the extent of infection given in Fig. 5.5, for these cell lines, in 2fTGH cells 
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SFV4nsP3∆50 induces 3 times more IFN than SFV4, while in Hs 633T cells SFV4 
induces 3 times more IFN than SFV4nsP3∆50.  
 
Figure 5.5: Comparison of SFV4, SFV4-RDR and SFV4nsP3∆50 infection 
in 2fTGH and Hs 633T cells 
(i) 2fTGH cells or Hs 633T cells were infected with SFV4 at MOI 5 for 24 h or 
mock-infected (D & H) and immunostained for virus nsP1. NsP1 is stained red (A & 
E). The nuclei are stained blue (B & F). Merged images (C & G). (ii) 2fTGH 
(horizontal stripes) and (iii) Hs 633T (vertical stripes) cells infected with SFV4, 
SFV4-RDR or SFV4nsP3∆50 that stained positive for nsP1 were calculated as a 
percentage of the total number of cells as determined by counting nuclei (blue). Bars 
are the mean of 15 microscope fields; error bars are standard deviations of the mean.  
 
In conclusion, SFV4-RDR and SFV4nsP3∆50, in general, induce greater 
levels of IFN than WT SFV4 in both mouse and human fibroblasts. 
 
5.3.2 Comparison of the effect of IFN on SFV4, SFV4-RDR and 
SFV4nsP3∆50 virus production in fibroblasts 
An IFN sensitivity assay was carried out to compare the effect of IFN pre-treatment 
on the replication of SFV4, SFV4-RDR and SFV4nsP3∆50 at MOI 5 in 2fTGH, 
L929, Hs 633T and NIH 3T3 cells (2.5). SFV4 was first compared to SFV4-RDR 
and a mock-infected control (Fig. 5.6). No infectious virus was detected in the mock-
infected control (data not shown). Following IFN pre-treatment, both SFV4 and 
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SFV4-RDR showed a reduction in infectious virus titre of ≥75 % relative to the 
mock-treated control. SFV4-RDR appeared to be less affected by IFN pre-treatment 
than SFV4 (Fig. 5.6.i, ii and iv).   
 
Figure 5.6: Effect of IFN pre-treatment on SFV4 and SFVnsP2RDR 
replication in fibroblasts 
The IFN sensitivity assay was carried out on (i) 2fTGH cells, (ii) L929 cells, (iii) Hs 
633T cells or (iv) NIH 3T3 cells infected with SFV4 (blue) or SFV4-RDR (RDR, 
pink). Infectious virus titres in IFN treated cells were normalised to mock-treated 
cells infected with virus. Striped columns are human cell lines (i & iii) and clear 
columns mouse cell lines (ii & iv). Each column represents the mean of three 
experiments; bars are standard deviations of the mean. * significance (p <0.05 and by 
the Mann-Whitney test). 
 
 The IFN sensitivity assay was carried out on SFV4, SFV4nsP3∆50 at MOI 5 
or a mock-infected control (2.5). No infectious virus was detected in the mock-
infected control (data not shown). Following IFN treatment, both SFV4 and 
SFV4nsP3∆50 showed a reduction in infectious virus titre of ≥75 % relative to the 
mock-treated control (Fig. 5.7). One possible explanation for the apparent different 
sensitivity of SFV4, SFV4-RDR and SFV4nsP3∆50 to IFN pre-treatment is that 
SFV4-RDR and SFV4nsP3∆50 initially infects fewer cells in the culture than SFV4, 
which is, in part, due to the IFN response (Breakwell et al., 2007). IFN pre-treatment 
renders the majority of the culture into an antiviral state. The difference between IFN 
treated and untreated cultures would be more apparent in SFV4 infections compared 
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to SFV4-RDR or SFV4nsP3∆50, as a greater percentage of cells were initially 
infected by SFV4 and would now be protected. Taken together, the mutant viruses 
and SFV4 were sensitive to IFN pre-treatment and this sensitivity was not dependent 
on whether the cells were human or mouse (Figs 5.6 and 5.7).  
 
Figure 5.7: Effect of IFN pre-treatment on SFV4 and SFVnsP3∆50 
replication in fibroblasts 
The IFN sensitivity assay was carried out on (i) 2fTGH cells, (ii) L929 cells, (iii) Hs 
633T cells or (iv) NIH 3T3 cells infected with SFV4 (blue) or SFV4nsP3∆50 
(Delta50, grey). Infectious virus titres in the IFN treated cells were normalised to the 
mock treated cells. Striped columns are human cell lines (i & iii) and clear columns 
are mouse cell lines (ii & iv). Each column represents the mean of three experiments; 
bars are standard deviations of the mean. * significant (p <0.05 by the Mann-
Whitney test). 
 
5.2.2 Do SFV4, SFV L10 or SFV A7(74) inhibit the 
phosphorylation of STAT1 during the infection of fibroblasts? 
In chapter 4 it was demonstrated that strains of SFV induced the production of low 
levels of functional IFN in fibroblasts relative to SeV. This data suggests that SFV 
may antagonise the IFN system, either at the signalling or, most likely, the induction 
phase. The ability of SFV to antagonise IFN induction has been previously 
investigated in this laboratory (Breakwell et al., 2007). However, IFN signalling in 
SFV infected cells has not been analysed. Recent studies have shown that the related 
alphaviruses CHIKV and SINV can inhibit IFN signalling by inhibiting the 
phosphorylation of STAT1. The phosphorylation of STAT1 is essential for IFN 
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signalling (Fros et al., 2010; Simmons et al., 2010). To determine if SFV also 
inhibits the phosphorylation of STAT1 and, therefore, IFN signalling, a Western blot 
was carried out on 2fTGH, Hs 633T, L929 and NIH 3T3 cells infected with SFV4, 
SFV L10 or SFV A7(74) to detect phosphorylated STAT1. MOI 30 was used in 
order to infect all the cells at the same time. Cells were lysed at 10 h post-infection as 
IFN is produced early after infection with SFV (Breakwell et al., 2007) and any 
phosphorylation of STAT1 should have occurred by this time. At 10 h post-infection, 
cultures were treated with IFN-α for 45 minutes to induce STAT1 phosphorylation 
or with PBSA as a negative control. Blots were probed for phosphorylated STAT1, 
and then β-actin as a loading control. Mock-infected and mock-treated cell lysates 
were included as a negative control. Mock-infected lysates treated with IFN were 
included as a positive control to show the amount of phosphorylated STAT1 possible 
within the cell culture. The experiment was repeated three times with each cell line 
and representative blots are shown in Fig. 5.8.  
In all four cell lines, no phosphorylated STAT1 was detected in the negative 
control (Fig. 5.8). STAT1 was the expected size (STAT1α is 91 kDa and STAT1β is 
84 kDa). The β-actin bands were the correct size (42 kDa) and generally uniform in 
each blot indicating that similar amounts of protein were loaded into each lane. In all 
four cell lines, SFV4, SFV L10 and SFV A7(74) infection resulted in no detectable 
phosphorylated STAT1. In all four cell lines, SFV4, SFV L10 and SFV A7(74) 
infected cells treated with IFN had less phosphorylated STAT1 than uninfected cells 
treated with IFN. The SFV4 lanes on the blot from the NIH 3T3 lysates shown in 
Fig. 5.8.iv were damaged, however, in other blots SFV4 IFN treated cells induced 
low levels of phosphorylated STAT1 in NIH 3T3 cells relative to the positive 
control. These results indicate that all three viruses specifically inhibited the IFN 
signalling pathway in fibroblasts at or upstream of the phosphorylation of STAT1. 
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Figure 5.8: Western blot for phosphorylated STAT1 in fibroblast cells 
infected with SFV4, SFV L10 or SFV A7(74) 
(i) 2fTGH, (ii) Hs 633T, (iii) L929 and (iv) NIH 3T3 cells were infected with SFV4, 
SFV L10 or SFV A7(74) at MOI 30 for 10 h or mock-infected and then treated with 
IFN-α (+) mock treated (-). A Western blot was carried out using the cell lysates and 
the blot was probed for phosphorylated STAT1 (STAT1-P) and then β-actin (Actin). 
Each experiment was repeated three times and a representative blot is shown.  
 
 The Western blots in Fig. 5.8 showed a difference in the amount of 
phosphorylated STAT1 induced by infection with SFV L10 compared to SFV4 or 
SFV A7(74) in the 2fTGH and Hs 633T cells, which was not observed in mouse 
cells. The band intensity on these blots was quantified and compared using ImageJ 
(2.6.6). The phosphorylated STAT1 bands were normalised to the corresponding 
band intensity of β-actin. The STAT1 band intensity was greatest in SFV4 infected 
cells and lowest in SFV L10 infected cells (Fig. 5.9). This suggests that SFV L10 
either induces less phosphorylation of STAT1 or is more efficient at inhibiting the 
phosphorylation of STAT1 in human cells than SFV4 and SFV A7(74).  




Figure 5.9: There are lower levels of phosphorylated STAT1 in SFV L10 
infected 2fTGH and Hs 633T cells compared to SFV4 and SFV A7(74) 
The intensity of bands from three 2fTGH and Hs 633T Western blots were 
determined using ImageJ and band intensity was normalised to actin for each lane 
and then compared to SFV4 to generate relative band intensities.   
 
 The levels of phosphorylated STAT1 during infection with SFV could be 
affected by virus degradation of STAT1. The levels of phosphorylated STAT1 would 
decrease as a result of a total decrease in STAT1 levels. To investigate this 
possibility, a Western blot was carried out on the lysates from 2fTGH and L929 cells 
infected with SFV L10, SFV A7(74) and SFV4 at MOI 30 for 10 h. Blots were 
probed for STAT1 and then β-actin as a loading control. Each phosphorylated 
STAT1 band was normalised to the corresponding β-actin to account for loading 
discrepancies and relative values are shown in Fig. 5.10. Similar levels of STAT1 
were detected in cells infected with SFV L10, SFV A7(74) and SFV4. The strains do 
not appear to be degrading STAT1, which suggests that the observed decrease in 
phosphorylated STAT1 is a result of SFV directly affecting the phosphorylation of 
STAT1. This could either be due to differential induction or differential suppression 
of the phosphorylation of STAT1. 
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Figure 5.10: Western blot for STAT1 in 2fTGH and L929 cells infected 
with SFV4, SFV L10 or SFV A7(74) 
A Western blot was carried out on cell lysates from (i) 2fTGH and (ii) L929 cells 
infected with SFV4, SFV L10 or SFV A7(74) at MOI 30 for 10 h or mock-infected. 
Blots were probed for STAT1 and then β-actin (Actin). Each experiment was 
repeated three times and a representative blot is shown. Each STAT1 band was 
normalised to the corresponding β-actin band using ImageJ and the relative band 
intensity value is shown. 
 
In conclusion, strains of SFV inhibited the phosphorylation of STAT1 in both 
human and mouse fibroblasts. One possibility is that SFV infection does not induce 
IFN production and, therefore, no IFN is present to induce the IFN signalling 
pathway and produce the phosphorylation of STAT1. An alternative hypothesis is 
that strains of SFV prevent the phosphorylation of STAT1 by directly antagonising 
the IFN signalling pathway. The result that IFN treatment of cells already infected 
with SFV does not induce the phosphorylation of STAT1 indicates that SFV is 
antagonising the IFN signalling pathway. However, it would be useful to confirm 
that SFV inhibits the IFN signalling pathway, perhaps by using STAT1 or Jak1 
reporter plasmids. 
 
5.2.3 Comparison of the levels of phosphorylated STAT1 in 
fibroblasts infected with SFV4, SFV4-RDR and 
SFV4nsP3∆50  
In fibroblasts, SFV L10, SFV A7(74) and SFV4 either directly inhibit the 
phosphorylation of STAT1 or act upstream to reduce phosphorylated STAT1 
levels(Fig. 5.8). To analyse  the effect of the nsP2RDR and nsP3∆50 genetic changes 
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of levels of phosphorylated STAT1, a Western blot was carried out on 2fTGH, Hs 
633T, L929 and NIH 3T3 cells infected with SFV4, SFV4-RDR or SFV4nsP3∆50 at 
MOI 30 for 10 h. At 10 h post-infection, cultures were treated with IFN-α for 45 
minutes to induce STAT1 phosphorylation or with PBSA as a negative control. Blots 
were probed for phosphorylated STAT1, and then β-actin as a loading control. 
Mock-infected and mock-treated cell lysates were included as a negative control. 
Mock-infected lysates treated with IFN were included as a positive control. The 
experiment was repeated three times with each cell line and representative blots are 
shown in Figs 5.11, 5.12, 5.13 and 5.14. Band intensities on the blot were compared 
using ImageJ (2.6.6). Each phosphorylated STAT1 band was normalised to the 
corresponding β-actin band and then compared to the phosphorylated STAT1 band 
intensity in the IFN control. Relative intensity values are shown in the graph below 
each blot.  
In 2fTGH cells, no phosphorylated STAT1 was detected in the cells with no 
virus and no IFN (Fig. 5.11). Phosphorylated STAT1 was barely detectable in SFV4 
infected cells, but was clearly present following addition of IFN following IFN 
challenge. In contrast to Fig. 5.8, in this experiment SFV4 infected cells had similar 
level of phosphorylated STAT1 following IFN treatment as the IFN control. 
Essentially, similar results to SFV4 were observed in lysates from 2fTGH cells 
infected with SFV4nsP3∆50. In contrast, good levels of phosphorylated STAT1 was 
detected in 2fTGH cells infected with SFV4-RDR and these were increased only 
slightly following IFN treatment. 
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Figure 5.11: Western blot for phosphorylated STAT1 in 2fTGH cells 
infected with SFV4, SFV4-RDR or SFV4nsP3∆50 
(i) 2fTGH cells were infected with SFV4, SFV4-RDR or SFV4nsP3∆50 at MOI 30 
for 10 h or mock-infected and then treated with IFN-α (+) mock treated (-). A 
Western blot was carried out using the cell lysates and immunostained for 
phosphorylated STAT1 (STAT1-P) and then β-actin (Actin). The experiment was 
repeated three times and a representative blot is shown. (ii) The intensity of the bands 
on the blot was normalised to actin in each lane and then compared to the IFN 
control using ImageJ and a relative intensity graph was created.  
 
The experiment was repeated in Hs 633T cells. Similar results were observed 
on Western blots using Hs 633T cells infected with SFV4, SFV4-RDR or 
SFV4nsP3∆50 as described above (Fig. 5.12). As in the previous experiment (Fig. 
5.8), SFV4 induced lower levels of phosphorylated STAT1 compared to the positive 
control. The SFV4 infected and IFN treated lysate band was approximately 30 % of 
the intensity of the positive control (Fig. 5.12.ii). Again, strong bands for 
phosphorylated STAT1 were detected in Hs 633T cells infected with SFV4-RDR 
both with and without IFN treatment.  




Figure 5.12: Western blot for phosphorylated STAT1 in Hs 633T cells 
infected with SFV4, SFV4-RDR or SFV4nsP3∆50 
(i) Hs 633T cells were infected with SFV4, SFV4-RDR or SFV4nsP3∆50 at MOI 30 
for 10 h or mock-infected and then treated with IFN-α (+) mock treated (-). A 
Western blot was carried out using the cell lysates and immunostained for 
phosphorylated STAT1 (STAT1-P) and then β-actin (Actin). The experiment was 
repeated three times and a representative blot is shown. (ii) The intensity of the bands 
on the blot was normalised to actin in each lane and then compared to the IFN 
control using ImageJ and a relative intensity graph was created. 
 
To investigate if similar results would be observed in mouse fibroblasts, the 
experiment was repeated using L929 and NIH 3T3 cells. Similar results to 2fTGH 
and Hs 633T cells were observed in both cell lines (Figs 5.11, 5.12, 5.13 and 5.14). 
Phosphorylated STAT1 was only detected in cells infected with SFV4nsP3∆50 
following IFN treatment, apart from in the L929 cells (Figs 5.11, 5.12, 5.13 and 
5.14). In NIH 3T3 cells, the results were more dramatic and no phosphorylated 
STAT1 was detected in SFV4 infected cultures even following IFN treatment (Fig. 
5.14).  
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Figure 5.13: Western blot for phosphorylated STAT1 in L929 cells 
infected with SFV4, SFV4-RDR or SFV4nsP3∆50 
(i) L929 cells were infected with SFV4, SFV4-RDR or SFV4nsP3∆50 at MOI 30 for 
10 h or mock-infected and then treated with IFN-α (+) mock treated (-). A Western 
blot was carried out using the cell lysates and immunostained for phosphorylated 
STAT1 (STAT1-P) and then β-actin (Actin). The experiment was repeated three 
times and a representative blot is shown. (ii) The intensity of the bands on the blot 
was normalised to actin in each lane and then compared to the IFN control using 
ImageJ and a relative intensity graph was created. 
 
 




Figure 5.14: Western blot for phosphorylated STAT1 in NIH 3T3 cells 
infected with SFV4, SFV4-RDR or SFV4nsP3∆50 
(i) NIH 3T3 cells were infected with SFV4, SFV4-RDR or SFV4nsP3∆50 at MOI 30 
for 10 h or mock-infected and then treated with IFN-α (+) mock treated (-). A 
Western blot was carried out using the cell lysates and immunostained for 
phosphorylated STAT1 (STAT1-P) and then β-actin (Actin). The experiment was 
repeated three times and a representative blot is shown. (ii) The intensity of the bands 
on the blot was normalised to actin in each lane and then compared to the IFN 
control using ImageJ and a relative intensity graph was created. 
 
In conclusion, in both human and mouse fibroblasts, infection with SFV4, 
SFV L10 or A7(74) results in no or only very low levels of phosphorylated STAT1 
and SFV infection prevents IFN induced increase in levels of phosphorylated 
STAT1. The nsP2 NLS sequence is important in this suppression. NsP3 may also be 
involved. 
 
5.2.4 Summary of findings 
• In human and mouse fibroblasts, SFV4-RDR and SFV4nsP3∆50 infection 
induced more IFN than SFV4 infection. 
• Following pre-treatment of human and mouse fibroblasts with IFN; SFV4, 
SFV4-RDR and SFV4nsP3∆50 showed a large reduction in replication. This 
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reduction was less extreme in SFV4-RDR and SFV4nsP3∆50 infection than in 
SFV4 infection. 
• In human and mouse fibroblasts, SFV4, SFV L10 and SFV A7(74) infection 
give rise to no or very low levels of phosphorylated STAT-1 and prevent an 
increase in these levels in response to IFN treatment. 
• In human fibroblasts, SFV L10 infection induced lower levels of phosphorylated 
STAT1 than either SFV4 or SFV A7(74). 
• In human and mouse fibroblasts, SFV4-RDR infection induced greater levels of 
phosphorylated STAT1 than SFV4. SFV4-RDR induced phosphorylation of 
STAT1 even without IFN treatment. 
• SFV4nsP3∆50 infection induced phosphorylation of STAT1 following IFN 
treatment. In general, SFV4nsP3∆50 induced greater levels of phosphorylated 
STAT1 than SFV4. 
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5.3 Discussion 
In chapter 4 it was demonstrated that strains of SFV induced the production of low 
levels of functional IFN in fibroblasts relative to SeV (Figs 4.6 and 4.7). This data 
suggests that SFV may antagonise the IFN system, either at the signalling or, most 
likely, the induction phase. The ability of SFV to antagonise IFN induction has been 
previously investigated in this laboratory (Breakwell et al., 2007). During SFV4 
infection in MEFs, NF-KB and IRF-3 both enter the nucleus, but fewer IFN-β 
transcripts are produced in comparison to the SFV4 mutant SFV4-RDR (Breakwell 
et al., 2007). The mechanism by which SFV antagonises the IFN induction pathway 
remains unclear and would be an interesting area of future research. IFN signalling in 
SFV infected cells has not been analysed. Recent studies have shown that the related 
alphaviruses CHIKV and SINV can inhibit IFN signalling by preventing the 
phosphorylation of STAT1 (Fros et al., 2010; Simmons et al., 2010). 
Phosphorylation of STAT1 is essential for IFN signalling. In this chapter, 
experiments were carried out to determine if SFV also inhibits the phosphorylation 
of STAT1 and, therefore, IFN signalling. 
In the experiments presented here, all three strains were shown to inhibit the 
phosphorylation of STAT1 in four different fibroblast cell lines (Fig. 5.8). One 
possible explanation is that SFV infection does not induce IFN production and, 
therefore, no IFN is present to activate the IFN signalling pathway. An alternative 
explanation is that strains of SFV prevent the phosphorylation of STAT1 by directly 
antagonising the IFN signalling pathway. In general, levels of phosphorylated 
STAT1 were lower in SFV infected cells treated with IFN than in uninfected cells 
treated with IFN (Fig. 5.8). This data suggests that SFV can directly antagonise IFN 
signalling. However, experiments are required in the future to confirm that SFV can 
antagonise IFN signalling, perhaps using STAT1 or JAK1 reporter plasmids. 
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In human fibroblast cells, following SFV4, SFV L10 and SFV A7(74) 
infection different amounts of phosphorylated of STAT1 were detected (Fig. 5.8). 
Lower levels of phosphorylated STAT1 were detected following infection with SFV 
L10 than either SFV A7(74) or SFV4 (Fig. 5.9). In SINV infection, the virulence of 
different strains has been attributed to their ability to inhibit the phosphorylation of 
STAT1 (Simmons et al., 2010). The ability of SFV L10 to inhibit the 
phosphorylation of STAT1 could explain the increased virulence of SFV L10 
compared to SFV A7(74) or SFV4. In this hypothesis, SFV L10 inhibits the 
phosphorylation of STAT1 preventing IFN signalling and induction of the antiviral 
state more efficiently than SFV4 or SFV A7(74). However, similar results were not 
observed in mouse fibroblasts (Fig. 5.8). One possible explanation for this result is 
that the strains of SFV interact with the IFN system differently in human cells 
compared to in mouse cells.  
In the data presented, all three strains of SFV were found to limit the 
phosphorylation of STAT1, either through antagonising IFN induction or IFN 
signalling. The decrease in phosphorylated STAT1 was not due to degradation of 
STAT1, as observed with paramyxoviruses (Fig. 5.10) (Young et al., 
2000;Andrejeva et al., 2002;Parisien et al., 2002). The flaviviruses WNV (Guo et al., 
2005), JEV (Lin et al., 2004), Langat virus (Best et al., 2005) and DENV (Ho et al., 
2005) all inhibit the phosphorylation of STAT1 and IFN signalling. The flavivirus 
protein NS5 inhibits the phosphorylation of STAT1 by preventing the activation of 
proteins upstream in the pathway (Lin et al., 2004;Ho et al., 2005;Guo et al., 
2005;Best et al., 2005). NS5 can also inhibit IFN signalling by binding to STAT2 
and sequestering the protein for degradation (Ashour et al., 2009). In DENV 
infection, another protein called NS4B also prevents the phosphorylation of STAT1 
(Munoz-Jordan et al., 2003).  
The mechanism by which alphaviruses may inhibit the phosphorylation of 
STAT1 and the virus proteins involved remain to be elucidated. The literature 
suggests a role for nsP2 in CHIKV infection (Fros et al., 2010) and nsP1 in SINV 
infection (Simmons et al., 2010). To investigate the potential role of SFV nsP2, a 
mutant with a point mutation in the NLS, SFV4-RDR, was utilised (Rikkonen et al., 
1992). SFV4 and SFV4-RDR both have similar replication kinetics in BHK-21 cells 
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(Rikkonen et al., 1992), both induce protein shutoff at similar rates (Breakwell et al., 
2007) and neither virus inhibits the translocation of the transcription factors NF-kB 
and IRF-3 to the nucleus (Breakwell et al., 2007). However, SFV4-RDR replicates 
less efficiently and induces more IFN than SFV4 in MEFs (Breakwell et al., 2007). 
Furthermore, SFV4-RDR is less virulent in mice than SFV4 (Fazakerley et al., 
2002). These results suggest that (i) SFV4-RDR cannot inhibit the IFN pathway, 
either induction or signalling, as efficiently as SFV4, (ii) nsP2 is important in 
mediating the interaction of SFV with the IFN pathway and (iii) the difference in 
IFN induction between SFV4-RDR and SFV4 is not due to differences in the 
translocation of the transcription factors or host protein shutoff. In the data presented 
here, SFV4-RDR induced significantly more IFN than SFV4 in four different 
fibroblast cell lines as expected (Fig. 5.3). SFV4-RDR also induced greater levels of 
phosphorylated STAT1 than SFV4 in four different fibroblast cell lines, even without 
the addition of IFN (Figs 5.11, 12, 13 and 14). This data suggests that WT nsP2 is 
required to prevent IFN signalling, either through differing induction or differing 
antagonism of the IFN signalling pathway relative to SFV4. NsP2 is a 
multifunctional protein that probably interacts with the type-I IFN pathway at various 
stages. 
The mechanism by which WT nsP2 inhibits the phosphorylation of STAT1 is 
an exciting area of research within our laboratory. One possible mechanism by which 
nsP2 could inhibit STAT1 phosphorylation is that nsP2 enters the nucleus and 
inhibits IFN induction, probably via shutoff of transcription, and prevents the 
downstream phosphorylation of STAT1. SFV4-RDR nsP2 only enters the nucleus at 
low levels (Rikkonen et al., 1992) and, therefore, would be less efficient at inhibiting 
this process. A recent study on SINV infection in NIH 3T3 cells demonstrated that 
inhibition of IFN production occurs at approximately 2 h post-infection, while the 
phosphorylation of STAT1 is inhibited at between 6 to 8 h post-infection (Frolov et 
al., 2012). The authors suggest that SINV can inhibit the IFN response, probably via 
shutoff of transcription, before preventing the phosphorylation of STAT1. Another 
possible mechanism is that nsP2 binds STAT1 or a protein important in STAT1 
phosphorylation in the cytoplasm and this inhibits the phosphorylation of STAT1. In 
SFV4-RDR, the structure of nsP2 is altered which may affect its ability to interact 
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with other proteins. Current experiments in our laboratory provide strong evidence 
for the second mechanism (Dr. Gerald Barry, personal communication).  
The role of SFV nsP3 as a virulence determinant is not fully elucidated. The 
literature suggests that nsP3 functions in replication of the virus genome (Peranen et 
al., 1988;Hahn et al., 1989;de Groot et al., 1990;Peranen, 1991;Lemm & Rice, 
1993;Lemm et al., 1994;Shirako & Strauss, 1994;Wang et al., 1994;Strauss & 
Strauss, 1994;LaStarza et al., 1994a;Peranen et al., 1995;Salonen et al., 
2003;Neuvonen et al., 2011) and as a virulence determinant (Tarbatt et al., 
1997;Tuittila et al., 2000;Tuittila & Hinkkanen, 2003). In this chapter, the mutant 
virus SFV4nsP3∆50 was utilised to investigate the hyperphosphorylated region of 
nsP3. SFV4nsP3∆50, which has a deletion of 50 amino acids in the hypervariable 
domain of nsP3, replicates less efficiently in vitro and is less virulent in vivo than 
SFV4 (Vihinen et al., 2001). One possible explanation for the difference between 
SFV4 and SFV4nP3∆50 is that SFV4nsP3∆50 does not inhibit the IFN response as 
efficiently as SFV4. In the data presented here, SFV4nsP3∆50 generally induced 
significantly more IFN production than SFV4 in fibroblasts (Fig. 5.4). However, 
unlike SFV4-RDR, phosphorylated STAT1 was normally detected in cells infected 
with SFV4nsP3∆50 only following IFN treatment (Figs 5.11, 5.12, 5.13 and 5.14). 
This suggests that if nsP3 interacts with the IFN system, it is by a different 
mechanism from that of nsP2. 
One possible explanation for the difference in IFN induction between SFV4 
and SFV4nsP3∆50 is that the hypervariable region of nsP3 inhibits proteins within 
the IFN induction and/or signalling pathways. Yeast-2-hybrid assays are underway 
within our laboratory to investigate which cellular proteins SFV nsP3 and, in 
addition, CHIKV nsP3 bind to. It will be interesting to see if the proteins identified 
are involved in the IFN response. An alternative explanation for the difference in 
IFN induction between SFV4 and SFV4nsP3∆50 is that SFV4nsP3∆50 replicates 
less efficiently than SFV4. A recent report suggests that the hyperphosphorylated 
region is important for replication of the virus genome (Neuvonen et al., 2011). It 
would be extremely interesting to investigate SFV4nsP3∆50 further and determine 
how it is affecting IFN induction. 
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One objective of this chapter was to investigate whether SFV4-RDR and 
SFV4nsP3∆50 differed in their sensitivity to IFN compared to SFV4. Both SFV4-
RDR and SFV4nsP3∆50 are less virulent compared to SFV4 in vivo (Vihinen et al., 
2001). Therefore, it was hypothesised that SFV4-RDR and SFV4nsP3∆50 would be 
more sensitive to the effects of IFN pre-treatment than SFV4 and that this would 
explain the virulence in mice. However, SFV4-RDR and SFV4nsP3∆50 appeared to 
be less affected by IFN pre-treatment than SFV4 (Figs 5.6 and 5.7). One possible 
explanation for the apparent different sensitivity of SFV4 and the mutant viruses to 
IFN pre-treatment is that the mutant viruses initially infect fewer cells in culture that 
SFV4 which is, in part, due to the IFN response (Breakwell et al., 2007). IFN pre-
treatment renders the majority of the culture into an antiviral state. The difference 
between IFN treated and untreated cultures would be more apparent in SFV4 
infections compared to SFV4-RDR, as a greater percentage of cells were initially 
infected by SFV4 and would now be protected.   
 
5.3.1 Final summary 
The data presented in chapter 4 and 5 suggests that SFV may antagonise the IFN 
pathway at both the induction and signalling stage. SFV appears to directly inhibit 
IFN signalling by limiting the phosphorylation of STAT1, either by directly binding 
STAT1 or by preventing upstream events. The NLS motif in nsP2 was required for 
this function, as demonstrated using SFV4-RDR. This finding could explain why 
SFV4-RDR is less virulent in mice than SFV4. The role of nsP3 remains unclear, but 
the data presented here enhances our understanding. SFV4nsP3∆50 replicated less 
efficiently and induced more IFN than SFV4. Future studies could include 
determining (i) how SFV inhibits IFN induction; (ii) the mechanism by  which SFV 
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Chapter 6: Comparison of the genetic 
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6.1 Introduction 
SFV was one of the first viruses to be sequenced. In 1980 the structural protein ORF 
of Prototype virus was sequenced, followed by the nsP ORF in 1986 (Garoff et al., 
1980;Takkinen, 1986). However, these sequences were generated using the 
technology available at the time and subsequent studies have identified several 
mistakes. Newer sequences have been generated and published in online databases; 
in 2002 the original Prototype sequence (accession number J02361.1) was replaced 
with an SFV sequence labelled SFV 42S RNA genome (accession number X04129) 
in the NCBI database. To allow accurate comparisons between studies in the 
literature, it is important to identify the original SFV isolate(s) and the laboratory 
where the various strains of SFV were derived. This thesis has focused on the 
laboratory strains of SFV held at the University of Edinburgh (EDI): SFV L10, SFV 
A7(74) and SFV4. The history of each of these strains is summarised below and in 
Table 6.1. 
6.1.1 SFV L10 
SFV L10 was isolated from a pool of 130 Aedes africanus mosquitoes captured in 
the Semliki Forest, Uganda (Smithburn & Haddow, 1944) and passaged eight times 
by ic inoculation in adult mouse brains followed by two passages ic in neonatal 
mouse brains (Bradish et al., 1971). Prototype virus was isolated from the same 
mosquito sample as SFV L10 and passaged 4 times by ic inoculation in mice 
(Bradish et al., 1971). Historically, the literature has referred to SFV L10 and 
Prototype virus interchangeably. However, the strains underwent different passaging 
conditions, as mentioned above, which may have selected for differences in the 
genetic sequence (Bradish et al., 1971). There are no published studies that analyse 
the genetic sequence of SFV L10. 
The laboratory strain of SFV L10 used in EDI was provided by Prof. H.E. 
Webb, St. Thomas’ Hospital, London, England and has been stored at -80oC with 
minimum passage. This virus was obtained by Prof. Webb from Dr C. Bradish at 
Porton Down. This SFV L10 has been used in several studies both in EDI and 
previously at St Thomas’ Hospital (Oaten et al., 1980;Amor & Webb, 1986;Khalili-
Shirazi et al., 1988;Fazakerley et al., 1993;Fazakerley, 2002). The stock of SFV L10 
held at EDI, referred to in this chapter as L10-EDI, has not been sequenced. An SFV 
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sequence labelled ‘L10’ was deposited in the NCBI database, accession number 
Ay112987, by Logue et al., 2002 from Trinity College Dublin, Ireland (IRE). The 
provenance of this L10-IRE is unclear. 
6.1.2 SFV4 
SFV4 was generated as a molecular cDNA clone of Prototype virus expressed under 
the control of a SP6 promoter (also known as SP6-SFV4) (Liljestrom et al., 1991). 
Since the creation of SFV4, multiple studies have used it to generate mutant viruses, 
such as SFV4-RDR and SFV4nsP3∆50 (Rikkonen et al., 1992;Vihinen et al., 2001). 
SFV L10 and SFV4 have similar replication kinetics in cell culture. SFV4 is virulent 
in adult mice following ic inoculation or in inoculation at high dose. However, unlike 
L10-EDI, ip inoculation with SFV4 is avirulent in adult mice, unless administered at 
high dose (Glasgow et al., 1991;Fazakerley, 2002).  
Our plasmid stock of SFV4 was obtained from Prof. A. Merits, Institute of 
Technology, University of Tartu, Estonia. Prof. Merits has compiled and verified the 
sequence of SFV4 by Solexa (Illumina) sequencing and this sequence will be termed 
SFV4-EST. The SFV4-EST plasmid originated from the Karoliska institute in 
Sweden and was created by Liljestrom et al (1991). The published sequence of this 
will be termed SFV4-SWE.  
6.1.3 SFV A7(74) 
The SFV strain AR2006 was isolated from Aedes argenteopunctatus mosquitoes in 
Mozambique (McIntosh et al., 1961). SFV A7 was derived from the AR2006 strain 
of SFV by passaging seven times by ic inoculation in neonatal mice. SFV A7(74) 
was derived from the AR2006 strain of SFV by passaging seven times by ic 
inoculation in neonatal mice, followed by two clonal selections from plaques in 
monolayers of primary chick embryo cells (CEFs) (Bradish et al., 1971).  
One sequence for SFV A7(74) is available in the literature: SFV A7(74) 
determined by Santagati et al (1994), University of Turku, Finland. This sequence 
was supplied by Dr. A. Hinkkanen, University of Turku, Finland. A sequence for 
SFV A7 is also available; published by Tarbatt et al., (1997), Trinity College, 
Dublin, Ireland. In this chapter the sequences generated in Finland and Ireland will 
be termed A7(74)-FIN and A7-IRE respectively. A7(74)-FIN was obtained from 
Prof. Webb, St. Thomas’ Hospital, London, England who received the virus from Dr. 
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Bradish, Porton Down, England. The source of A7-IRE in Tarbatt et al (1997) was 
not reported. Another strain of SFV A7(74) referenced in the literature was obtained 
from Prof. H. Smith, University of Birmingham, England. This will be referred to as 
A7(74)-BIR (Logue et al., 2008). The sequence of A7(74)-BIR is not available in the 
NCBI database. 
The version of SFV A7(74) held at EDI, like A7(74)-FIN, was obtained from 
Prof. Webb, St. Thomas’ Hospital, London, England, and has since been used in 
many studies (Fazakerley & Webb, 1987;Fazakerley et al., 1988;Fazakerley et al., 
1993). This version of SFV A7(74), termed A7(74)-EDI, has not been sequenced. 
However, a considerable body of research exists on this virus. A7(74)-EDI is virulent 
in mice under 11 days old and, like L10-EDI, rapidly spreads throughout the brain. 
However, as mice become older the spread of A7(74)-EDI is restricted, at least in the 
brain, to perivascular foci and the mice survive (Pathak & Webb, 1974;Fleming, 
1977;Fazakerley et al., 1993;Oliver et al., 1997;Oliver & Fazakerley, 1998). 
6.1.4 Objectives 
1. Sequence L10-EDI and A7(74)-EDI by Solexa (Illumina) sequencing and 
confirm sequences using PCR. 
2. Align and compare the genetic sequence of L10-IRE with L10-EDI at the 
nucleotide and amino acid level to identify differences. 
3. Align and compare the genetic sequence of A7-IRE and A7(74)-FIN with 
A7(74)-EDI at the nucleotide and amino acid level to identify differences. 
4. Align and compare the genetic sequence of L10-EDI and A7(74)-EDI with 
SFV4-EST at the nucleotide and amino acid level to identify differences. 
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6.2.1 Solexa (Illumina) sequencing of SFV4-EST, L10-EDI and 
A7(74)-EDI  
Details of the virus strains used in the following section are provided in Table 6.1. A 
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Table 6.1: Strains of SFV referred to in chapter 6. 







Isolated from a pool of 130 Aedes africanus 
mosquitoes captured in the Semliki Forest, 
Uganda and passaged 4 times by ic 
inoculation in mice. Complete genome 








SFV L10 L10-EDI Edinburgh stock. Isolated from a pool of 130 
Aedes africanus mosquitoes captured in the 
Semliki Forest, Uganda and passaged eight 
times by ic inoculation in adult mouse brains 
followed by two passages ic in neonatal 
mouse brains. Obtained from, Prof. Webb, St. 
Thomas’ Hospital, London, England, who 
received it from Dr. Bradish, Porton Down, 





SFV L10 L10-IRE Unknown origin. Accession number 
AY112987. 
(Logue et al., 
2002) 
SFV4 SFV4-SWE cDNA clone generated from Prototype virus.  (Liljestrom et 
al., 1991) 
SFV4 SFV4-EST Edinburgh stock. cDNA clone of Prototype 
virus obtained from Prof. P. Liljestrom, 
Karolinska Insitute, Stockholm, Sweden and 
sequenced by Prof. Merits, Institute of 
Technology, University of Tartu, Estonia. 
 
SFV A7(74) A7(74)-EDI Edinburgh stock. Derived from the AR2006 
strain of SFV that was isolated from Aedes 
argenteopunctatus mosquitoes in 
Mozambique. AR2006 was passaged seven 
times by ic inoculation in neonatal mice, 
followed by clonal selection from plaques in 
monolayers of primary CEFs to give SFV 
A7(74). Obtained from Prof. Webb, St. 
Thomas’ Hospital, London, England, who 
received it from Dr. Bradish, Porton Down, 
England. Not sequenced. 
(McIntosh et al., 
1961;Bradish et 
al., 1971) 
SFV A7(74) A7(74)-FIN Same background as A7(74)-EDI, which is 
described above. Sequenced by Santagati et al 
(1994), University of Turku, Finland. 
Sequence from Dr. Hinkkanen, University of 
Turku, Finland. 
(Santagati et al., 
1994) 
SFV A7(74) A7(74)-BIR Unknown origin. Obtained from Prof. Smith, 
University of Birmingham, UK and the 5’ 
UTR was sequenced by Logue et al (2008). 
(Logue et al., 
2008). 
SFV A7 A7-IRE Unknown origin. Accession number Z48163. (Tarbatt et al., 
1997) 
 
The complete genomes of L10-EDI and A7(74)-EDI were determined using Solexa 
(Illumina) sequencing at the Roslin Institute’s ARKgenomics facility (2.13.2). The 
sequences generated were named ARKL10-EDI for L10-EDI and ARKA7(74)-EDI 
for A7(74)-EDI. The complete sequences are shown in Appendix 1.  
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6.2.2 Comparison of the nsP2 and nsP3 sequences generated 
by Solexa (Illumina) sequencing and by PCR 
sequencing 
To confirm that the sequences of ARKL10-EDI and ARKA7(74)-EDI generated by 
Solexa (Illumina) sequencing and subsequent bioinformatic analysis were correct, 
PCR sequencing was carried out to determine the sequences of nsP2 and nsP3 in 
L10-EDI and A7(74)-EDI (2.13.1). SFV4-EST was included to confirm the sequence 
of SFV4-EST. NsP2 and nsP3 were chosen for PCR sequencing, as these proteins 
were studied in chapter 5. 
At the amino acid level, the nsP2 and nsP3 PCR derived sequence for 
A7(74)-EDI aligned perfectly to ARKA7(74)-EDI (data not shown). Similarly, the 
nsP2 and nsP3 PCR derived amino acid sequence for SFV4-EST aligned perfectly to 
SFV4-EST (data not shown). The amino acid PCR derived sequence for L10-EDI 
nsP3 also aligned perfectly to ARKL10-EDI nsP3 (data not shown). However, the 
L10-EDI PCR derived amino acid sequence for nsP2 had a single difference at 
position 754 compared to ARKL10-EDI. The PCR was repeated and this result was 
confirmed. This variation at amino acid 754 is likely to represent genetic variation 
within the population. Solexa (Illumina) sequencing identifies all RNA sequences in 
the sample, while PCR often amplifies one genotype. Both amino acids at position 
754 were hydrophilic (aspartic acid in ARKL10-EDI and asparagine in L10-EDI). 
This substitution is unlikely to affect the secondary structure of nsP2. Taken 
together, this data confirms the accuracy of the Solexa (Illumina) sequences of nsP2 
and nsP3 in L10-EDI, A7(74)-EDI and SFV4-EST. 
 
6.2.3 Comparison of the genetic sequences of L10-IRE to L10-
EDI at the nucleotide and amino acid level. 
The complete genetic sequences of ARKL10-EDI and L10-IRE were aligned and 
compared for nucleotide differences (Table 6.2). Across the genome, 19 nucleotide 
differences were identified between ARKL10-EDI and L10-IRE. These differences 
mainly mapped to nsP2. The structural ORF sequence was identical between both 
strains. Nucleotide position 1 in L10-IRE was G. This was not present in ARKL10-
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EDI and may be an error in the L10-IRE sequence. The L10-IRE sequence was most 
likely generated from cDNA cloned into a DNA vector and the extra G is probably 
the last nucleotide of the SP6 vector promoter.  
 
Table 6.2: Nucleotide changes in L10-IRE compared to ARKL10-EDI. 
Numbering is according to the nucleotide (nt) position in ARKL10-EDI. -, gap in 
sequence. 
nt Position L10-EDI L10-IRE Region 
0 - G 5’ UTR 
101 C T nsP1 
1016 G A nsP1 
1066 C A nsP1 
1084 C A nsP1 
- (2375 in L10-
IRE) - G nsP2 
- (2376 in L10-
IRE) - A nsP2 
2388 C - nsP2 
2398 G - nsP2 
2534 G A nsP2 
2562 T C nsp2 
2612 C A nsP2 
2661 C G nsP2 
3858 G - nsP2 
3859 C - nsP2 
3860 C - nsP2 
5847 C G nsP4 
5898 T C nsP4 
6348 C A nsP4 
 Next, the genetic sequence of ARKL10-EDI and L10-IRE were compared at 
the amino acid level (Table 6.3). Between ARKL10-EDI and L10-IRE, 18 amino 
acid differences were identified of which 11 produced a change in biochemistry. 
Amino acids 227 – 234 in nsP2 are probably the result of a frame-shift (personal 
communication with Prof. Merits). Most noteworthy is the substitution of 
a 103arginine residue in L10-IRE to a 103proline residue in L10-EDI, which is located 
in nsP4. Proline disrupts the secondary structure of proteins and is normally located 
at the end of α-helices or β-sheets. 
 The replicase region of L10-IRE differed substantially from L10-EDI at both 
the nucleotide and amino acid level (Tables 6.2 and 6.3). Possible explanations for 
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the sequence differences between ARKL10-EDI and L10-IRE include (i) the strains 
were passaged differently and this selected for differences in the genetic sequence or, 
more likely, (ii) there are errors in the L10-IRE replicase sequence. 
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Table 6.3: Amino acid changes in L10-IRE compared to ARKL10-EDI. 
Numbering is according to the amino acid (aa)1 position in ARKL10-EDI or aa2 position in individual ARKL10-EDI proteins. 
Dark grey, hydrophilic amino acid residue; light grey, hydrophobic amino acid residue; white, weakly hydrophilic and -, gap in 
sequence. 
Region nsP1            
aa position1 6 311            
aa position2 6 311            
L10-EDI H E            
L10-IRE Y K            
              
Region nsP2 
aa position1 764 765 766 767 768 770 771 817 826 843 859 1258 1259 
aa position2 227 228 229 230 231 233 234 280 289 306 322 721 722 
L10-EDI L D I Q A T V D M H S S L 
L10-IRE N W T S R N S N T N C - I 
              
Region nsP4           
aa position1 1921 1938 2088           
aa position2 103 120 270           
L10-EDI P V A           
L10-IRE R A D           
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6.2.4 Comparison of the genetic sequences of A7(74)-FIN and 
A7-IRE to A7(74)-EDI at the nucleotide and amino acid level. 
Much of our understanding about SFV A7(74) is from studies using A7(74)-EDI, 
A7(74)-FIN and A7-IRE (Glasgow et al., 1994;Santagati et al., 1995;Tarbatt et al., 
1997;Tuittila et al., 2000;Tuittila & Hinkkanen, 2003;Neuvonen et al., 2011). To 
determine if ARKA7(74)-EDI, A7(74)-FIN and A7-IRE have similar sequences, the 
complete genetic sequences of the three strains were aligned and compared for 
nucleotide differences (Table 6.4). Across the genome, five nucleotide differences 
were identified between ARKA7(74)-EDI and A7(74)-FIN. One difference was at 
position 21 in the 5’ untranslated region (UTR) where ARKA7(74)-EDI encoded G 
and A7(74)-FIN A. However, the A in A7(74)-FIN is likely to be a sequencing error; 
in Logue et al (2008), it is reported that A7(74)-FIN contains G at nucleotide position 
21 not A.  
 On comparing the genetic sequence of ARKA7(74)-EDI and A7-IRE, 11 
nucleotide differences were identified, these were located throughout the genome. In 
addition, A7-IRE encoded an extra 2771 nucleotides in the 3’ UTR, which were not 
present in ARKA7(74)-EDI. On blasting the 2771 nucleotide sequence in the NCBI 
database, the sequence had 99 % homology to the pSP64 cloning vector. Therefore, 
these additional nucleotides are actually part of the cloning vector and not the A7-IRE 
sequence. Possible explanations for the other genetic differences between 
ARKA7(74)-EDI and A7-IRE include (i) the strains were passaged differently in the 
laboratory and this selected for differences in the genetic sequence or (ii) errors were 
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Table 6.4: Nucleotide changes in A7(74)-FIN and A7-IRE compared to 
ARKA7(74)-EDI. 
Numbering is according to the nucleotide (nt) position in ARKA7(74)-EDI. Red 





FIN A7-IRE  Region 
21 G A A 5' UTR 
35 A A T 5' UTR 
42 T T C 5' UTR 
223 T T C nsP1 
256 T T C nsP1 
3701 A A G nsP2 
3883 C T C nsP2 
4124 A G A nsP3 
5881 A T A nsP4 
6313 T T A nsP4 
6721 A G A nsP4 
7183 C C T capsid 
10802 C C A E1 
11336 T T C E1 
11704 A A G E1 
11758 – 14529 - - 2771 nt 3’ UTR 
 
Next the genetic sequence of ARKA7(74)-EDI, A7(74)-FIN and A7-IRE were 
compared at the amino acid level (Table 6.5). Only one amino acid substitution was 
identified between ARKA7(74)-EDI and A7(74)-FIN; nsP3 at position 11 is  
isoleucine in ARKA7(74)-EDI and valine in A7(74)-FIN. As isoleucine and valine 
are both hydrophobic amino acids, this substitution is unlikely to affect the structure 
and function of nsP3. The high sequence similarity between ARKA7(74)-EDI and 
A7(74)-FIN suggests that observations made using A7(74)-FIN virus would be 
applicable to A7(74)-EDI virus and the single amino acid difference fits well with the 
very close ancestry of these viruses (both from Prof. Webb in London).  
At the amino acid level ARKA7(74)-EDI and A7-IRE were also extremely 
similar with only two amino acid differences; of which only one is likely to produce a 
change in biochemistry. In nsP2 at amino acid position 669, ARKA7(74)-EDI had a 
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serine while A7-IRE had a glycine. Glycine is a small amino acid, which can have a 
large impact on the secondary structure of proteins. 
 
Table 6.5: Amino acid changes in A7(74)-FIN and A7-IRE compared to 
ARKA7(74)-EDI. 
Numbering is according to the amino acid (aa)1 position in ARKA7(74)-EDI and aa2 
position in individual ARKA7(74)-EDI proteins. Dark grey, hydrophilic amino acid 
residue; light grey, hydrophobic amino acid residue and white, weakly hydrophilic. 
 
Region nsP2 nsP3 E1 
aa position1 1206 1347 1134 
aa position2 669 11 319 
A7(74)-EDI S I T 
A7(74)-FIN S V T 
A7-IRE G I K 
 
In conclusion, the high sequence similarity between ARKA7(74)-EDI, A7-
IRE and, in particular, A7(74)-FIN suggests that observations made using these 
viruses are applicable to A7(74)-EDI.  
 
6.2.5 Comparison of the sequences of L10-EDI and A7(74)-EDI 
to SFV4-EST at the nucleotide and amino acid level. 
Most of the SFV pathogenesis work has been done using L10-EDI, A7(74)-EDI and 
SFV4-EST and it is for these viruses that there is a need to relate phenotype to 
genotype. The complete genetic sequences of ARKL10-EDI, ARKA7(74)-EDI and 
SFV4-EST will first be compared at the amino acid level. Amino acid substitutions 
resulting in a change in the biochemistry of the amino acid are potentially the most 
important as these could affect the secondary and tertiary structure of the protein and, 
therefore, its function. Following consideration of changes at the protein level, change 
in the 5’ and 3’ UTR and the inter-genic region between the two ORFs will be 
considered.  
SFV4-EST and ARKL10-EDI were almost identical across the genomes. In 
the replicase region, ARKL10-EDI had only one amino acid substitution compared to 
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SFV4-EST. This was in nsP3 at amino acid position 48 (Table 6.6). The expression of 
a hydrophobic amino acid in ARKL10-EDI (48alanine) compared to a hydrophilic 
amino acid in SFV4-EST (48glutamic acid) could alter the structure of nsP3. This 
difference is analysed further in section 6.2.7. In the structural region, 5 amino acid 
substitutions were identified between SFV4-EST and ARKL10-EDI. These were 
located in the capsid protein and envelope glycoprotein (E) 2. Biochemically, the 
greatest difference was between a hydrophilic amino acid and a neutral amino acid in 
the capsid protein: 63arginine in SFV4-EST and 63glycine in ARKL10-EDI. The 
capsid protein facilitates the packaging of viral RNA (Frolova et al., 1997). The 
change of glycine to arginine at position 63 could affect this process. The amino acid 
substitutions identified in nsP3 and capsid are likely determinants of the virulence 
difference between SFV4-EST and L10-EDI in adult mice (L10-EDI is virulent 
following low dose extraneural inoculation whereas SFV4-EST is not). 
The sequence of ARKA7(74)-EDI differed substantially from SFV4-EST. 
Across the genome, ARKA7(74)-EDI had 36 different amino acid residues, a deletion 
of seven amino acids and an opal stop codon compared to SFV4-EST. Most of these 
differences mapped to nsP3. In nsP1, two substitutions replaced a hydrophobic amino 
acid residue with a hydrophilic one; 237cysteine in SFV4-EST and 237serine in 
ARKA7(74)-EDI; 308tyrosine in SFV4-EST and 308histidine in ARKA7(74)-EDI. 
Cysteine can make covalent bonds while histidine is charged, therefore these could be 
particularly important substitutions. In nsP2, the greatest biochemical change 
was 515valine in SFV4-EST to 515glutamic acid in ARKA7(74)-EDI. This changes a 
hydrophobic residue to a charged hydrophilic one. Amino acid 515 is located in the 
nsP2 protease domain and is associated with cleavage of the replicase polyprotein 
(Merits et al., 2001). This difference is analysed further in section 6.2.6. In nsP3, four 
substitutions produced large changes in the amino acid biochemistry. These 
substitutions were located in the macro domain (positions 48 and 70) and the 
hypervariable domain (positions 394 and 442). In addition, ARKA7(74)-EDI nsP3 
had an opal codon at position 476, which was not present in SFV4-EST or ARKL10-
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EDI. In SFV4-EST and ARKL10-EDI the opal codon was replaced by an arginine 
codon. ARKA7(74)-EDI had a deletion of seven amino acids (386A – GIADLA) in the 
nsP3 hypervariable domain. The differences in nsP3 between SFV4-EST (or 
ARKL10-EDI) and ARKA7(74)-EDI were substantial at the biochemical level and 
may be responsible for the difference in virulence in adult mice between these strains. 
In nsP4, two amino acid substitutions were identified. These were very conservative 
changes; aspartic acid to glutamic acid, both of which are negatively charged, 
arginine to lysine, both of which are positively charged. 
In the capsid protein, one amino acid difference was identified between SFV4-
EST and ARKA7(74)-EDI, which replaced a hydrophobic amino acid for a 
hydrophilic or neutral one: 62arginine in SFV4-EST and 62glycine in ARKA7(74)-
EDI. In E3, one amino acid substitution switched a hydrophobic residue for a 
hydrophilic one (12alanine in SFV4-EST and 12threonine in ARKA7(74)-EDI). In E2, 
only one amino change was non-conservative; 215methionine in SFV4-EST 
to 215lysine in ARKA7(74)-EDI. Finally, in E1, three amino acid changes substituted 
a hydrophobic amino acid residue for a hydrophilic one: 65arginine in SFV4-EST 
and 65serine in ARKA7(74)-EDI, 228methionine in SFV4-EST and 228threonine in 
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Table 6.6: Amino acid changes in ARKL10-EDI and ARKA7(74)-EDI compared to SFV4-EST. 
Numbering is according to the amino acid (aa)1 position in SFV4-EST and aa2 position in individual SFV4-EST proteins. Dark 
grey, hydrophilic amino acid residue; light grey, hydrophobic amino acid residue; white, weakly hydrophilic; -, gap in 
sequence and *, opal codon. Circles identify changes ARKA7(74)-EDI most likely to affect structure and function: red, 
ARKL10-EDI compared to SFV4-EST; green, ARKA7(74)-EDI compared to SFV4-EST.  
Region nsP1 nsP2 
        aa position1 237 308 387 427 484 534 679 1052 1216 1258 
        aa position2 237 308 387 427 484 534 142 515 679 721 
        SFV4 C Y I R V H V V F S 
        L10 C Y I R V H V V F S 
        A7(74) S H V K A R I E Y N 
        
                   Region nsP3 nsP4 
 aa position1 1384 1406 1537 1585 1722 1723 1724 1725 1726 1727 1728 1730 1778 1785 1812 1974 2429 
 aa position2 48 70 201 249 386 387 388 389 390 391 392 394 442 449 476 156 611 
 SFV4 E A F N A G I A D L A D A L R D R 
 L10 A A F N A G I A D L A D A L R D R 
 A7(74) A G L D - - - - - - - A T F * E K 
 
                
   Region Capsid E3 E2 E1 
aa position1 62 63 85 279 291 370 437 495 545 548 700 704 722 880 930 1043 1112 1188 
aa position2 62 63 85 12 24 37 104 162 212 215 367 371 389 65 115 228 297 373 
SFV4 A R N A V V K K N M V V V A R M I R 
L10 A G K A V I T E N M V V V A R M I R 
A7(74) T R K T A I T E S K A A A S K T T K 
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In addition to the replicase and structural ORF, the alphavirus genome 
contains a 5’ UTR, an inter-genic nucleotide sequence between the ORFs and a 3’ 
UTR. These regions can affect the secondary structure of the genome and have been 
associated with enhancing replication and virulence in several alphaviruses including 
SFV (Kuhn et al., 1992;Atkins et al., 1999;Fayzulin & Frolov, 2004;Logue et al., 
2008). The nucleotide sequences of these three regions in SFV4-EST, ARKL10-EDI 
and ARKA7(74)-EDI were aligned and compared. In the 5’ UTR, SFV4-EST 
differed from SFVL10-EDI at one nucleotide, position 59 (Fig. 6.1.i). Comparison of 
the 5’ UTR between SFV4-EST and ARKA7(74)-EDI identified four substitutions at 
positions 21, 35, 42 and 59. Three of these substitutions were also observed in two 
published studies, one of which compared A7(74)-FIN to Prototype virus while the 
other compared SFV4-SWE to A7(74)-BIR (Santagati et al., 1994;Logue et al., 
2008). Chimera studies in which the 5’ UTR nucleotides at position 21, 35 and 42 in 
SFV4-SWE were replaced with those from A7(74)-BIR attenuated the virulence of 
SFV4-SWE in adult mice (Logue et al., 2008).  
No differences were detected between the three strains in the inter-genic 
region. In the 3’ UTR, ARKL10-EDI had 36 fewer nucleotides at the C-terminus 
than SFV4-EST (Fig. 6.1.ii). The 3’ UTR differed substantially between SFV4-EST 
and ARKA7(74)-EDI. One previous study reported that A7(74)-FIN encodes 334 
additional nucleotides in the 3’ UTR compared to Prototype virus (Santagati et al., 
1994). These additional nucleotides contain 5 repeating motifs (Santagati et al., 
1994). As shown in Fig. 6.1.ii, extra nucleotides and repeating motifs were detected 
in the 3’ UTR of ARKA7(74)-EDI, but not in SFV4-EST. This is in agreement with 
Santagati et al. (1994). 






Figure 6.1: Comparison of the nucleotide sequence of the 5’ UTR and 3’ 
UTR of ARKL10-EDI and ARKA7(74)-EDI compared to SFV4-EST. 
The (i) 5’ UTR and (ii) 3’ URT of SFV4 (SFV4-EST), L10 (ARKL10-EDI) and 
A7(74) (ARKA7(74)-EDI) were aligned and compared for percentage similarity 
using Jalview 2.7. Colours range from dark blue (highly conserved) to white 
(variable). The green lines mark tandem repeats 1 to 5.  
 
 In conclusion, the data presented here indicate high sequence conservation 
throughout the genome between SFV4-EST and ARKL10-EDI; only 7 differences 
were identified which were located in the 5’ UTR, nsP3, capsid and E2. In addition, 
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ARKL10-EDI had 37 fewer nucleotides in the 3’UTR compared to SFV4-EST. In 
contrast, several amino acid differences were identified between the genetic sequence 
of ARKA7(74)-EDI and SFV4-EST. 
 
6.2.6 Comparison of the sequences encoding nsP2 and nsP3 
in SFV4-EST, L10-EDI and A7(74)-EDI  
The data presented in chapter 5 indicated the importance of nsP3 and, in particular, 
nsP2 in the interaction of SFV with the IFN response. Therefore, the amino acid 
sequences for SFV4-EST, L10-EDI and A7(74)-EDI nsP2 and nsP3 were analysed in 
greater depth using the Solexa (Illumina) generated sequences. The sequences 
encoding SFV4-EST, ARKL10-EDI and ARKA7(74)-EDI nsP2 and nsP3 were 
compared for evolutionary divergence at the nucleotide and the amino acid level 
using Mega5 (2.13.2), as shown in Table 6.7. The evolutionary divergence between 
SFV4-EST and ARKL10-EDI was very low in both nsP2 and nsP3 at the nucleotide 
and amino acid level (≤ 0.1 divergence). SFV4-EST was engineered from Prototype 
virus, which was isolated from the same mosquito sample as SFV L10. Therefore 
SFV4-EST would be expected to be similar to ARKL10-EDI. ARKA7(74)-EDI had 
greater evolutionary divergence from ARKL10-EDI and SFV4-EST, especially in 
nsP3 (≤ 3.5 at the nucleotide level and ≤ 1.5 at the amino acid level compared to 
ARKL10-EDI), which is expected considering the viruses were isolated from 
different pools of mosquitoes.  
 
Table 6.7: Estimates of the evolutionary divergence between SFV4-EST, 
ARKL10-EDI and ARKA7(74)-EDI nsP2 and nsP3 at the nucleotide and 
amino acid level. 
The percentage of nucleotide (nt and amino acid (aa) differences per site in nsP2 and 
nsP3 between SFV4-EST, ARKL10-EDI and ARKA7(74)-EDI are shown. A value 
of 0 suggests no evolutionary divergence. The analyses were conducted in Mega5. 
  nt level aa level 
 SFV4/L10 SFV4/A7(74) L10/A7(74) SFV4/L10 SFV4/A7(74) L10/A7(74) 
nsP2 0.1 1.3 1.3 0.1 0.5 0.6 
nsP3 0.1 3.5 3.4 0.1 1.5 1.3 
 
One amino difference between SFV4-EST and ARKL10-EDI was identified 
in nsP3, while several differences were observed between SFV4-EST and 
ARKA7(74)-EDI in nsP2 and nsP3 (Table 6.6). To investigate the potential 
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importance of these amino acid substitutions, the amino acid sequences of SFV4-
EST, ARKL10-EDI and ARKA7(74)-EDI nsP2 and nsP3 were compared to a panel 
of alphaviruses using Jalview 2.7 (2.13.2). Viruses selected for this comparison were 
the closely related CHIKV, O’nyong-nyong virus, Mayaro virus, Barmah Forest 
virus and the more distantly related WEEV and VEEV.  
   Nine different alphavirus nsP2 amino acid sequences were aligned and 
analysed for the percentage of amino acid similarity using Jalview 2.7 (Fig. 6.2). 
Percentage similarity is indicated by colour, ranging from highly conserved (dark 
blue), through to variable (white). Conserved amino acid sequences could be 
identified in all nine viruses. These regions are likely to be important in the function 
of nsP2, for example in processing the replicase polyprotein. SFV4-EST, ARKL10-
EDI and ARKA7(74)-EDI appeared to be more similar to each other than to the other 
viruses, as expected; for example at amino acid position 112 the three strains of SFV 
express serine while all the other alphaviruses studied express alanine. The 650RRR 
nuclear localisation signal (NLS) was identified in SFV4-EST, ARKL10-EDI and 
ARKA7(74)-EDI, but not in the other alphaviruses analysed.  
In Table 6.6, the greatest biochemical difference identified in nsP2 between 
SFV4-EST and ARKA7(74)-EDI was at position 1052 (amino acid position 515 in 
nsP2); SFV4-EST expressed a valine while ARKA7(74)-EDI expressed glutamic 
acid. The other alphaviruses analysed, like ARKA7(74), all had 515glutamic acid. 
This amino acid is located in the protease domain of nsP2 (Merits et al., 2001).  
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Figure 6.2: Comparison of the amino acid sequence of the nsP2 in a 
panel of alphaviruses. 
The nsP2 amino acid sequence of SFV4-EST (SFV4), ARKL10-EDI (L10), 
ARKA7(74)-EDI (A7(74)), CHIKV, O’nyong-nyong virus, Mayaro virus, Barmah 
Forest virus, WEEV and VEEV were aligned and compared for percentage similarity 
using Jalview 2.7. Colours range from dark blue (highly conserved) to white 
(variable).  
 
Crystal structures of the CHIKV and VEEV nsP2 protease domains are 
available in the Protein Data Bank, 3TRK and 2HWK respectively (www.rcsb.org/). 
3D structures of the SFV4-EST and ARKA7(74)-EDI nsP2 protease domains were 
predicted using the program Phyre2 (2.14). SFV4-EST and ARKA7(74)-EDI were 
modelled to the crystal structure of the CHIKV nsP2 protease domain with 100 % 
confidence. The predicted 3D structure of the SFV4 nsP2 protease domain is shown 
in Fig. 6.3.   
 
Figure 6.3: Predicted structure of the SFV4 nsP2 protease domain. 
(i) Ribbon diagram of the nsP2 protease domain showing the N-terminus (N), C-
terminus (C) and the active site (A). The nsP2 protease domain consists of a α-
helices rich N-domain and a α-helices and β-sheet rich C-domain. (ii) Surface 
representation of the nsP2 protease domain. Structures were generated using Phyre2 
and formatted using UCSF Chimera. 
 
 The nsP2 protease structure consists of two domains: the N-terminal domain 
and the C-terminal domain. The N-terminal domain is largely helical and is a 
cysteine protease domain, while the C-terminus is a combination of α-helices and β-
sheets and is a methyltransferase-like domain (Russo et al., 2006). The active site is 
located adjacent to the interface between the two domains and amino acids 
predominately from the N-domain are associated with its function in processing the 
replicase polyprotein (Merits et al., 2001;Russo et al., 2006;Russo et al., 2010).  
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 To predict the importance of amino acid 515 on the function of nsP2, the 
position and orientation of amino acid 515 was identified in the predicted 3D 
structure of the SFV4-EDI and ARKA7(74)-EDI nsP2 protease domain (Fig. 6.4). 
Amino acid 515 was located close to the active site and orientated outwards (Fig. 
6.4). This data indicates that amino acids 515 is likely to affect replication by altering 
the interaction of nsP2 with the replicase polyprotein cleavage sites. In conclusion, 
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Figure 6.4: Predicted structures of the SFV4-EDI and ARKA7(74)-EDI 
nsP2 protease domain. 
(i) Sections of the ribbon structures of SFV4-EDI and ARKA7(74)-EDI nsP2 
protease domains showing the location of amino acid 515 (green); valine (V) and 
glutamic acid (E). (ii) Combined ribbon and surface structure of SFV4-EDI and 
ARKA7(74)-EDI nsP2 protease domains. (iii) Surface structure of SFV4-EDI and 
ARKA7(74)-EDI nsP2 protease domains. Structures were generated using Phyre2 
and formatted using UCSF Chimera. 
 
Next, the nsP3 amino acid sequences of SFV4-EST, ARKL10-EDI and 
ARKA7(74)-EDI were analysed. The nsP3 amino acid sequences from the nine 
alphavirus used previously were aligned and analysed for the percentage of amino 
acid similarity (Fig. 6.5). The conserved macro domain (largely highly conserved - 
dark blue), and the hypervariable domain (largely variable – white), were apparent. 
In Table 6.6, one amino acid differences was observed between SFV4-EST and 
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ARKL10-EDI in the nsP3 macro domain at position 48; glutamic acid in SFV4-EST 
and alanine in ARKL10-EDI. Amino acid 48 varied between the nine alphaviruses 
studied, although alanine was most common at this position (Fig. 6.5).  
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Figure 6.5: Comparison of the amino acid sequence of the nsP3 in a 
panel of alphaviruses. 
The nsP3 amino acid sequence of SFV4-EST (SFV4), ARKL10-EDI (L10), 
ARKA7(74)-EDI (A7(74)), CHIKV, O’nyong-nyong virus, Mayaro virus, Barmah 
Forest virus, WEEV and VEEV were aligned and compared for percentage similarity 
using Jalview 2.7. Colours range from dark blue (highly conserved) to white 
(variable).  
 
The nsP3 macro domain crystal structures are available in the Protein Data 
Bank for CHIKV and VEEV, 3PG and 3GQE respectively (www.rcsb.org). 3D 
structures of the SFV4-EST, ARKL10-EDI and, also, ARKA7(74)-EDI nsP3 macro 
domains were predicted using the program Phyre2 (2.14). SFV4-EST and 
ARKA7(74)-EDI were modelled to the crystal structure of the CHIKV nsP3 macro 
domain with 100 % confidence. The predicted 3D structure of the SFV4 nsP3 macro 
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Figure 6.6: Predicted structure of the SFV4 nsP3 macro domain. 
(i) Ribbon and (ii) Surface representation diagrams of the nsP3 macro domain 
showing the active site (A). Structures were generated using Phyre2 and formatted 
using UCSF Chimera. 
 
 The nsP3 macro domain is comprised of six β-sheets surrounded by four α-
helices. The active site is an adenosine binding pocket (Malet et al., 2009). To 
predict the importance of amino acid 48 on the function of nsP3, the position and 
orientation of amino acid 48 was identified in the 3D structure of SFV4-EDI and 
ARKL10-EDI nsP3 macro domain (Fig. 6.7). Amino acid 48 was located in a loop 
orientated inwards, away from the active site (Fig. 6.7). Taken together, amino acid 
48 is unlikely to affect the function of nsP3, at least in the macro domain.  
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Figure 6.7: Predicted structures of the SFV4-EDI and ARKL10-EDI nsP3 
macro domain. 
(i) Sections of the ribbon structures of SFV4-EDI and ARKL10-EDI nsP3 macro 
domains showing the location of amino acid 48 (green); glutamic acid (E) and 
alanine (A). (ii) Combined ribbon and surface structures of SFV4-EDI and ARKL10-
EDI nsP3 macro domains. (iii) Surface structures of SFV4-EDI and ARKL10-EDI 
nsP3 macro domains. Structures were generated using Phyre2 and formatted using 
UCSF Chimera. 
In Table 6.6, most amino acid differences between SFV4-EST and 
ARKA7(74)-EDI mapped to nsP3. Biochemically, the most important amino acid 
substitutions in the macro domain were at positions 48 and 70. Amino acid 48 has 
been analysed in detail above in the context of SFV4-EST and ARKL10-EDI and the 
results can be applied to ARKA7(74)-EDI (Fig. 6.7). At amino acid position 70, 
SFV4-EST expressed alanine and ARKA7(74)-EDI glycine. Analysis of a panel of 
alphaviruses demonstrated that all alphaviruses apart from SFV4-EST and ARKL10-
EDI expressed 70glycine (Fig. 6.8). 70glycine is a completely different size and 
structure to 70alanine. In addition, amino acid 70 is located close to the active site 
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(Fig. 6.8). The data indicate that amino acid 70 is likely to affect the function of nsP3 
and, therefore, virulence of SFV4-EST and ARKA7(74)-EDI. 
Other potentially important differences between SFV4-EST and ARKA7(74)-
EDI were located in the nsP3 hypervariable domain. Seven amino acids were 
identified in SFV4-EST and ARKL10-EDI (386A – GIADLA), which were not 
present in ARKA7(74)-EDI or any other alphavirus studied (Fig. 6.8). The 
hypervariable domain is predicted to be highly disordered and no crystal structure is 
currently available. Therefore, it is difficult to predict how changes in this region 
affect the structure and function of nsP3.  
 
 
Figure 6.8: Predicted structures of the SFV4-EDI and ARKA7(74)-EDI 
nsP3 macro domain. 
 (i) Sections of the ribbon structures of the SFV4-EDI and ARKA7(74)-EDI nsP3 
macro domain showing the location of amino acid 70 (green); alanine (A) and 
glycine (G). (ii) Combined ribbon and surface structures of the SFV4-EDI and 
ARKA7(74)-EDI nsP3 macro domains. (iii) Surface structures of the SFV4-EDI and 
ARKA7(74)-EDI nsP3 macro domains. Structures were generated using Phyre2 and 
formatted using UCSF Chimera. 
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In conclusion, the amino acid sequence of SFV4-EST differed from 
ARKL10-EDI at position 48 in nsP3. However, the results presented here indicate 
that this amino acid is unlikely to affect the function of nsP3 and, therefore, the 
virulence of SFV4-EST and ARKL10-EDI. Biochemically important amino acid 
substitutions between SFV4-EST and ARKA7(74)-EDI were identified at position 
515 in nsP2 and positions 48 and 70 in nsP3. Further analysis, using the predicted 3D 
structure of the ARKA7(74)-EDI nsP2 protease domain, indicated that amino acid 
515 is most likely to affect the function of ARKA7(74)-EDI nsP2 and SFV4-EDI, 
which could affect virulence.   
 
6.2.7 Summary of findings 
• The complete genomes of L10-EDI and A7(74)-EDI were sequenced using 
Solexa (Illumina) sequencing.  
• The genetic sequence of L10-IRE was compared to L10-EDI. The replicase 
region of L10-IRE had 19 nucleotide differences compared to L10-EDI, of 
which 12 produced amino acid changes with large changes in the biochemistry. 
The structural region was identical between L10-EDI and L10-IRE at both the 
nucleotide and amino acid level.  
• The genetic sequence of A7(74)-FIN and A7(74)-EDI were compared and are 
very similar at both the nucleotide and amino acid level. Five nucleotide 
differences were identified, of which only one produced an amino change. This 
difference was located in nsP3 at position 11. 
• The genetic sequence of A7-IRE was compared to A7(74)-EDI. Across the 
genome, 11 nucleotide differences were identified and an additional 2771 
nucleotides were encoded by A7-IRE in the 3’ UTR which were not present in 
A7(74)-EDI. However, at the amino acid level only two amino acid differences 
were identified. These were located in nsP2 and E1 at position 669 and 319 
respectively.  
• The genetic sequence of SFV4-EST and L10-EDI were compared. Across the 
genome seven substitutions were identified that were located in the 5’ UTR, 
nsP3, capsid and E2. L10-EDI had 37 fewer nucleotides in the 3’UTR compared 
Chapter 6  Results 
 199 
to SFV4-EDI. In nsP3, the amino acid difference was located at position 48 in 
the macro domain.  3D modelling suggests this change is unlikely to affect 
function. 
• Several differences were identified throughout the genetic sequence of 
ARKA7(74)-EDI compared to SFV4-EST. In nsP2 and nsP3, three 
biochemically important changes were identified.  These were in the nsP2 
protease domain at position 515 and in the nsP3 macro domain at positions 48 
and 70. NsP2 515 is located close to the protease domain active site, orientated 
outwards and therefore likely to affect function.  In the nsP3 macro domain, 
amino acid 48 is located in a loop away from the active site. In contrast, amino 
acid 70 is located closer to the active site, is a large change in biochemistry and 
is likely to be more important in affecting the function of nsP3 than amino acid 
48. 
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6.3 Discussion 
In this chapter the genetic sequences of L10-EDI, A7(74)-EDI and SFV4-EST, in 
particular the genes encoding nsP2 and nsP3, were determined and compared. SFV 
L10 and SFV A7(74) differ in virulence in adult mice (Bradish et al., 1971), however 
the genetic factor(s) behind this are unknown. SFV4 is a molecular cDNA clone of 
Prototype virus, which is closely related to SFV L10 (Liljestrom et al., 1991). 
However, during the cloning process an unknown genetic change must have occurred 
since after ip inoculation SFV4 is avirulent in adult mice, while SFV L10 is virulent 
(Glasgow et al., 1991;Fazakerley, 2002). 
The genetic sequences of L10-EDI (ARKL10-EDI) and A7(74)-EDI 
(ARKA7(74)-EDI) were generated by Solexa (Illumina) sequencing and confirmed 
in part (nsP2/nsP3) using PCR sequencing (2.13.1, 2.13.2). Solexa (Illumina) 
sequencing is a powerful tool that sequences all DNA in a sample to generate a 
consensus sequence with a high confidence. In contrast, traditional PCR rapidly 
sequences  a single genotype in the population. Both techniques are useful depending 
on the aim. The sequence of SFV4, referred to here as SFV4-EST, was recently 
generated by Prof. Merits, Institute of Technology, University of Tartu, Estonia. PCR 
sequencing confirmed the sequences of nsP2 and nsP3 in SFV4-EST and SFV 
A7(74)-EDI (obtained by Solexa (Illumina) sequencing). However, in L10-EDI, the 
amino acid sequence of nsP2 differed at position 754 between the sequence 
generated by Solexa (Illumina) sequencing and PCR. The amino acids are both 
hydrophilic and, therefore, constitute a minor change which is unlikely to affect the 
secondary structure of nsP2. One possible explanation for the difference between the 
Solexa (Illumina) sequencing results and the PCR sequencing results is that both 
sequences are present in the virus population. Potentially, the sequence identified by 
PCR was present at a lower abundance than that identified by Solexa (Illumina) 
sequencing. In HCV infections, deep sequencing technology has facilitated the 
detection of a master sequence and quasispecies within a sample. Quasispecies are 
viral subpopulations that have small sequence variations compared to the master 
sequence (Ruiz-Jarabo et al., 2000;Domingo & Wain-Hobson, 2009;Verbinnen et 
al., 2010). 
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There is one sequence for SFV L10 available on the NCBI database, L10-
IRE. However, comparison of the genetic sequences of ARKL10-EDI and L10-IRE 
identified 19 nucleotide differences resulting in 18 amino acid changes (Tables 6.2 
and 6.6). All the differences identified were located in the replicase ORF and most 
mapped to nsP2. The majority of these amino acid differences appear to be due to a 
frame-shift (discussion with Prof. Merits). Possible explanations for the differences 
between ARKL10-EDI and L10-IRE include (i) L10-IRE has a different passage 
history to ARKL10-EDI that selected for genetic changes or, more likely, (ii) there 
were mistakes during the sequencing of L10-IRE. This data indicate that experiments 
using L10-IRE cannot be directly applied to ARKL10-EDI and that these two stocks 
of virus both labelled SFV L10 must be considered different. 
Much of our understanding about SFV A7(74) comes from studies using 
A7(74)-EDI, A7(74)-FIN and A7-IRE (Glasgow et al., 1994;Santagati et al., 
1995;Tarbatt et al., 1997;Tuittila et al., 2000;Tuittila & Hinkkanen, 2003;Neuvonen 
et al., 2011). The genetic sequences of A7(74)-FIN and A7-IRE were compared to 
A7(74)-EDI at both the nucleotide and amino acid level. The amino acid sequences 
of A7(74)-FIN and A7-IRE were extremely similar to A7(74)-EDI; one amino acid 
difference was identified between A7(74)-EDI and A7(74)-FIN and two amino acid 
differences between A7(74)-EDI and A7-IRE (Table 6.5). This data indicate that the 
observations made with A7(74)-FIN and A7-IRE can be applied to A7(74)-EDI. 
Next, the genetic sequences of SFV4-EST and L10-EDI were compared. The 
sequences were highly conserved with only seven substitutions identified (Table 
6.6). These were located in the 5’ UTR, nsP3, capsid and E2 (Table 6.6 and Fig. 6.1). 
In addition, L10-EDI encoded 37 fewer nucleotides than SFV4-EST in the 3’UTR. In 
nsP3, the amino acid substitution was located in the macro domain at amino acid 
position 48; SFV4-EST expressed glutamic acid and ARKL10-EDI expressed 
alanine. The macro domain is highly conserved between alphaviruses, rubella virus, 
HEV and the coronaviruses, although its function remains to be fully elucidated 
(Koonin & Dolja, 1993;Pehrson & Fuji, 1998;Neuvonen & Ahola, 2009). During 
alphavirus infection, the macro domain is associated with replication of the virus 
genome and in attachment of replication complexes to cellular membranes (Peranen 
et al., 1988;Peranen, 1991;Peranen et al., 1995;Salonen et al., 2003;Tuittila & 
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Hinkkanen, 2003). It is difficult to predict the importance of amino acid 48 on nsP3 
function and the virulence of SFV-EST and ARKL10-EDI. Amino acid position 48 is 
highly variable between alphaviruses (Fig. 6.5). In addition, amino acid 48 is located 
in a loop, orientated inwards, away from the active site (Fig. 6.7). Furthermore, 
deletion of nsP3 residues 25 – 49 in SFV4-EST had a limited affect on virus 
replication in BHK-21 cells (Lulla et al., 2012). In contrast, in one study, substitution 
of 48glutamic acid in SFV4-SWE for 48alanine in A7(74)-FIN produced a virus 
incapable of replication in vitro (Tuittila & Hinkkanen, 2003). Taken together, this 
data indicate that amino acid 48 is unlikely to affect SFV replication. However, one 
possibility is that amino acid 48 affects the interaction of nsP3 with the host immune 
system, as opposed to directly altering virus replication. In MHV (coronavirus) 
infection, the macro domain functions as an IFN antagonist (Eriksson et al., 2008). In 
Lulla et al (2012), BHK-21 cells were used to assess the replication of SFV4-EST 
and SFV4-EST with a deletion of nsP3 residues 25 – 49. BHK-21 cells are IFN 
incompetent and, therefore, if the nsP3 macrodomain is important in controlling the 
host IFN response this would not be seen in this experimental design.  
Based on this information it is difficult to predict how important amino acid 
48 is for SFV virulence. Engineering of SFV4-EST constructs is currently underway 
in the laboratory of Prof. Merits to produce clones of SFV4-EST with different 
combinations of amino acids identified in ARKL10-EDI. Further analysis of other 
amino acid substitutions was beyond the scope of this thesis. The pathogenesis of 
these constructs will then be assessed in adult mice by our laboratory in Edinburgh 
and functional IFN levels will be measured. 
The genetic sequence of ARKA7(74)-EDI had several changes compared to 
SFV4-EST, which mostly mapped to nsP3 (Table 6.6). This has been previously 
reported for A7(74)-FIN compared to SFV4-SWE (Tarbatt et al., 1997;Tuittila et al., 
2000). Several studies suggest that nsP3 is a virulence determinant in A7(74)-FIN 
infection (Tarbatt et al., 1997;Tuittila et al., 2000;Tuittila & Hinkkanen, 2003). In 
nsP3, the important biochemical differences identified in this study between A7(74)-
EDI and SFV4-EST were amino acid substitutions at positions 48 (glutamic acid in 
SFV4-EST and alanine in ARKA7(74)-EDI), 70 (arginine in SFV4-EST and glycine 
in A7(74)-EDI), 394 (aspartic acid in SFV4-EST and alanine in ARKA7(74)-EDI) 
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and 442 (alanine in SFV4-EST and threonine in ARKA7(74)-EDI) a deletion of 7 
amino acids in A7(74)-EDI and an opal codon in ARKA7(74)-EDI not identified in 
SFV4-EST (Table 6.6). Amino acid 48 and 70 are located within the macro domain. 
Amino acid 48 has been discussed above. In the panel of alphaviruses, only SFV4-
EST and ARKL10-EDI expressed 70glycine (Fig. 6.2). This amino acid difference 
between SFV4-EST and ARKA7(74)-EDI is likely to affect the function of nsP3 due 
to (i) glycine is smaller and has a completely different structure to alanine and (ii) 
amino acid 70 is located relatively close to the active site (Fig. 6.4). Indeed, a clone 
based on A7(74)-FIN engineered to express 70glycine produced mild to severe 
paralysis in adult mice following ip inoculation (A7(74)-FIN is avirulent in adult 
mice) (Tuittila & Hinkkanen, 2003). The role of the nsP3 macro domain and, in 
particular, this amino acid during SFV infection remains unclear. This would be an 
interesting area for future work. Amino acids 394 and 442 are located in the 
hypervariable domain. The hypervariable is predicted to be highly disordered and no 
crystal structure is currently available. Therefore, it is difficult to predict how 
changes in this region affect the structure and function of nsP3 without mouse 
experiments.  
In chapter 5, nsP2 was shown to be important in determining the virulence 
of SFV4-EST. Therefore, the nsP2 amino acid sequence was analysed further. The 
nsP2 amino sequence of SFV4-EST and ARKL10-EDI were identical, while the 
amino acid sequence of SFV4-EST and ARKA7(74)-EDI differed on four occasions. 
One biochemically important amino acid substitution was identified at position 515, 
valine was identified in SFV4-EST and glutamic acid in ARKA7(74)-EDI (Table 
6.6). In the panel of alphaviruses, only SFV4-EST expressed 515glutamic acid. Amino 
acid 515 is located in the active site of the nsP2 protease domain (Fig. 6.4). The 
protease domain is associated with cleavage of the polyprotein and replication of the 
virus genome (Suopanki et al., 1998;Vasiljeva et al., 2003;Russo et al., 2006). 
However, a specific role for this amino acid during SFV replication has not been 
described. This amino acid could potentially be involved in replication efficiency 
through processing the replicase polyprotein and/or in interaction with the immune 
system. It would be interesting to substitute the amino acid at position 515 in A7(74)-
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EDI nsP2 with the amino acid in SFV4-EST and investigate how this affects the 
pathogenesis of the virus in mice.  
In conclusion, the sequence analysis presented here demonstrates the 
similarity of SFV4-EST to L10-EDI and suggests amino acids that may determine 
the virulence of SFV L10 relative to SFV4 in adult mice. The data confirms reports 
that the genetic sequence of SFV A7(74) differs from SFV4 on multiple occasions 
and suggests amino acid substitutions that may be important in determining SFV 
virulence in adult mice. 
 
6.3.1 Final summary 
For the first time two strains of SFV held at EDI, L10-EDI and A7(74)-EDI, were 
sequenced and compared to other database sequences. The results comparing L10-
EDI to SFV4-EST were extremely interesting; only seven differences were 
identified. These substitutions are currently under investigation. Multiple amino acid 
differences were identified between A7(74)-EDI and SFV4-EST, as expected. One 
particularly interesting amino acid difference was located in the active site of the 
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Chapter 7: Final discussion 
This thesis investigated the interaction of SFV with host cell stress responses, in 
particular the autophagy and type-I IFN responses. The cell stress response is 
employed by cells to control internal conditions following a stressful stimulus, such 
as virus infection. Cell stress responses include the type-I IFN response, autophagy, 
UPR and, if the cell cannot recover, apoptosis. Previous studies have demonstrated 
that SFV infection induces the type-I IFN response, the UPR, apoptosis and, more 
recently, autophagy (Bradish et al., 1975;Barry et al., 2010;Eng et al., 2012). At the 
beginning of this thesis three hypotheses were set out: (i) SFV infection induces 
autophagy in cell culture utilises this response to enhance virus replication and (ii) the 
quality, quantity and/or protective efficacy of the IFN response differ between strains 
of SFV and between human and murine cells and (iii) the replicase proteins nsP2 
and/or nsP3 antagonise the IFN response. 
In chapter 3 the hypothesis that ‘SFV infection induces autophagy in cell 
culture and subverts autophagy to enhance virus replication’ was investigated. Strains 
of SFV rapidly induced the accumulation of autophagosomes by 1 h post-infection in 
Huh7 cells. Most RNA viruses studied to date induce autophagy in cell culture. 
Autophagy enhances the replication of CHIKV, which is closely related to SFV, in 
HEK293 cells (Krejbich-Trotot et al., 2011). Similarly, autophagy enhances the 
replication of PV (Jackson et al., 2005), Coxsachievirus B3 virus (Wong et al., 2008), 
FMDV (O'Donnell et al., 2011), DENV (Lee et al., 2008), JEV (Li et al., 2012a), 
SARS-CoV (Prentice et al., 2004) and HCV (Dreux & Chisari, 2009). In contrast, 
during SINV infection autophagy appears to selectively target capsid protein for 
degradation in autolysosomes, although replication is unaffected (Orvedahl et al., 
2010). Other studies have shown that autophagy has no affect on the replication of 
MHV and HRV2 (Brabec-Zaruba et al., 2007;Zhao et al., 2007b).  
In the data presented here neither the inhibition nor the induction of 
autophagy affected SFV replication at a high MOI of 5. In addition, the 
autophagosome marker GFP-LC3 colocalised with nsP3 or dsRNA in <5 % of cells in 
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the monolayer at 6 and 24 h post-infection. Similar results were observed for capsid 
and GFP-LC3 colocalisation experiments. However, at a low MOI of 0.01, rapamycin 
induction of autophagy appeared to reduce SFV replication at 5 and 6 h post-
infection; the opposite effect on replication was observed with 3MA inhibition of 
autophagy. This effect at high MOI, when all cells are infected, suggests that 
autophagy does not function either as a site of replication for SFV or, to a large 
extent, as a mechanism to degrade SFV proteins. Similar results were observed by 
Eng et al (2012), who investigated the interaction of SFV with autophagy in HOS and 
MEFs. The results at a low MOI, when only a few cells are infected, could indicate 
that rapamycin pre-treatment is delaying virus release or reducing numbers of 
infectious viruses released, while 3MA enhances this. Indeed, 5 – 6 h post-infection is 
consistent with the time at which the second round of virus infection is expected. In 
conclusion, SFV induces the accumulation of autophagosomes in vitro, which has an 
antiviral effect on SFV replication only at a low MOI. 
The hypothesis that ‘the quality and/or the quantity and/or the protective 
efficacy of the IFN response differ between strains of SFV and between human and 
murine cells’ was investigated in chapters 4 and 5. The results were complicated, 
which indicates the complexity of the type-I IFN response. Three strains of SFV were 
investigated that differ in virulence in adult mice: virulent SFV L10 and avirulent 
SFV A7(74) and SFV4. The experiments were carried out in both human and mouse 
fibroblasts that are believed to have an intact type-I IFN response. In chapter 4, all 
three strains were shown to be highly sensitive to both human and mouse IFN-α pre-
treatment, as demonstrated by a reduction in titre of >75 %. The strains did not differ 
in sensitivity to IFN-α pre-treatment, disagreeing with the hypothesis suggested in 
(ii). These results differed from a study by Deuber and Pavlovic (2007) in which a 
virulent strain of SFV (SFV L10) was less sensitive to IFN pre-treatment than an 
avirulent strain of SFV (SFV V42); SFV L10 replicated to higher titres than SFV V42 
following IFN pre-treatment. The differing results between Deuber and Pavlovic 
(2007) and the data presented here could be due to (i) differences between V42 and 
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SFV4 and SFV A7(74), (ii) variations between the cells used and/or (iii) differences 
in the experimental protocol. Based on these results, it is unlikely that IFN induction 
is responsible for the mild infection of SFV in humans suggested in hypothesis (ii). 
However, the results presented here do not exclude the possibility that IFN does 
determine the pathogenesis of other alphaviruses, such as CHIKV, in mice. CHIKV is 
avirulent in mice unless the mice are deficient in the type-I IFN system (Couderc et 
al., 2008). It would be interesting to directly compare CHIKV and SFV induction of 
IFN and sensitivity to the effects of IFN in both human and mouse cells. This 
experiment was planned as part of the present study, but was not carried out due to 
the unavailability of containment level 3 laboratory spaces. 
In another experiment, human and mouse fibroblasts were infected with the 
three strains of SFV and the amount of functional IFN produced was measured. Two 
particularly interesting observations were made, (i) SFV4 induced more functional 
IFN than SFV L10 in mouse fibroblasts and (ii) strains of SFV induced less 
functional IFN than SeV in fibroblasts. SFV4 was derived from Prototype virus, 
which was isolated from the same pool of mosquitoes as SFV L10 (SMITHBURN & 
Harrow, 1944;Liljestrom et al., 1991). However, during the cloning process the 
virulence of SFV4 following ip inoculation in adult mice was lost (Glasgow et al., 
1991;Fazakerley, 2002). The results presented here indicate that changes in the 
sequence of SFV4 have made it less efficient at inhibiting the IFN response than SFV 
L10. This could explain the difference in pathogenesis between the strains in adult 
mice.  
In chapter 6, Solexa (Illumina) sequencing and PCR facilitated the 
comparison of our laboratory strains of SFV L10 and SFV A7(74) with the molecular 
clone SFV4 at the nucleotide and amino acid level. Sequence comparison of SFV4 
and SFV L10 at the amino acid level identified 9 substitutions located in the 5’ UTR, 
nsP3, capsid, E1 and E2. Biochemical analysis of the amino acid residues predicted 
that the substitutions with the greatest impact on function were in nsP3 and capsid. 
Comparison of the amino acid 48 in nsP3 between members of the alphavirus genus 
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indicated that this is a variable position and may, therefore, have a limited affect on 
virulence. However, amino acid 48 proved vital for SFV A7(74) replication (Tuittila 
& Hinkkanen, 2003). Without analysing the affect of these changes in vivo it is 
difficult to predict their importance to virulence. Currently, a series of SFV4 
constructs are being created by our collaborators in the laboratory of Prof. Andres 
Merits, Institute of Technology, University of Tartu, Estonia that will encode the SFV 
L10 amino acid substitutions. These will be compared by our laboratory in adult mice 
for virulence and IFN production. This experiment should determine the difference(s) 
between SFV4 and SFV L10 that dictate virulence in adult mice. 
The second observation, that strains of SFV induce less functional IFN than 
SeV, has been reported for other alphaviruses, including CHIKV and SINV (Burke et 
al., 2009). Another study demonstrated that SFV4 induces less functional IFN and 
fewer IFN-β transcripts than SFV4 with a mutation in nsP2, termed SFV4-RDR 
(Breakwell et al., 2007). Taken together, these data indicate that SFV can inhibit the 
IFN, either at the induction or signalling stage. The mechanism by which SFV 
inhibits the IFN signalling pathway was investigated in chapter 5. A panel of 
fibroblasts was infected with the three strains of SFV and then challenged with IFN-α 
treatment 10 h later. All three strains of SFV restricted the phosphorylation of STAT1 
compared to the uninfected IFN-treated control. Inhibition of STAT1 phosphorylation 
was reported for cells infected with CHIKV and SINV (Simmons et al., 2010; Fros et 
al., 2010). Several viruses target and inhibit the type-I IFN signalling pathway 
through different mechanisms. The paramyxovirus PIV5 expresses V protein that 
promotes the polyubiquitylation of STAT1 and targets STAT1 for degradation 
(Didcock et al., 1999;Andrejeva et al., 2002;Ulane & Horvath, 2002;Precious et al., 
2005). HeV and MV sequester STAT1 into cytoplasmic high molecular complexes 
(Rodriguez et al., 2003;Palosaari et al., 2003). Flaviviruses, such as DENV and JEV, 
express the protein NS5 that directly disrupts the phosphorylation and activation of 
STAT1 (Munoz-Jordan et al., 2003;Lin et al., 2004;Guo et al., 2005;Ho et al., 
2005;Best et al., 2005;Ashour et al., 2009). SARS-CoV indirectly inhibits STAT1 
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activity by the virus protein ORF6 binding nuclear transport protein karyopherin α2, 
which prevents the nuclear translocation of STAT1 (Frieman et al., 2007). In 
addition, the inhibition of IFN-β induction by viruses prevents all downstream 
processes, including STAT1 phosphorylation. SFV does not induce total STAT1 
degradation, as demonstrated by Western blot. Therefore, SFV does not appear to 
antagonise STAT1 phosphorylation through the same mechanism as PIV5. 
The hypothesis that ‘the replicase proteins nsP2 and/or nsP3 antagonise the 
IFN response’ was also investigated in chapter 5. Experiments demonstrated that the 
NLS motif in nsP2 was required to inhibit STAT1 phosphorylation; greater levels of 
STAT1 phosphorylation were detected in lysates from cells infected with SFV4-RDR 
compared to WT SFV4. One possible mechanism by which nsP2 could inhibit 
STAT1 phosphorylation is that nsP2 enters the nucleus and disrupts the IFN-
β promoter, which is downstream of the transcription factors IRF-3 and NF-KB. 
nsP2RDR is largely restricted to the cytoplasm and would not efficiently disrupt the 
IFN-β promoter. SFV4-RDR induces the production of more functional IFN than 
SFV4 (chapter 4). Therefore, the high levels of phosphorylated STAT1 during SFV4-
RDR infection may be the result of increased IFN signalling, relative to SFV4. A 
recent study suggested that inhibition of the type-I IFN response during SINV 
infection in vitro occurred prior to the inhibition of STAT1 phosphorylation (Frolov 
et al., 2012). An alternative mechanism is that nsP2 binds STAT1 or a protein 
important in STAT1 phosphorylation in the cytoplasm and this inhibits STAT1 
phosphorylation. The levels of phosphorylated STAT1 detected during SFV4 
infection remained low, even after IFN stimulation. This could indicate a specific role 
of SFV4 and perhaps nsP2 in antagonising the IFN signalling pathway. In SFV4-
RDR, the structure of nsP2 is altered which may affect its ability to interact with 
other proteins. Current experiments in our laboratory provide strong evidence for the 
second mechanism (Dr. Gerald Barry, personal communication).  
In conclusion, nsP2 is a multifunctional protein that probably interacts with 
the type-I IFN pathway at various stages. These results highlight the importance of 
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controlling the type-I IFN response for SFV replication and spread. Future research 
could focus on investigating the interaction of nsP2 with other proteins involved in 
the type-I IFN response and comparing this to nsP2 encoded by other alphaviruses, 
such as CHIKV. 
In chapter 5, the potential role of nsP3 in antagonising the type-I IFN response 
was also investigated. NsP3 is implicated in virus replication, association of the RC 
with cellular membranes and as a virulence determinant (Hahn et al., 1989;Lemm & 
Rice, 1993;Lemm et al., 1994;Shirako & Strauss, 1994;Wang et al., 1994;LaStarza et 
al., 1994a;Tarbatt et al., 1997;Tuittila et al., 2000;Tuittila & Hinkkanen, 2003). The 
interaction of nsP3 with the type-I IFN response has not previously been investigated. 
NsP3 can be divided into 3 domains: the macrodomain towards the N-terminus, the 
domain conserved between alphaviruses and the hypervariable domain towards the C-
terminus (Koonin & Dolja, 1993; Pehrson & Fuji, 1998; Neuvonen & Ahola, 2009; 
Peranen, 1991; Vihinen & Saarinen, 2000). The interaction of nsP3, and in particular 
the hypervariable domain, with the type-I IFN response was analysed using the 
mutant SFV4nsP3∆50, which has a deletion of 50 amino acids in the 
hyperphosphorylated region. SFV4nsP3∆50 replicates less efficiently in vitro and is 
less virulent in vivo than WT SFV4 (Vihinen et al., 2001). In the data presented here, 
SFV4nsP3∆50 replicated less efficiently in cell culture and induced significantly 
more IFN than WT SFV4. Higher levels of STAT1 phosphorylation were detected in 
lysates from cells infected with SFV4nsP3∆50 compared to SFV4. However, the 
trend observed by Western blot was different to SFV4-RDR: SFV4-RDR induced 
STAT1 phosphorylation even without IFN-α challenge, while SFV4nsP3∆50 only 
induced STAT phosphorylation following IFN-α challenge. This observation 
indicates that SFV4-RDR and SFV4nsP3∆50 interact with the type-I IFN response 
via different mechanisms.  
One hypothesis for the difference in IFN induction between WT SFV4 and 
SFV4nsP3∆50 is that the hypervariable region of nsP3 inhibits proteins within the 
IFN induction and/or signalling pathways. An alternative hypothesis is that 
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SFV4nsP3∆50 replicates less efficiently than SFV4 and, therefore, (i) does not enter 
the spherules (invaginations in cytoplasmic cell membranes) as efficiently for 
replication and does not ‘hide’ from the immune response and/or (ii) does not 
produce as many virus proteins that inhibit the immune response and/or (iii) does not 
induce host cell macromolecular synthesis shutoff as efficiently as WT SFV4. In a 
recent study, the hyperphosphorylated region was identified to have SH2 domains 
which are suggested to target the RC to cellular membranes (Neuvonen et al., 2011). 
In SFV4nsP3∆50 this region is lost, which would affect replication. The data 
presented here offer a greater insight into the role of nsP3 and the 
hyperphosphorylated region during SFV infection, although much is still unknown 
about nsP3. Future studies could focus on why SFV4nsP3∆50 induces more IFN that 
WT SFV4 and with which cellular proteins nsP3 interacts. It would be interesting to 
compare the activity of nsP3 between different alphaviruses, in particular CHIKV. 
This thesis enhances SFV research by providing a comprehensive comparison 
of three commonly used strains of SFV: SFV L10, SFV A7(74) and SFV4 and their 
interaction with the autophagy and the type-I IFN responses. This thesis demonstrates 
a novel mechanism by which strains of SFV can antagonise the type-I IFN pathway 
by inhibiting STAT1 phosphorylation and further elucidates the role of nsP2 and 
nsP3 during infection. Overall, the studies presented here provide a greater 
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